MYAWARE

England & Wales · Charity number 1046443

Details

Other names	MYASTHENIA GRAVIS ASSOCIATION, MYAWARE
Status	Registered
Legal form	Charitable company
Company number	03038358
Registered	1995-05-19
Register	View on the Charity Commission register

Contact

Address	myaware College Business Centre The College Uttoxeter New Road Derby DE22 3WZ
Phone	01332290219
Email	info@myaware.org
Website	www.myaware.org

Activities

Objects: TO PROMOTE ANY CHARITABLE PURPOSES FOR THE BENEFIT OF THOSE PERSONS WHO SUFFER FROM MYASTHENIA GRAVIS, AND IN PARTICULAR BUT WITHOUT LIMITATION TO RELIEVE SICKNESS, HARDSHIP AND DISTRESS AND PROVIDE COMFORT AND SUPPORT TO PEOPLE SUFFERING FROM MYASTHENIA GRAVIS AND TO PROMOTE AND ENCOURAGE EDUCATION AND RESEARCH INTO MYASTHENIA GRAVIS AND TO PUBLISH THE USEFUL RESULTS OF ANY SUCH RESEARCH.

Activities: The charity provides local and national support, advice and information for people affected by myasthenic syndromes (Myasthenia Gravis; Ocular Myasthenia Gravis; Congenital Myasthenic Syndromes and Lambert Eaton Myasthenic Syndrome) and their families. It raises medical and public awareness of these conditions and funds research to reduce their impact and ultimately a find cure.

Downloaded from opencharities.uk/ew/1046443

Classification

- **How:** Makes Grants To Organisations, Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** General Charitable Purposes, Education/training, The Advancement Of Health Or Saving Of Lives, Disability
- **Who:** People With Disabilities, Other Charities Or Voluntary Bodies, The General Public/mankind

Geography

- **Area of benefit:** IN PRACTICE, UNITED KINGDOM AND REPUBLIC OF IRELAND
- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£449,135	£1,054,088	-	-
2024-03-31	£1,178,400	£1,068,135	£2,140,950	18
2023-03-31	£329,444	£716,633	-	-
2022-03-31	£706,904	£1,022,153	£2,406,293	19
2021-03-31	£992,799	£1,052,417	£2,703,049	24

Trustees

Name	Role	Appointed
ANDREW JOHN ROBINSON		
Claire Wen		2024-02-19
DR Bethan Lang		2013-12-10
Dr Channa Hewamadduma		2024-07-24
Dr Katherine Dodd		2025-07-25
Dr SAIJU JACOB		2018-03-29
Jon Rio		2016-09-01
Rashmi Rungta		2020-11-01
Sara Jones		2024-05-08

Downloaded from opencharities.uk/ew/1046443

Linked charities

- MYASTHENIA GRAVIS ASSOCIATION (OLD) (1046443-1)

Downloaded from opencharities.uk/ew/1046443

MYAWARE

England & Wales - Charity number 1046443

Accounts

myaware
Fighting Myasthenia Together

Report of the Trustees and Financial Statements

For the Year Ended 31st March 2025

Myaware is a Registered Charity No. England & Wales 1046443. Scotland SC044744.
Company Limited by Guarantee No. 3038358 (England & Wales)

Contents **Page**

- Chair's Report 1
- CEO's Report 2
- Report of the Trustees 7
  - Objectives and Activities of the Charity 7
  - Achievement and Performance 8
  - Future Developments 19
  - Reference and Administrative Details 20
  - Structure Governance & Management 21
  - Financial Review 23
  - Statement of Trustees Responsibilities 25
- Report of the Independent Auditors 26
- Statement of Financial Activities 30
- Balance Sheet 31
- Cash Flow Statement 32
- Notes to the Cash Flow Statement 33
- Notes to the Financial Statements 34-46

Chair's Report

As I write my final report as Chair of myaware, I am filled with immense pride and gratitude for all that we have achieved together. Myaware's mission, to support everyone affected by Myasthenia, empower our community, and drive progress through research and advocacy, remains as vital as ever. It has been a privilege to witness the strength, resilience, and generosity of our members, supporters, and partners over the years.

This year, we have continued to build on our national support model, ensuring that every person living with a Myasthenia condition, wherever they are in the UK, can access the information, advice, and community they need. Our online support sessions, telephone helpline, and dedicated social media groups have remained lifelines for many, providing connection and reassurance in challenging times.

We have further strengthened our welfare benefits and advice service, helping members navigate complex systems and secure the support they deserve. Our commitment to funding and championing high-quality research has continued, with new partnerships and projects launched to deepen understanding of Myasthenia and accelerate progress towards better treatments and, ultimately, a cure.

Throughout the year, we have worked closely with healthcare professionals, academic partners, and industry stakeholders to ensure that the voices and experiences of people living with Myasthenia are heard and valued. Together, we have advocated for improved access to care, greater awareness, and meaningful policy change.

None of this would be possible without the unwavering support of our donors, fundraisers, corporate partners, trusts, and foundations. Your belief in our mission, and your willingness to stand with us, has enabled myaware to remain a beacon of hope and support for so many. Thank you for your generosity, your expertise, and your trust.

These past years have not been without their challenges. The ongoing pressures on health and social care, the cost-of-living crisis, and the lasting impact of the pandemic have tested us all. Yet, time and again, our community has shown remarkable adaptability, compassion, and determination. I am confident that myaware will continue to thrive and evolve, guided by these values.

As I step down as Chair, I want to express my deepest thanks to the Board of Trustees, our dedicated staff team, and every member of the myaware community. It has been an honour to serve alongside you. I look forward to seeing myaware continue to grow, innovate, and make a lasting difference in the lives of people with Myasthenia.

With heartfelt thanks and best wishes for the future,

Trevor Ranson
Chair, myaware

CEO's Report

Membership

Historic research publications have stated that there were approx. 12,000 people living with myasthenia in the UK. In December 2021 a research paper entitled *Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019*, written by Iain Carey was published outlining that this data is now estimated at 20,000 people in the UK.

In April 2025, myaware recorded a 37.95% increase in active membership, rising from 2,746 to 3,788 over the financial year spanning April 2024 to March 2025. Myaware began implementing lifetime memberships effective from January 2024, to ensure that members can continue to access information and support throughout their myasthenia journey, without interruption. Our large increase in membership reflects this.







CEO's Report - continued

Myaware national support services
Myaware members have access to a comprehensive range of online and telephone support services, offering guidance to individuals and their families from diagnosis onward. In 2024–25, myaware continued to expand and improve its digital offerings, ensuring members could easily access reliable information, expert advice, and peer support. We maintained our commitment to a nationally coordinated delivery model, further streamlining services across the UK to enhance consistency and accessibility.

Connecting our members online

Zoom sessions and webinars
Over the past year, we delivered 38 online Zoom sessions, creating opportunities for members to connect, share experiences, and discuss common challenges. These sessions were led by our expert National Support Coordinators and our Benefits and Welfare Officer, who provided compassionate updates on support services, awareness initiatives, and research developments, along with essential guidance on living well with myasthenia.

We also hosted three webinars, building on the success of the previous year. To launch My Awareness Month 2024, Dr. Channa Hewamadduma presented a session on the importance of lifestyle and exercise for individuals with Generalised Myasthenia Gravis. As part of the same awareness initiative, three of the UK's Myasthenia Specialist Nurses led a 'Frequently Asked Questions' webinar, addressing the most common queries raised by their patients.

In another webinar, our Research and Partnerships Manager, Charlotte Campbell, shared the latest findings on lung and bone health in relation to myasthenia. All webinars were facilitated by our dedicated support team.

Myaware continues to offer a diverse range of monthly Zoom sessions tailored to members who are newly diagnosed, as well as peer support sessions for the wider community. We also provide age-specific and condition-specific sessions, alongside new offerings for carers and welfare-related topics. Our goal is to reduce feelings of isolation by supporting members through the early stages of diagnosis and helping them stay connected with others facing similar experiences.

We're proud to report that over 1,209 members attended our online sessions this year—a nearly 15% increase from the previous year—highlighting the growing impact of our digital support services.

"Very pleased with session, learnt a lot and when I do these sessions, feel much better knowing that there are other people out there with the same diagnosis but some of a lot worse than I am. Which makes me grateful that I have more good days than bad days."

"These events are very helpful. Discussing MG and its impacts with people who have direct experience of the condition (sufferers AND their partners who also live with this) gives some really helpful insights and knowledge. Thank you all for doing this."

"I find them very instrumental in my recovery. I was diagnosed on 29th May 2003. Severe recurrence about 7 months ago. The Myasthenia group now is so different from the 2003 era. I enjoy the Zoom meetings where there are a variety of questions. With the members at heart."

CEO's Report - continued

Peer support network via social media
Myaware currently facilitates and manages six national closed Facebook groups, connecting 1,282 individuals living with myasthenia and their family members. This year, we expanded our online peer support network by launching dedicated groups for those affected by Congenital Myasthenic Syndromes (CMS) and Lambert-Eaton Myasthenic Syndromes (LEMS), offering these rarer patient communities a safe space to share experiences and access support.

These groups serve as a vital 24/7 lifeline, providing peer-to-peer connection, updates from myaware, and answers to frequently asked questions. Our national peer support group is open to all members, regardless of age, location, or type of myasthenia. We also offer tailored groups including:

- Myaware Kids – for parents of children diagnosed with any form of myasthenia
- Young Generation – for members aged 18–39, with discussions focused on education, employment, pregnancy, and other relevant topics
- Carers Group – newly introduced this year, offering support and resources for those caring for someone with myasthenia

These online communities play a crucial role in reducing isolation and fostering connection among those affected by myasthenia across the UK.

> *"I have finally been officially diagnosed with CMS and I am in a bit of shock, it is bittersweet for sure... I am so grateful for the myaware Facebook group, it has been such an encouragement"*

Support offered by the team

Telephone and Email, Support and Information
Our team are available Monday to Friday 9am to 5pm by telephone and email. Whether members have a question they want answering or want to know more about myaware objectives or services, our dedicated Head Office and the Support Team members are here to help inform and guide our members.

Emotional support service
People can have many reactions to myasthenia, and for this reason our National Support Coordinators are here to listen and when needed can help point you to specialist support.

> *"Your response, as always, was extremely helpful, empathetic and kind. I cannot thank you enough. You are a brilliant organisation run by brilliant individuals."*

Benefits and welfare advice service
The benefits system is complex, the rules can change, and when living with an unpredictable and sometimes debilitating condition like myasthenia, it can be difficult to find the energy and time to fully research every opportunity to improve your quality of life. Myaware's dedicated Welfare officer is here to help our members navigate the benefits system and check if they are entitled to any financial assistance, or support relating to transport, employment, or education.

CEO's Report - continued

Benefits and welfare advice service - continued

This year myaware has responded to 615 benefits and welfare enquiries.



These enquiries were divided among topics like employment, housing, and transport. Almost half of these enquiries were focused on benefits.

Like all our support services this advice is available to all members in England, Scotland, Wales, and Northern Ireland. The service is provided by telephone, on the myaware website and via our Zoom sessions, and is available Monday to Friday, 9am to 5pm.

"Thank you so much for this... I really appreciate all the info you provided, especially for the [Council Tax] benefit, which I had been led to believe I couldn't get any help with."

"Thank you again for helping me win this decision, I thought this would drag out to years of stress arguing with the DWP."

Website information

In an increasingly digital world, the myaware website (found at www.myaware.org), is one of the most useful digital and communication tools the charity has. Our website exists to establish and maintain a relationship with the Myasthenia community and a broad range of stakeholders.

From April 2024 to March 2025, over 118,000 people visited the myaware website, with 95,000 of them being first-time visitors. On average, each visitor spent over a minute exploring the site. In total, users interacted with the website more than 1.1 million times, including reading articles, clicking links, and using support resources. The most popular website pages included: 'Drugs to Avoid', 'What is Myasthenia?', 'Support' and 'Ocular Myasthenia' – all providing essential information and guidance.

Most visitors found the site through Google searches, followed by direct visits and referrals from trusted sources like NHS and Facebook. The highest levels of engagement came from users in London, New York, Birmingham, and Edinburgh, showing that myaware continues to reach and support people both in the UK and internationally.

CEO's Report – continued

Website information - continued

Together, the myaware website and the charity's social media acts as a digital hub enabling us to share the fantastic stories of our members and how they have been empowered to understand their conditions, have greater say on the treatments and therapies available, and connect with other members who have Myasthenia related conditions via peer-to-peer support. Our website includes lots of helpful information including current research on Myasthenia, drugs to avoid, and places to find additional support. We also use our website to promote good news stories, fundraising events, and future online community sessions.

The main objectives of the website are to provide advice and support for members and carers, to increase awareness in primary and acute medical audiences, as well as the general public, and fund much needed research, enhancing medicines, surgical treatments and therapeutic interventions. In addition, users can access the charity's annual accounts, online shop, register for support events, and attain membership information. We urge anyone visiting our website to become a myaware member, whether they have a Myasthenia diagnosis, are a relative, carer or a healthcare professional with an interest in the Myasthenia.

Website Accessibility
Our website utilises the ReachDesk accessibility toolbar, which ensures visitors can access our content in a way that suits them best. Including text-to-speech, reading and translation support. Over the course of the year, the ReachDeck tool was estimated to be used around 6,444 times on the myaware website. The most actively used features were speech playback, with approximately 756 uses, and translation tools, used around 252 times, helping visitors listen to content aloud or access it in their preferred language. These figures reflect myaware's ongoing commitment to making its online information accessible, inclusive, and user-friendly for all.

Booklets, leaflets and flyers
For those who prefer printed materials, myaware offers a comprehensive library of information booklets and leaflets tailored to different audiences. These include resources for individuals living with Myasthenia Gravis, LEMs, Ocular Myasthenia, and Congenital Myasthenia. We also provide specialised guides on Myasthenia and CMS during pregnancy, as well as healthcare guides for medical professionals, including a dedicated booklet on Ocular Myasthenia. In addition, we produce a range of flyers that promote myaware's services and support offerings.

As I conclude this annual report as Interim CEO, I want to express my heartfelt thanks to everyone who makes myaware such a supportive and forward-thinking community. The dedication of our members, volunteers, and staff is evident in every story, statistic, and service described in these pages. I am inspired by the progress we have made together, whether that's welcoming new members, expanding our digital reach, or making our resources more accessible than ever before.

Looking ahead, I am excited to work with you all to shape a new strategy that builds on these achievements and ensures myaware continues to be a lifeline for everyone affected by myasthenia. Thank you for your trust, your engagement, and your commitment to our shared mission.

Marc Smith
Interim CEO, myaware

REPORT OF THE TRUSTEES

The trustees, who are also directors of the charity for the purposes of the Companies Act 2006, present their report together with the financial statements for the year ending 31st March 2025. These statements are also prepared to meet the requirements of the directors' report and accounts under the Companies Act.

The financial statements comply with the Charities Act 2011, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the charity's Articles of Association, and 'Accounting and Reporting by Charities: Statement of Recommended Practice' (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES OF THE CHARITY

Myaware exists to support people affected by myasthenia and related conditions, to raise awareness, and to fund research aimed at reducing the impact of these conditions and ultimately finding a cure.

Our core support services include:

- Support and information sessions delivered via Zoom, covering research updates, general support, and benefits and welfare advice.
- Monthly new member support sessions via Zoom.
- Condition-specific and age-specific Zoom sessions, including support for children (up to age 18) and young people (ages 18–39).
- Information and support available through the myaware website.
- Social media services, including closed, secure groups for peer support and public pages for information and signposting.
- Telephone and online welfare and benefits advice service.

We raise vital awareness of myasthenia by:

- Representing our members through membership of umbrella organisations such as the UK Neurological Alliances, Rare Disease UK, and National Voices.
- Providing targeted information for members and the general public via our website.
- Supplying information packs for clinicians throughout the UK.

Our commitment to research:

- Funding research projects focused on the cause, cure, prevention, treatment, and quality of life for people with myasthenia and related conditions.
- Supporting the training of clinicians in the field of myasthenia.
- Communicating research outcomes and future opportunities transparently to members and stakeholders.

To achieve these aims, we undertake a range of fundraising activities. We are deeply grateful to everyone who supports us financially and to our dedicated volunteers who contribute to both support and fundraising. Raising unrestricted funds to cover the charity's core costs, such as postage, telephone, printing, online services, and other essential expenses, remains a key challenge, and we are especially thankful to those who make donations that can be used flexibly in this way.

REPORT OF THE TRUSTEES

Grant Making Policy

The charity may award grants to scientific research, specialist myasthenia nurses, and training fellowships in support of its objectives and activities.

Grants are awarded by the Board of Trustees when funds are available and only when the charity's reserves position allows for the commitment of funds to multi-year projects.

Research grants are subject to a rigorous peer review process, overseen by the myaware Medical Committee.

Public Benefit

The trustees have referred to the Charity Commission's general guidance on public benefit when reviewing myaware's aims and objectives and in planning future activities. In particular, the trustees always consider how planned activities will contribute to the charity's objectives and benefit the public.

ACHIEVEMENT AND PERFORMANCE

How we receive our money:

Donations and legacies - £184,623
Other trading activities - £183,483
Investment income - £81,029
TOTAL - £449,135



REPORT OF THE TRUSTEES

How we spend our money:

Support – £725,425
Research – £195,878
Awareness – £121,094
Fundraising – £11,691
TOTAL – £1,054,088



The above data indicates a deficit of just over £0.6 million. While this is a significant shortfall, we have been fortunate to receive several substantial legacies in recent years, which have helped sustain the charity during this period. The Trustees acknowledge that this level of deficit is not sustainable in the long term, and a strategic plan is being developed to reduce the gap between income and expenditure.

Support of Members

Our membership grew significantly during the financial year, increasing by 37.95% to 3,788 members. We welcomed 746 new members, each of whom received a *newly diagnosed support pack*. In January 2024, we transitioned to a lifetime membership model, which contributed to this substantial growth and enabled us to reach and support more individuals affected by myasthenia.

We continue to keep our members informed and connected through quarterly newsletters, which provide news, support, encouragement, and recognition for those who contribute through donations and fundraising. This year, we also brought together specialist myasthenia nurses from across the UK, fostering collaboration and sharing expertise across the sector.

REPORT OF THE TRUSTEES

Support of Members - continued

Throughout the year, we delivered 38 Zoom sessions led by our national support coordinators and Benefits & Welfare Officer. As part of My Awareness Month in June 2024, we hosted two webinars, one led by Dr. Channa Hewamadduma and another by the Myasthenia Specialist Nurses. A third webinar, focusing on the latest findings on lung and bone health, was delivered by our Research & Partnerships Manager.

In total, 1,209 members attended these national Zoom and webinar sessions (an increase of nearly 15% compared to the previous year) accessing peer support, information and friendship.

Our closed, members-only Facebook groups remain a safe and supportive space, with 1,282 members engaging to share experiences, ask questions, and receive guidance.

We provide telephone and email support Monday to Friday, 9am to 5pm, offering advice, information, and a listening ear through our dedicated support team and head office staff.

Our Benefits and Welfare Officer supported 615 members this year, an increase of over 70% from last year. This remarkable growth reflects the compassionate and effective support being provided.

Research

The Research and Partnerships Manager (R&PM) oversaw the continued support of a variety of projects funded by myaware. The R&PM also prepared and pursued the execution of contracts related to funding new projects within the research budget for the financial year 2024-2025. This department also oversaw the advertisement, assessment, and delivery of funding agreements with five myasthenia specialist nurses in the United Kingdom. The details of these projects and contracts are as follows:

Professor Isabel Leite (Oxford): *The Establishment and Use of a UK Database for Myasthenic Disorders*:

At present, the database coordinator is being funded by myaware until September 2025. Dr Ashraghi is working with the coordinator to continue populating the database for this period and then reassess the need for further funding. During this time, myaware will receive a yearly summary.

There are at present 801 patients entered:

- 494 Tier 1
- 35 are Tier 2
- 272 are Tier 3

Diagnosis:

- 781 MG
  - 90% AChR
  - 4.4% MuSK
  - 5.6% Seronegative
- LEMS: 18
- CMS: 2

REPORT OF THE TRUSTEES

Research - continued

- Sex distribution: 51.6% male, 48.4% female.
- Mean age at diagnosis 50 years.
- Mean duration of disease 9.9 years (0-71.65)
- Mean current age 60 years.
- Selected ethnicities: 71.5% White British, 2.4% Indian, 1.8% Black African, 1.8% Black Caribbean, 22.5% Not documented in patient records.

Reassuringly, the demographics of the patients in the registry reflect what we would expect to see in an MG population based on previous studies. This supports the integrity and quality of the data being entered into the database.

Oxford University Hospitals	414
UCLH/NHNN	Actively consenting with plan to enter in bulk.
University Hospitals Birmingham	141
University Hospitals Southampton	15
University Hospitals Sussex	27
Greater Glasgow	67
Imperial College Healthcare NHS Foundation Trust	41
Nottingham University Hospitals	43
Sheffield Teaching Hospitals	28
St George's Hospital NHS Foundation Trust	25
Barts Health NHS Trust	Actively consenting with plan to enter in bulk.
Northern Care Alliance	Actively consenting with plan to enter in bulk.
Swansea Bay University Health Board	Actively consenting with plan to enter in bulk.
Hywel Dda	Actively consenting with plan to enter in bulk.

Sites in process of being set up:

Hull University Teaching Hospital

Northampton General Hospital

Gloucester Hospitals NHS

Royal Cornwall Hospitals

Moorefield's Eye Hospital

Chelsea and Westminster Hospitals

Dartford and Gravesham

Alder Hay Children's Hospital

REPORT OF THE TRUSTEES

Research - continued

Dr Katy Dodd (Manchester): *Optimising the Immunosuppressive Management of Myasthenia Gravis:*

With funding from myaware, Dr Dodd, alongside Dr Sussman and immunology experts at the University of Manchester, examined T cells in the blood of patients with acetylcholine receptor antibody-positive myasthenia gravis (AChR-MG). She has found that those who have ongoing symptoms despite immunosuppression treatment have low "regulatory" T cells. Regulatory T cells help to regulate overactive immune responses. This may open further avenues for therapy, as there are several methods used in other autoimmune diseases to "boost" regulatory T cells, which would be worth studying in myasthenia gravis.

AChR antibodies are known to activate the complement system, another component of the immune system. Complement activation is known to cause further disruption at the nerve-muscle junction, but wider effects on the rest of the immune system are less well studies. The team looked at the expression of complement receptors on T cells and showed that these are increased in those who have more active and difficult to treat disease. Further work is needed to better understand how this might further impact upon the immune response. Additionally, following rituximab therapy, those who had the worst response demonstrated persistent elevation of complement receptors on T cells, suggesting that treatments targeting the complement system may have been better suited to those individuals.

There was no difference seen in the expression of "immune checkpoints" on the T cells in the different patient groups. These checkpoints are of interest in myasthenia, as when blocked by certain cancer treatments, a severe form of myasthenia can be triggered. Going forwards Dr Dodd, with collaborators from the Manchester Centre for Cancer Research are collecting blood samples from patients with this new form of myasthenia, to try to better understand it.

This work has been part of a wider project in which Dr Dodd has also studied other immune cell types and markers in AChR-MG, with funding from the NorthCare Charity and the Neuromuscular Study Group. Those with refractory disease have been found to have specific immune changes, including higher proportions of "memory" B cells and certain complement proteins, and lower proportions of dendritic cells. Additionally, there are wider inflammatory immune changes including higher frequencies of monocytes, and high production of inflammatory cytokines from B cells when stimulated.

The work is due to be submitted for publication in the near future but has been presented at national and international medical conferences.

Hayley Ramjattan (Oxford) – *CMS Monitoring*:

This project set out to address the absence of key clinical outcome measures in Congenital Myasthenic Syndromes (CMS). Hayley Ramjattan, a specialist neuromuscular physiotherapist based in Oxford, sought to gain a better understanding of the natural progression of CMS and the different clinical phenotypes. This 2-year study recruited 50 patients and is currently being prepared for publication.

REPORT OF THE TRUSTEES

Research - continued

Professor Isabel Leite (Oxford) - *COVID-19 Vaccine Response in Myasthenia Gravis Patients:*

The funding agreement for this project has now been signed by Oxford University and countersigned by the myaware CEO. Recruitment for an appropriate researcher to undertake this work is underway.

Professor Isabel Leite (Oxford) - *Maternal acetylcholine receptor antibody-associated neonatal disorders: frequency and mechanisms:*

This clinical fellowship is being undertaken by Dr Ezgi Bakiricioglu Duman and began in October 2024. Dr Duman has been developing her lab skills and familiarizing herself with the methodologies that will be used for the duration of the DPhil project. These methods include live cell-based assay, radioimmunoassay, and flow cytometry. This is in preparation for the arrival of serum samples from pregnant women with clinical information for their offspring of up to two years of age. It is also planned that Dr Duman will collect serum samples from pregnant mothers with myasthenia gravis at John Radcliffe Hospital to begin characterisation.

Dr Adam Handel (Oxford) – M*yArchive: an irreplaceable resource for myasthenia gravis research:*

Emeritus Professor Nick Willcox built up a store of approximately 6,000 blood and tissue samples from over 2,000 people with myasthenia gravis dating back to 1980. These samples held at the University of Oxford are an irreplaceable and unique resource, which could help provide insight into why people develop myasthenia gravis and how those people respond to treatments.

MyArchive is a proposed method to safeguard the legacy of the donors and make sure that these samples are used in the best possible way to advance research into myasthenia. MyArchive provides access to these samples to research groups who can help to answer key research questions about disease mechanisms and their trends over time.

A panel of researchers based in Oxford coordinates the supply of MyArchive samples to a wide collaborative network to ensure that individual donor's samples are used for those experiments most likely to lead to breakthroughs in our understanding or treatment of myasthenia. MyArchive also promotes and enables excellence in research to best inform people with myasthenia about their condition and identify possible new treatments for the future.

Supporting MyArchive has enabled researchers around the world to benefit from access to an irreplaceable archive of tissues from people with myasthenia.

This has clear benefits to people with myasthenia gravis, since the diverse research projects that would be possible with MyArchive have both basic immunological and translational impact on the care of people with myasthenia gravis. It is likely that these research avenues will cast light on the causes and potentially identify new targets for treatment avenues in myasthenia.

Myaware also honours the legacy of those people with myasthenia gravis, who so kindly donated samples to Emeritus Professor Nick Willcox's team since 1980, and so supporting this archive ensures that their samples are best used to help research in myasthenia gravis.

REPORT OF THE TRUSTEES

Research - continued

MyArchive is now live at the University of Oxford website:
https://www.ndcn.ox.ac.uk/research/myarchive

Dr Nicholas Jones (Swansea) – *Interrogating the contribution of adaptive immunometabolism in myasthenia gravis:*

This collaborative project between the University of Swansea and The George Washington University in Washington DC, USA, looks to examine the roll of immune-cell metabolism in myasthenia gravis. Dr Jones' group in Swansea is looking to confirm their hypothesis surrounding targets for potential new treatments for myasthenia gravis that focus on immune-cell metabolism. At present, thirteen samples from myasthenia gravis patients have been received in Swansea after being sent over from Washington. These samples have been run through a substantially optimised flow cytometry panel and the data is in the process of being analysed. It is hoped that this data will identify further therapeutic targets for myasthenia gravis.

Dr Sithara Ramdas (Oxford) – *Future Management of Congenital Myasthenia Syndromes:*

This project looks to tackle delay in diagnosis for patients with congenital myasthenia syndromes (CMS) who present symptoms at birth. This delay can potentially result in death in severe cases and in others the inability to perform day to day activities, affecting their education, careers, and overall physical and mental wellbeing.

Dr Ramdas is looking to develop a pathway to help predict the likely type of CMS in a baby identified through newborn screening. This will help the medical teams manage these patients and apply the appropriate treatment strategy. Dr Ramdas has so far completed analysis of 252 patients from the Oxford CMS database focusing on age of onset and symptoms of onset, delineating those with onset under 2 years of age against over 10 years and over 18 years.

In addition to this, a pilot study will be undertaken to assess if a wearable device will help measure fatigable weakness in CMS patients, which could prove to be a crucial and premier outcome measure for CMS. This is currently in the early stages of design and planning.

Lastly, Dr Ramdas will look at the impact of CMS and disease burden, including economic impact, for CMS patients and their families. This will be crucial information to have for regulatory authorities as they review the cost effectiveness of new treatments and will be part of decision making on including CMS as part of routine national newborn screening programmes in the future. Five questionnaires focusing on quality of life and economic costs will be released to collect this data and approval has been granted by the hospital governance team.

Support - Nurses

Imperial College Healthcare NHS Trust - Development of an MG thymic subspecialist AHP/nurse:

This project aims to introduce an Allied Health Professional (AHP) that focuses on post-operative care of thymoma and thymic hyperplasia patients, assisting with the development of a dedicated thymic Multidisciplinary Team in collaboration with Oxford. This dedicated role aims to improve patient care, minimise complications and reduce length of stay, as well as assist with long term follow up procedures.

REPORT OF THE TRUSTEES

Support – Nurses - continued

University Hospitals Birmingham - Additional specialist nursing support:

Myaware are helping to fund a new part time specialist nurse at University Hospitals Birmingham. It is hoped that by increasing the specialist nurses resource that this Trust will be able to support with monitoring Rituximab patients and assist with the implementation of a telephone service for patients.

Salford Royal Hospital, Manchester - Expanding myasthenia care and specialist nurse service:

This grant will enable the establishment of a helpline for myasthenia patients to access nursing support, create a new immunosuppression initiation clinic, providing dedicated support for patients with questions or who are new to this type of treatment and require blood monitoring. The team at Salford will also use this funding to provide support for patients who are admitted to hospital due to fluctuations or crisis in their myasthenia and provide increased emotional and social support.

St George's NHS Foundation Trust / Southwest London ICB / Surrey Heartlands ICB – Myasthenia Specialist Nurse:

This funding ensures the continuation of the current specialist nurse, who supports patients in Southwest London and Surrey and the administration of novel therapeutics at St George's. The myasthenia gravis nurse will act as a point of contact for patients including for relapsing patients which will enable a responsive MG service and rapid assessment and treatment of deteriorating patients.

Working across Southwest London and Surrey, including multiple Trusts and a large geography, the specialist nurse will ensure equity of access to specialist myasthenia care, irrespective of who is seeing the patient in a general neurology service. The specialist nurse will ensure a safe introduction of disease modifying drugs and close blood monitoring in the initial treatment stage and therefore improve patient safety.

With this support, they will be able to counsel patients on side effects of treatments including steroids or steroid sparing agents. Finally, they will accelerate the workup and therefore access of patients to novel disease modifying therapies.

King's College Hospital NHS Foundation Trust - Training for in-post specialist nurse

Myaware have provided funding to further the training of an in-post specialist nurse at King's College hospital. The specialist nurse will attend two courses that will cover essential topics such as systemic and structured history-taking assessment and physical examination skills. They will also pursue a course in non-medical prescribing which will also further benefit not only the specialist nurse but their patients.

Partnerships

The research and partnerships manager has continued to engage with external stakeholders, providing insight into educational projects with the Neurology Academy, sitting on the national myasthenia gravis steering group with the Health Innovation Network, and collaborating where appropriate with pharmaceutical companies to elevate the patient voice and unmet needs of the community.

REPORT OF THE TRUSTEES

Partnerships - continued

The research and partnerships manager has delivered an engaging workshop at MG: Connects in Birmingham, partnering with clinical staff around the country to identify better ways the charity can work alongside healthcare professionals. This meeting identified the need to share our patient packs with clinical staff so that myaware resources can be better integrated into the treatment pathway for myasthenia patients around the country.

There has been a successful application for funding from external partner UCB (£41,620.12) which cover the costs of attendance at both Pulse: Live events this coming year, in Newcastle and Glasgow. This funding will also go towards supporting our welfare and support services, ordering merchandise for myasthenia awareness month, and providing an update to our website. Additionally, these activities are also supported by funding from Merck (£17,824) received in the 2025/26 financial year.

Awareness

Raising awareness of myasthenia and related conditions remains a central pillar of myaware's mission. Throughout the year, we have continued to champion greater understanding of myasthenia among healthcare professionals, patients, carers, and the wider public.

Our team has actively participated in a range of national and international events, including the London UCB Patient Day, the EuMGA Summit in Amsterdam, the Association of British Neurologists (ABN) Conference, the NEC, the RCGP Event in Liverpool, and the BJGP Conference. These opportunities have enabled us to share the experiences of those living with myasthenia, promote the latest research, and strengthen relationships with clinicians, researchers, and industry partners.

We have also maintained a strong digital presence, with our website and social media channels providing accessible, up-to-date information to a growing audience. Over 118,000 people visited the myaware website this year, with our online resources and support groups continuing to play a vital role in connecting individuals and families affected by myasthenia. Our printed materials, including booklets and leaflets, remain in high demand among both patients and healthcare professionals.

In addition, myaware has continued to represent the myasthenia community through membership of umbrella organisations such as the UK Neurological Alliances, Rare Disease UK, and National Voices. We have supplied information packs for clinicians across the UK and provided targeted resources for both members and the general public.

Our awareness initiatives are supported by the dedication of our staff, volunteers, and partners, whose efforts ensure that myasthenia remains visible and understood within the healthcare sector and beyond. We are grateful for the continued support that enables us to advocate for improved care, earlier diagnosis, and better outcomes for everyone affected by myasthenia.

REPORT OF THE TRUSTEES

Review of Income Activities



The Fundraising department recruited a full time Events Fundraiser (in post from October 2024) and a part time Community Fundraiser (in post from September 2024) the positive results of which have begun to show in the 2024~2025 income. Despite the ongoing external challenges of the cost-of-living crisis, we are incredibly grateful to all those who were able to continue to support myaware.

- During the year we were grateful to 9 people who remembered myaware in their wills. Restricted bequests totalled £1,000, and unrestricted bequests totalled £39,034.18.
- Donations have increased by 8.8% since last year to £94,618
- Corporate donations and affinity programmes have raised £8,663 during the period.
- We received £53,270 from trusts and grant giving organisations this year. An increase of 43% since last year. One of the donations for £41,620 was received from the UCB UK biopharmaceutical company as a restricted grant. Other donations ranged from £50 to £2,000.
- Income received via events increased by 124% on the previous year and totalled £92,955. This can be seen as a direct result of a dedicated part time Community Fundraiser and a full time Events Fundraiser being in post from September and October 2024 respectively.
- During this financial year myaware received £49,971 in In Memoriam donations and we are extremely grateful to those who have chosen to remember their loved ones by donating to myaware.
- Our quarterly fundraising appeals have been well received and have increased in income by 65.5% on the previous year to £19,498.

REPORT OF THE TRUSTEES

Impact and Value

Myasthenia means muscle weakness. It affects the muscles that allow voluntary movement, but not the automatic ones like the heart. In myasthenia, the brain's signals to the muscles are disrupted, making everyday activities such as walking, smiling, and talking extremely challenging. When swallowing and breathing are affected, it can become a medical emergency.

Myaware is dedicated to providing accessible support services and reliable information to everyone diagnosed with myasthenia. Recent research now estimates that around 20,000 people in the UK are living with myasthenia, a significant increase from previous figures. As of April 2025, myaware supports nearly 19% of those diagnosed, with active membership rising by 37.95% this year to 3,788 members. Our aim is to continue raising awareness so that everyone diagnosed can access the support they need to live well with myasthenia.

A myasthenia diagnosis can be life-changing. Myaware strives to make life easier for people with myasthenia and their families by:

Accessible information and support online, by telephone, or via email:

- 38 online Zoom support sessions delivered this year, providing information, advice, and peer connection.
- Three national webinars, including sessions led by specialist nurses and researchers.
- Six secure, closed Facebook groups, including groups for Congenital Myasthenic Syndromes (CMS), Lambert-Eaton Myasthenic Syndromes (LEMS), carers, and young people, providing 24/7 peer support.
- National Facebook, Twitter, and Instagram pages offering information and signposting.
- Telephone and email support available Monday to Friday, 9am–5pm, via our dedicated support and head office teams.
- Benefits and Welfare advice service, with 615 enquiries supported this year, a 70% increase from last year.
- Comprehensive online information for people living with myasthenia, their families, and healthcare professionals via our website, which saw over 118,000 visitors and 1.1 million interactions this year.

Increased awareness among the public and healthcare professionals:

- A comprehensive website offering accessible information on all aspects of living with myasthenia.
- A range of detailed booklets and leaflets, including resources for rarer myasthenia conditions and for healthcare professionals.
- Newly diagnosed information packs sent to all new members.
- Clinic awareness packs for GP surgeries, neurology clinics, dentists, opticians, and pharmacies.
- Representation of our members' needs at the Neurological Alliance, Rare Disease UK, National Voices, and the annual MG Connects meeting for neurologists.

Commitment to research and clinical training:

- Responsible funding of research projects in the areas of cause, cure, prevention, treatment, and quality of life.
- Support for the training of clinicians in the field of myasthenia.
- Transparent communication of research outcomes and opportunities to members and stakeholders.

REPORT OF THE TRUSTEES

FUTURE DEVELOPMENTS, AMBITIONS AND LONG-TERM STRATAGIES

As demand for our support continues to grow, myaware is committed to making every penny count and finding fresh, imaginative ways to connect with and support our community. We're focused on building a future where no one affected by myasthenia feels alone or unheard.

Since the pandemic, we've embraced a digitally connected support model, allowing us to reach people wherever they are. Through Zoom, social media, phone, and email, our national support team has been able to offer help, guidance, and community to more individuals than ever before.

Listening to our members is at the heart of everything we do. Our annual member survey, along with quick polls and feedback forms on social media, help shape the services we offer. We're also introducing new ways for people to share their experiences, including short "How did we do?" questionnaires, so we can keep improving and responding to real needs.

We're investing in our website to make it more intuitive, accessible, and informative, ensuring that vital resources are easy to find and available to everyone, including those with additional accessibility needs. This includes ongoing improvements to digital tools that make our content more inclusive.

Looking ahead, we're excited to deepen our relationships with healthcare professionals to help improve diagnosis and treatment pathways. We'll continue to represent our members at national forums such as the Neurological Alliance and Rare Disease UK, ensuring that the voices of people with myasthenia are heard where it matters most.

We remain deeply committed to using our restricted research funding responsibly, supporting projects that explore the causes, treatments, and potential cures for myasthenia, and ultimately, improving the quality of life for everyone affected.

Finally, we continue to uphold the highest standards in data protection, ensuring full compliance with the UK General Data Protection Regulation (2018). You can read our privacy policy here: https://www.myaware.org/privacy-policy

REPORT OF THE TRUSTEES

REFERENCE AND ADMINISTRATIVE DETAILS

Myaware is Company Limited by Guarantee.

Registered Company Number in England and Wales: 3038358

Registered Charity Number in England and Wales: 1046443

Registered Charity Number in Scotland: SC044744

Registered Office
Myaware
The College Business Centre
Uttoxeter New Road
Derby
DE22 3WZ

Auditors
Johnson Tidsall Limited
Chartered Accountants
81 Burton Road
Derby
DE1 1TJ

Solicitors
Ellis-Fermor & Negus
2 Devonshire Avenue
Beeston
Nottingham
NG9 1BS

Bankers
Virgin Money
11 Smithy Row
Nottingham
NG1 3EJ

Interim Chief Executive Officer
Marc Smith (appointed 30.06.2025)

Trustees
Trevor Ranson – Chair
Andrew Robinson – Treasurer
Professor Bethan Peach
Jon Rio
Professor Saiju Jacob
Rashmi Rungta
Claire Wen
Sara Jones (appointed 08.05.2024)
Tony Ferrari (resigned 08.07.2024)
Dr Channa Hewamadduma (appointed 24.07.2024)
Penny Henrion (resigned 15.02.2025)
Dr Fiona Norwood (resigned 05.06.2025)
Dr Katy Dodd (appointed 25.07.2025)

More information regarding the Trustees can be found at:

https://www.myaware.org/pages/faqs/category/meet-the-board

REPORT OF THE TRUSTEES

STRUCTURE, GOVERNANCE & MANAGEMENT

Myaware is a company limited by guarantee, incorporated on 27th March 1995 (number 3038358), a registered charity in England and Wales (number 1046443) and a charity registered in Scotland (number SC044744). It is governed by its Memorandum and Articles of Association adopted on 27th March 1995 and amended on 29th March 2018.

Subject to the provisions of the Companies Act 2006, the articles and to any directions given by special resolution, the business of the Company is managed by the trustees who may exercise all the powers of the Company. No alteration of the articles and no such direction shall invalidate any prior act of the trustees which would have been valid if that alteration had not been made or that direction had not been given. The powers given by this article and a meeting of trustees at which a quorum is present may exercise all the powers exercisable by the trustees.

The pay and remuneration of the senior managers of myaware is considered annually by the trustees. The board of Trustees meets during the budget setting process to review salary levels, increment payments and inflation rises. The Trustees consider benchmark information relating to similar posts in similar organisations within the charity sector to assist with their decision. We continue to work in partnership with other organisations with shared interest, including Neurological Alliance and Rare Disease UK.

Fundraising and data protection

Myaware operates within a strict fundraising policy and never uses telephone cold-calling; purchase address lists to write unsolicited letters, share the membership list to third parties or use any other methods or approaches that may be deemed as harassing or pressurising the recipient. We always respect the privacy of those who share their personal information with us.

Recruitment, appointment, induction and training of new Trustees

Only members of the charity may become Trustees.

The Articles of Association allow the Trustees to appoint candidates to become a Trustee (and Director), either to fill a vacancy, or to strengthen the Board. Candidates become known to the Board through personal knowledge or research of existing Trustees, by interested members of the organisation volunteering their services or, occasionally, as a result of advertising by the Board. Before appointing a new Trustee, the Board will consider any perceived weaknesses in the current Board in terms of special abilities or experience which they believe to be lacking. A potential candidate will then be approached by the Chair. Where possible the candidate will be invited to attend one or more meetings of the Board as a nonvoting observer. The candidate may then be appointed as a Trustee by a formal motion of the Board.

The Chair takes care to ensure that new Trustees receive personal guidance on their responsibilities under the Charity's Articles, and Charity and Company law. They may also seek advice and assistance from the Treasurer and the other members of the Board.

A formal Trustee induction programme is currently being developed by the Interim Chief Executive Officer and the Senior Management Team.

REPORT OF THE TRUSTEES

Myaware Sub-committees

Medical Committee:
Professor Bethan Peach
Professor Saiju Jacob
Charlotte Campbell – Research & Partnerships Manager
Dr Channa Hewamadduma (appointed July 2024)
Sarah Cuthell (resigned July 2024)
Dr Heidi Harrison (appointed July 2024 and resigned January 2025)
Penny Henrion (resigned February 2025)
Dr Fiona Norwood (resigned June 2025)
Dr Katy Dodd (appointed July 2025)
Marc Smith – Interim Chief Executive Officer (appointed July 2025)

Finance Committee:
Andrew Robinson – Treasurer
Jon Rio
Rashmi Rungta
Jamie Caple – Accounts & Compliance Manager
Sarah Cuthell (resigned July 2024)
Dr Heidi Harrison (appointed July 2024 and resigned January 2025)
Marc Smith – Interim Chief Executive Officer (appointed July 2025)

The Chief Executive Officer (CEO) is appointed by the Trustees to manage the day-to-day operations of the charity. The CEO reports to the Chair as their line manager.

Risk Management

The organisation conducts an annual risk review to assess and manage potential threats to its operations and objectives. The 2024-25 review was carried out in June 2024 by a committee of Trustees. A further review took place in September 2025, led by the Interim CEO and the Senior Management Team, focusing on major risks across the charity. As a result of these assessments, systems and procedures have been implemented to effectively manage identified risks.

An annual budget proposal, outlining projected income and expenditure, is prepared by the CEO in collaboration with the Finance Committee and submitted to the Trustees for approval. Once agreed, this budget forms the basis for the charity's financial reserves, ensuring that ongoing commitments can be met.

Performance against the approved budget is monitored monthly by the Finance Committee and reviewed quarterly by the full Board. Any significant variances are considered by the Board, and where necessary, adjustments are made to mitigate financial or operational risks.

REPORT OF THE TRUSTEES

Financial Review

Financial Position

The organisation reported a total net deficit of £615,093 compared with a total net surplus of £130,370 in the previous year.

Unrestricted funds decreased by £374,522 to £1,426,942

Restricted funds decreased by £240,571 to £98,915

Incoming Resources

Total incoming resources for the year were £449,135 down by £729,265 from the previous year.

This year we received £184,623 in donations, of which £40,034 relates to legacy gifts. We received £1,980 in restricted funds.

Income from other trading activities increased by £63,747 to £183,483.

Investment income has decreased by £5,393 to £81,029.

Resources Expended

Total resources expended decreased by £14,047 to £1,054,088.

Research costs were decreased by £206,530 on previous year to £195,878 of which £117,229 was restricted.

Support costs were increased by £179,951 on previous year to £725,425 of which £171,652 was restricted.

Awareness costs increased by £13,496 to £121,094 of which £9,731 was restricted.

Fundraising costs were decreased by £964 to £11,691.

Total funds stand as £1,525,857 compared with £2,140,950 last year.

Funds at the year-end were made up of unrestricted funds of £1,426,942 (2024: £1,801,464) and restricted funds of £98,915 (2024: £339,486).

The reported deficit reflects a year of reduced legacy income compared to last year, which had significantly boosted the overall financial result in that year. While overall income declined, core donation levels have shown a modest increase when legacy gifts are excluded, and other trading activity continues to grow.

Restricted expenditure remained high, demonstrating the charity's commitment to delivering on donor intent and ensuring that designated funds are used appropriately. The scale of the deficit highlights the need for continued focus on income generation and cost control going forward.

REPORT OF THE TRUSTEES

Contingent Asset

During the year, the charity remained in contact with the solicitor managing a significant legacy, for which myaware is the sole beneficiary of the residual estate. As in the previous year, the Trustees have been unable to obtain a reliable estimate of the amount due. Accordingly, the legacy continues to be treated as a contingent asset. Further details are provided in note 23 on page 46 of these financial statements.

Reserves Policy

Reserves are held to ensure that planned and committed expenditure over the next five years can be met. Unrestricted funds not invested in tangible and intangible fixed assets (the free reserves) are held to meet a minimum of twelve months budgeted expenditure and to enable the charity to fulfil its planned and committed expenditure over the next five years which are not covered by restricted funds.

As of 31st March 2025, the 12 month's budgeted unrestricted expenditure equates to £896,760 and the free reserves, which amount to £1,377,748 leaving a surplus of £480,988 available for future expenditure. The surplus reflects legacies bequeathed. The charity cannot predict its legacy income year on year, and this can vary significantly. The surplus on funds generated is helping to fund our current year.

Going Concern

The Trustees have set a realistic budget for 2025/26, forecasting a net deficit of £474,433 on unrestricted funds. This reflects inflationary cost increases across core activities and a cautious assumption of no legacy income during the year.

Despite the projected deficit, going concern is not considered an issue. The charity continues to operate within its reserves policy, and the Trustees monitor liquidity on a monthly basis. The surplus of unrestricted funds provides a buffer to support operations, and on this basis, the Trustees consider the going concern basis for the preparation of these financial statements to be appropriate.

Principal Funding Sources

The charity benefitted during the year from a number of generous legacies amounting in total to £40,034.

Donations amounted to £94,618. Events fundraising generated £92,955 and In Memoriam donations raised £49,971.

Investment Policy and Objectives

Trustees agree on investments in compliance with the Articles of Association. The return on investment for the year was 4.3% (2024: 4.1%). If the change in value of investments is included, the return is 3.8% (2024: 5.1%). Note that these figures do not include interest earned on bank current accounts – such interest is identified in a line item in the notes to the accounts. The Trustees consider these results to be satisfactory in the current investment climate but aim to keep this under regular review.

REPORT OF THE TRUSTEES

Statement of Trustee Responsibilities

The Trustees (who are also the directors of myaware Company Limited by Guarantee for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with the applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland.

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application resources, including the income and expenditure of the charitable company for that period. In preparing those financial statements, the trustees are required to:

- Select suitable accounting policies and they apply them consistently.
- Observe the methods and principles in the Charity SORP.
- Make judgements and estimates that are reasonable and prudent.
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006, The Charities and Trustees Investment Act (Scotland) 2005 and The Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

- There is no relevant audit information of which the charitable company's auditors are unaware; and
- The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

The report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

ON BEHALF OF THE BOARD:

Mr Trevor Ranson, Chair of the Board of Trustees

DATE: 22 October 2025

REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES AND MEMBERS OF MYAWARE

Opinion

We have audited the financial statements of Myaware Company Limited by Guarantee (the 'charitable company') for the year ended 31 March 2025 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 March 2025 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and Regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Report of the Trustees for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Trustees has been prepared in accordance with applicable legal requirements.

REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES AND MEMBERS OF MYAWARE

Matters on which we are required to report by exception
In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees.

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) requires us to report to you if, in our opinion:

- adequate and proper accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to take advantage of the small companies exemption from the requirement to prepare a Strategic Report or in preparing the Report of the Trustees.

Responsibilities of trustees
As explained more fully in the Statement of Trustees' Responsibilities, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

In identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

-The nature and control environment of the charitable company

-Our discussions with management and governance including whether they had knowledge of any actual, suspected or alleged fraud

-The internal controls to mitigate the risks of fraud

Following our review, we have identified the following areas which are deemed to have the highest potential for fraud or material misstatement within the financial statements:

- The timing of revenue recognition
- The evaluation of estimates in respect of legacies
- The correct identification of restricted funds
- The timing and recognition of committed expenditure
- The risk of management override

We also considered any laws and regulations that were central to the operation of the charitable company including company law, charity law, employment law and health and safety.

The following procedures were undertaken in respect of the risks where we identified the potential for material misstatement:

Income from donations and legacies was considered a risk due to the volume and nature of these transactions. Income may be pledged but there may be a timing difference between commitment and receipt. The overall income of the charitable company could be materially understated.

Income transaction testing was performed to ensure completeness of income. Post year end donations and legacies were reviewed to ensure that income was recognised in the correct accounting period in accordance with the charitable company's accounting policy.

In respect of legacies, we also tested the accuracy of estimates by reviewing correspondence obtained from solicitors and executors which included the wills and statements of assets and liabilities of the deceased person's estate and where possible agreed to receipts after date.

Restricted funds in respect of income were tested to donor correspondence to ensure that the restrictions imposed were adhered to by the charitable company in expending those funds. This included vouching a sample of expenditure. In addition, we tested unrestricted income mindful of any non-recognition of restricted funds.

The testing of committed expenditure in relation to grants awarded by the charitable company in respect of research was tested by obtaining copies of the formal grant offer and agreeing the terms to the creditor provision in the financial statements. Trustees' board meeting minutes were reviewed, and all commitments noted in the year were agreed to the financial statements to ensure completeness.

A sample of journal entries were tested for appropriateness and enquiries made of management as to the procedures in place for posting journal entries. During our audit we considered any large, unusual journals or transactions outside the normal course of business which were highlighted as a result of our testing.

We reviewed the minutes of trustees' board meetings and controls put in place by the board of trustees including a review of their risk assessment.

At the planning stage we discussed with management any laws and regulations which were central to the operation of the charitable company.

The financial statements were reviewed alongside our disclosure checklists to identify any unusual or unexpected relationships or any areas of non-compliance. Discussions were held with management where it was considered additional disclosures were required.

We remained alert to any indications of fraud, material misstatement or non-compliance with laws and regulations throughout the audit including those relating to the financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report
This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and the trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

David Mellor FCA (Senior Statutory Auditor)
for and on behalf of Johnson Tidsall Limited
Chartered Accountants
& Statutory Auditor
Eligible to act as an auditor in terms of Section 1212 of the Companies Act 2006
81 Burton Road
Derby
Derbyshire
DE1 1TJ

Date: 22/10/2025

MYAWARE

STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING AN INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 MARCH 2025

	Notes	Unrestricted fund £	Restricted funds £	2025 Total funds £	2024 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	3	**182,643**	**1,980**	**184,623**	972,242
Other trading activities	4	**126,352**	**57,131**	**183,483**	119,736
Investment income	5	**81,029**	**-**	**81,029**	86,422
Total		**390,024**	**59,111**	**449,135**	1,178,400
EXPENDITURE ON					
Raising funds	6	**10,621**	**1,070**	**11,691**	12,655
Charitable activities	7				
Research		**78,649**	**117,229**	**195,878**	402,408
Support		**553,773**	**171,652**	**725,425**	545,474
Awareness		**111,363**	**9,731**	**121,094**	107,598
Total		**754,406**	**299,682**	**1,054,088**	1,068,135
Net gains on investments		**(10,140)**	**-**	**(10,140)**	20,105
NET INCOME/(EXPENDITURE)		**(374,522)**	**(240,571)**	**(615,093)**	130,370
RECONCILIATION OF FUNDS					
Total funds brought forward		**1,801,464**	**339,486**	**2,140,950**	2,010,580
TOTAL FUNDS CARRIED FORWARD		**1,426,942**	**98,915**	**1,525,857**	2,140,950

The notes form part of these financial statements

MYAWARE
COMPANY NUMBER 3038358
BALANCE SHEET
31 MARCH 2025

	Notes	Unrestricted fund £	Restricted funds £	**2025 Total funds £**	2024 Total funds £
FIXED ASSETS					
Intangible assets	14	-	-	-	-
Tangible assets	15	**6,216**	-	**6,216**	1,501
Investments	16	**231,239**	-	**231,239**	241,379
		237,455	-	**237,455**	242,880
CURRENT ASSETS					
Stocks	17	**2,604**	-	**2,604**	4,162
Debtors	18	**618,661**	-	**618,661**	838,534
Cash at bank and in hand		**580,746**	**638,048**	**1,218,794**	1,596,255
		1,202,011	**638,048**	**1,840,059**	2,438,951
CREDITORS					
Amounts falling due within one year	19	**(12,524)**	**(302,321)**	**(314,845)**	(237,449)
NET CURRENT ASSETS		**1,189,487**	**335,727**	**1,525,214**	2,201,502
TOTAL ASSETS LESS CURRENT LIABILITIES		**1,426,942**	**335,727**	**1,762,669**	2,444,382
CREDITORS					
Amounts falling due after more than one year	20	-	**(236,812)**	**(236,812)**	(303,432)
NET ASSETS		**1,426,942**	**98,915**	**1,525,857**	2,140,950
FUNDS	21				
Unrestricted funds				**1,426,942**	1,801,464
Restricted funds				**98,915**	339,486
TOTAL FUNDS				**1,525,857**	2,140,950

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies' regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 22 October 2025 and were signed on its behalf by:



Mr T Ranson - Chair

The notes form part of these financial statements

MYAWARE

CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 MARCH 2025

	Notes	2025 £	2024 £
Cash flows from operating activities			
Cash generated from operations	1	**(451,548)**	(522,431)
Net cash used in operating activities		**(451,548)**	(522,431)
Cash flows from investing activities			
Purchase of tangible fixed assets		**(6,942)**	(2,000)
Interest received		**81,029**	86,422
Net cash provided by investing activities		**74,087**	84,422
Change in cash and cash equivalents in the reporting period		**(377,461)**	(438,009)
Cash and cash equivalents at the beginning of the reporting period		**1,596,255**	2,034,264
Cash and cash equivalents at the end of the reporting period		**1,218,794**	1,596,255

The notes form part of these financial statements

NOTES TO THE CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 MARCH 2025

1. RECONCILIATION OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2025 £	2024 £
Net income/(expenditure) for the reporting period (as per the Statement of Financial Activities)	**(615,093)**	130,370
Adjustments for:		
Depreciation charges	**2,227**	5,264
(Gain)/losses on investments	**10,140**	(20,105)
Interest received	**(81,029)**	(86,422)
(Increase)/decrease in stocks	**1,558**	(676)
(Increase)/decrease in debtors	**219,873**	(721,827)
Increase/(decrease) in creditors	**10,776**	170,965
Net cash used in operations	**(451,548)**	(522,431)

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1/4/24 £	Cash flow £	At 31/3/25 £
Net cash			
Cash at bank and in hand	1,596,255	(377,461)	1,218,794
	1,596,255	(377,461)	1,218,794
Total	1,596,255	(377,461)	1,218,794

The notes form part of these financial statements

1. STATUTORY INFORMATION

Myaware is a charitable company, registered in England and Wales and Scotland. The charitable company's registered company number, registered charity numbers, registered office address and business address can be found in the reference and administrative details of the Report of the Trustees.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

The currency basis for the preparation of these financial statements is pound sterling (£).

Going concern
The trustees regularly monitor the charity's reserves policy and risk assessment. A realistic budget for 2025/26 has been prepared. Liquid funds and cash flow are monitored on a monthly basis. To date, no material uncertainties exist that would affect the preparation of the financial statements on a going concern basis.

Significant judgements and estimates
The following judgements (apart from those involving estimates) have been made in the process of applying the charitable company's accounting policies that have had the most significant effect on amounts recognised in the financial statements:

Legacies - when calculating amounts due on legacies, management considers the wills of the deceased, executors accounts and notifications received from executors. As at 31 March 2025 there is a legacy debtor, included in other debtors, of £569,280.

Grants - when calculating grant commitments, management considers the nature of the grants as being within the charity's objectives and the possible future benefits for people affected by myasthenia.

Income
All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received, and the amount can be measured reliably.

Donated services and goods are recognised as income when the charity has control over them, the economic benefit is probable and can be measured reliably. In accordance with the Charities SORP (FRS102), the volunteer time of Support Groups is not recognised. Information about their contribution is provided in the Trustees' Annual Report.

For donations to be recognised the charity will have been notified of the amounts and the settlement date. If there are conditions attached to the donation and this requires a level of performance before entitlement can be obtained, then income is deferred until those conditions are fully met or the fulfilment of those conditions is within the control of the charity, and it is probable that they will be fulfilled.

For legacies, entitlement is the earlier of the charity being notified of an impending distribution or the legacy being received. The income is recognised when the value of the legacy can be measured reliably.

Income from trading activities includes income earned from fundraising events and trading activities to raise funds for the charity. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred.

Investment income is earned through holding assets for investment purposes such as shares and bank deposit accounts. It includes dividends and interest. It is included when the amount can be measured reliably.

2. ACCOUNTING POLICIES - continued

Grants
Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the charity will comply with conditions attaching to them and the grants will be received using the accrual model.

Debtors
Other debtors are recognised at the settlement amount due. Prepayments are valued at the amount prepaid.

Expenditure
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Allocation and apportionment of support costs and governance
Resources expended are allocated to the particular activity where the cost relates directly to that activity. However, the cost of overall direction and administration on each activity, including the salary and overhead costs of the general office and regional staff, is apportioned on the following bases which are an estimate, based on staff time, of the amount attributable to each activity:

	Percentage allocation
Research	11%
Support	74%
Awareness	15%

Intangible fixed assets
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:

Computer software - over 3 years straight line

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 20% on cost
Computer equipment	- 33% on cost

Tangible fixed assets are stated at cost or deemed costs less accumulated depreciation. Cost includes costs directly attributable to making the asset capable of operating as intended.

Individual fixed assets costing £500 or more are capitalised at cost.

Investments
Investments are valued at market value which is deemed to be fair value. Movements in market value are reflected in the statement of financial activities as a net gain/(loss).

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Stock is valued on a first in first out basis.

Taxation
The charity is exempt from corporation tax on its charitable activities.

2. ACCOUNTING POLICIES - continued

Fund accounting
The charitable company has both restricted and unrestricted funds. All funds are used to benefit and promote its charitable objects.

Restricted funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose and the restriction means that the funds can only be used for specific projects or activities.

When donors specify that donations and grants are for particular purposes which do not amount to pre-conditions regarding entitlement, this income is included in incoming resources of restricted funds when receivable. The relevant expenditure is then matched as restricted expenditure.

Unrestricted funds are general funds that are available for use at the trustees' discretion in furtherance of any objectives of the charity.

Designated funds are unrestricted funds set aside at the discretion of the trustees for specific purposes.

Pension costs and other post-retirement benefits
The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Operating lease agreements
Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged to the SOFA on a straight line basis over the period of the lease.

Reserves
The charitable company maintains a level of reserves required to fulfil its objectives. The trustees monitor reserves at regular meetings.

Financial instruments
Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

3. DONATIONS AND LEGACIES

	2025	2024
	£	£
Donations	**94,618**	86,887
Legacies	**40,034**	856,054
In Memoriam	**49,971**	29,301
	184,623	972,242

The charity benefits greatly from the involvement of many helpers and volunteers, details of which are given in our annual report. In accordance with FRS102 and the Charities SORP (FRS102), the economic contribution of volunteers is not recognised in these financial statements.

4. OTHER TRADING ACTIVITIES

	2025	2024
	£	£
Affinity programmes	**1,119**	2,069
Appeals	**19,498**	11,782
Collections	**292**	2,825
Corporate	**7,544**	4,946
Grants	**41,620**	31,629
Lotteries	**5,081**	3,147
National events	**23,308**	15,063
Regional events	**69,647**	26,400
Sales of merchandise	**3,724**	4,375
Trusts	**11,650**	17,500
	183,483	119,736

5. INVESTMENT INCOME

	2025	2024
	£	£
Deposit account interest	**69,685**	76,693
Current account interest	**4,578**	3,234
Dividends on shares and other investments	**6,766**	6,495
	81,029	86,422

6. RAISING FUNDS

Raising donations and legacies

	2025	2024
	£	£
Merchandise	**5,129**	3,308
Events	**4,057**	6,454
Appeal mailings	**774**	1,331
Lottery	**1,731**	1,562
	11,691	12,655

7. CHARITABLE ACTIVITIES COSTS

	Direct Costs (see note 8)	Support costs (see note 9)	Totals
	£	£	£
Research	**176,422**	**19,456**	**195,878**
Support	**594,543**	**130,882**	**725,425**
Awareness	**94,564**	**26,530**	**121,094**
	865,529	**176,868**	**1,042,397**

8. DIRECT COSTS OF CHARITABLE ACTIVITIES

	2025	2024
	£	£
Staff costs	**563,161**	520,898
Medical research	**114,475**	317,424
Medical care	**157,331**	7,682
Travel and miscellaneous	**22,136**	28,626
MyNews & member communications	**5,884**	3,669
Meetings and conferences	**2,542**	1,094
	865,529	879,393

Grants payable during the year were as follows:

	2025	2024
	£	£
Commitments as at 1 April 2024	505,511	356,612
Commitments made in the year	259,123	316,970
Commitments released in the year	-	-
Grants paid during the year	(225,501)	(168,071)
Commitments as at 31 March 2025	539,133	505,511

9. SUPPORT COSTS

	Management	Governance costs	Totals
	£	£	£
Research	**17,384**	**2,072**	**19,456**
Support	**116,942**	**13,940**	**130,882**
Awareness	**23,704**	**2,826**	**26,530**
	158,030	**18,838**	**176,868**

Support costs, included in the above, are as follows:

Management

	Research	Support	Awareness	2025 Total activities	2024 Total activities
	£	£	£	£	£
Rental of premises	**1,653**	**11,123**	**2,255**	**15,031**	14,948
Utilities and insurance	**1,142**	**7,678**	**1,556**	**10,376**	18,391
Office equipment	**576**	**3,877**	**786**	**5,239**	2,793
Printing, postage and stationery	**973**	**6,543**	**1,326**	**8,842**	9,603
Photocopier costs	**81**	**546**	**111**	**738**	825
Support website	**2,974**	**20,008**	**4,056**	**27,038**	24,964
IT support & software	**5,697**	**38,325**	**7,769**	**51,791**	53,657
H R costs	**2,922**	**19,656**	**3,984**	**26,562**	19,281
General expenses	**995**	**6,692**	**1,356**	**9,043**	5,771
Bank charges	**126**	**846**	**171**	**1,143**	1,235
Amortisation of intangible fixed assets	**-**	**-**	**-**	**-**	3,023
Depreciation of tangible fixed assets	**245**	**1,648**	**334**	**2,227**	2,241
	17,384	**116,942**	**23,704**	**158,030**	156,732

9. SUPPORT COSTS - continued

Governance costs

	Research	Support	Awareness	2025 Total activities	2024 Total activities
	£	£	£	£	£
Trustees' expenses	**273**	**1,833**	**372**	**2,478**	4,537
Auditors' remuneration	**1,331**	**8,954**	**1,815**	**12,100**	8,810
Legal and professional fees	**468**	**3,153**	**639**	**4,260**	6,008
	2,072	**13,940**	**2,826**	**18,838**	19,355

10. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2025	2024
	£	£
Auditors' remuneration	**12,100**	8,810
Depreciation - owned assets	**2,227**	2,241
Computer software amortisation	**-**	3,023

11. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 March 2025 nor for the year ended 31 March 2024.

Trustees' expenses

	2025	2024
	£	£
Trustees' expenses	**2,478**	4,537

During the year 4 trustees (2024: 4) received reimbursement of their expenses for attending meetings totalling £911.

The charge for 2025 includes accommodation, meeting room hire and meals / refreshments for trustee meetings of £1,567 (2024: £1,277).

12. STAFF COSTS

	2025	2024
	£	£
Wages and salaries	**495,164**	456,502
Social security costs	**41,408**	37,158
Other pension costs	**26,589**	27,238
	563,161	520,898

The average number of full time equivalent employees during the year was 11 (2024:13).

The average monthly number of employees during the year was as follows:

	2025	2024
Fundraising, support and awareness	**13**	13
Management and operations of the charity	**5**	4
	18	17
Employees receiving emoluments in excess of £60,000.	1	1

The key management personnel of the charity comprises the Chief Executive Officer. The total employee benefits of the key management personnel of the charity amounted to £77,511 including pension contributions (2024: £74,658).

13. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund	Restricted funds	Total funds
	£	£	£
INCOME AND ENDOWMENTS FROM			
Donations and legacies	960,754	11,488	972,242
Other trading activities	93,679	26,057	119,736
Investment income	86,422	-	86,422
Total	1,140,855	37,545	1,178,400
EXPENDITURE ON			
Raising funds	12,655	-	12,655
Charitable activities			
Research	72,893	329,515	402,408
Support	518,476	26,998	545,474
Awareness	106,886	712	107,598
Total	710,910	357,225	1,068,135
Net gains on investments	20,105	-	20,105
NET INCOME/(EXPENDITURE)	450,050	(319,680)	130,370
RECONCILIATION OF FUNDS			
Total funds brought forward	1,351,414	659,166	2,010,580
TOTAL FUNDS CARRIED FORWARD	1,801,464	339,486	2,140,950

14. INTANGIBLE FIXED ASSETS

	Computer software £
COST	
At 1 April 2024	**95,007**
At 31 March 2025	**95,007**
AMORTISATION	
At 1 April 2024	**95,007**
Charge for year	-
Eliminated on disposal	-
At 31 March 2025	**95,007**
NET BOOK VALUE	
At 31 March 2025	-
At 31 March 2024	-

15. TANGIBLE FIXED ASSETS

	Fixtures and fittings £	Computer equipment £	Totals £
COST			
At 1 April 2024	**5,476**	**15,507**	**20,983**
Additions	-	**6,942**	**6,942**
Disposals	-	**(9,433)**	**(9,433)**
At 31 March 2025	**5,476**	**13,016**	**18,492**
DEPRECIATION			
At 1 April 2024	**5,476**	**14,006**	**19,482**
Charge for year	-	**2,227**	**2,227**
Eliminated on disposal	-	**(9,433)**	**(9,433)**
At 31 March 2025	**5,476**	**6,800**	**12,276**
NET BOOK VALUE			
At 31 March 2025	-	**6,216**	**6,216**
At 31 March 2024	-	1,501	1,501

16. FIXED ASSET INVESTMENTS

	Listed investments £
MARKET VALUE	
At 1 April 2024	**241,379**
Revaluations	**(10,140)**
At 31 March 2025	**231,239**
NET BOOK VALUE	
At 31 March 2025	**231,239**
At 31 March 2024	241,379

There were no investment assets outside the UK.

The historical cost of fixed asset investments as at 31 March 2025 was £89,858 (2024: £89,858).

17. STOCKS

	2025 £	2024 £
Finished goods	**2,604**	4,162

18. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025 £	2024 £
Other debtors	**579,917**	807,265
Prepayments and accrued income	**38,744**	31,270
	618,661	838,534

19. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025	2024
	£	£
Other creditors	1,063	26,007
Committed grants	302,321	202,079
Accruals and deferred income	11,461	9,363
	314,845	237,449

20. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

	2025	2024
	£	£
Committed grants	236,812	303,432

21. MOVEMENT IN FUNDS

	At 1/4/24	Net movement in funds	Transfers between funds	At 31/3/25
	£	£	£	£
Unrestricted funds				
General fund	1,801,464	(374,522)	-	1,426,942
Restricted funds				
Research	251,269	(208,454)	-	42,815
Support	67,141	(22,754)	-	44,387
Awareness	21,076	(9,363)	-	11,713
	339,486	(240,571)	-	98,915
TOTAL FUNDS	2,140,950	(615,093)	-	1,525,857

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Gains and losses	Movement in funds
	£	£	£	£
Unrestricted funds				
General fund	390,024	(754,406)	(10,140)	(374,522)
Restricted funds				
Research	10,168	(218,622)	-	(208,454)
Support	46,039	(68,793)	-	(22,754)
Awareness	2,904	(12,267)	-	(9,363)
	59,111	(299,682)	-	(240,571)
TOTAL FUNDS	449,135	(1,054,088)	(10,140)	(615,093)

21. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1/4/23 £	Net movement in funds £	Transfers between funds £	At 31/3/24 £
Unrestricted funds				
General fund	1,351,414	450,050	-	1,801,464
Restricted funds				
Research	563,262	(311,993)	-	251,269
Support	93,758	(26,617)	-	67,141
Awareness	2,146	18,930	-	21,076
	659,166	(319,680)	-	339,486
TOTAL FUNDS	2,010,580	130,370	-	2,140,950

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	1,140,855	(710,910)	20,105	450,050
Restricted funds				
Research	17,522	(329,515)	-	(311,993)
Support	381	(26,998)	-	(26,617)
Awareness	19,642	(712)	-	18,930
	37,545	(357,225)	-	(319,680)
TOTAL FUNDS	1,178,400	(1,068,135)	20,105	130,370

21. MOVEMENT IN FUNDS - continued

Restricted funds
Restricted funds comprise:

Research
Restricted funds in this class will be applied to:

a. Scientific and clinical research into the causes, disease mechanisms, diagnosis and epidemiology of Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndrome and other similar disorders of the Neuro-Muscular Junction.

b. The provision of equipment and facilities to support (a).

c. Provision of specialist medical facilities (including staff) where the Trustees consider that such provision has a significant impact on the effectiveness of (a).

Support
Restricted funds in this class will be applied to:

d. Development of new support groups of the charity, to foster the health and welfare of myasthenics and their families and carers.

e. Organisation of Regional Conferences to encourage mutual support between members, myasthenics, and support groups.

f. In exceptional circumstances - provision of specialist medical facilities (including staff) where the Trustees consider that such provision would have a major impact on the health and welfare of myasthenics, and alternative funding cannot be obtained.

Awareness
Restricted funds in this class will be applied to:

g. Preparation, publication and distribution of information about Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndrome and other similar disorders of the Neuro-Muscular Junction. (Including information on their causes, diagnosis and treatment, and issues concerning the lifestyle and quality-of-life of patients with these disorders). Publication and distribution includes development and maintenance of the association's internet websites.

h. Publicity and promotion of events to foster awareness, in the general public, national and local government, and other bodies, of these disorders, and the problems experienced by patients and their families and carers.

i. Activities to foster awareness in the medical profession of these disorders, and the problems experienced by patients and their families and carers.

j. Activities to foster awareness in the medical profession of the current state of best medical practice in the diagnosis and treatment of these disorders.

k. Regional and national events to disseminate information about these disorders to myasthenics, their families and carers (including information about current and planned future medical and scientific research).

For presentation purposes all restricted income receivable is allocated to one of the above three categories that best describes its restriction.

A detailed breakdown of the income and expenditure allocated to these categories is available on request.

22. EMPLOYEE BENEFIT OBLIGATIONS

The total contribution paid to Personal Pension Plans in the year for certain employees amounted to £24,661 (2024: £25,167).

23. CONTINGENT ASSET

In the previous financial year, the charity was notified of a significant unrestricted legacy of which myaware is the sole beneficiary of the residual estate. Probate was granted on 21 November 2023.

Initial reports indicated that the net estate at date of death amount to £6,953,855, with a residual value to the charity of around £3.5m. The residual value due to myaware is after specific bequests to beneficiaries including property and chattels which are granted free on inheritance tax.

The trustees recognise the charity's entitlement to the legacy but there is uncertainty as to the amount of payment due to myaware in respect of its residual interest in the estate. This uncertainty arises due to:

- No information has been received from the executors' solicitors regarding the expected value of the distribution which would provide us with a reasonable estimate of the residuary amount due to the charity.
- No distributions on account have been received to date.
- The estate at date of death includes a listed shares portfolio of around £5.3m. The timing of the realisation of this portfolio could have significant effect on the value to be distributed.

After due consideration, the trustees are of the opinion that the interest of the charity in this significant residual legacy cannot be measured reliably and therefore should be disclosed as a contingent asset until the criteria for income recognition are met.

24. OTHER FINANCIAL COMMITMENTS

At the year end the charity had financial commitments in respect of rent amounting to £15,764 (2024: £14,049) and other leases amounting to £5,280 (2024: £2,904).

25. RELATED PARTY DISCLOSURES

During the year, the charity did not pay any salary, benefits, or expense reimbursements to an employee who is the spouse of a trustee, of which there were none during the year (2024: £21,585).

26. ULTIMATE CONTROLLING PARTY

The charity is controlled by its Board of Trustees.

MYAWARE

England & Wales - Charity number 1046443

Accounts

myaware
Fighting Myasthenia Together

Myaware Report of the Trustees and Financial Statements for the Year Ended 31st March 2024



Myaware is a Registered Charity No. England & Wales 1046443. Scotland SC044744.
Company Limited by Guarantee No. 3038358 (England & Wales)

Contents

- Chair's Report 1
- CEO's Report 2
- Report of the Trustees 6
  - Objectives & Activities of the Charity 6
  - Achievement and Performance 7
  - Future Developments 14
  - Reference and Administrative Details 15
  - Structure Governance and Management 16
  - Financial Review 18
  - Statement of Trustees Responsibilities 21
- Report of the Independent Auditors 22
- Statement of Financial Activities 26
- Balance Sheet 27
- Cash Flow Statement 28
- Notes To the Cash Flow Statement 29
- Notes to the Financial Statements 30

Chair's Report - Trevor Ranson

At Myaware, we exist to work with everyone with a Myasthenia condition, their support networks and healthcare professionals to raise Myasthenia awareness and reduce time to diagnosis. We empower patients to navigate the UK healthcare system and obtain the best clinical outcomes possible and provide support to everyone with a Myasthenia condition. We fund evidence-based research to understand the origins and biology of Myasthenias, and use research to advance towards treatment, tests and cures - improving the everyday experience of people living with a Myasthenia condition. We achieve this vital work through the kindness and generosity of the community who support us and work with us to ensure all people with a Myasthenia condition can live well, now and in the future.

I would like to begin with the people at the heart of our work. The many people living with Myasthenia conditions we supported this year, who have in turn provided inspiration, motivation and insights from which we continue to learn from. They drive every aspect of our work and make everything worthwhile - Thank you.

This year we have continued to implement the new operational structure, in our move from a regional to a national support-service delivery model. Throughout the year, Myaware has provided a listening ear, delivering information and signposting to all our members via telephone, online support sessions and social media. Our welfare benefits and advice service remains popular, offering much needed financial and rights-based support. Alongside this, Myaware continues to champion, fund and value high-quality research via our partnership work with world-class academic institutions.

Our national model requires us to serve our membership community in a more innovative, collaborative and sustainable way. This year we have enhanced the use and development of our online systems, and we continue to integrate our financial and operational processes to ensure our infrastructure is as robust as possible. Every day we work with key stakeholders, including people living with Myasthenia conditions, specialist healthcare providers and industry partners to understand patient education gaps and address unmet needs, expand healthcare access, increase funding, and improve health policy reform through the inclusion of patient experience data.

I would like to say a big thank you to all our supporters who believe in us, choose to donate to us, fundraise for us, or remember us in their wills. And to our corporate partners, trusts and foundations, and the people who work for them. You enable us to do great work and offer your skills and expertise in kind - thank you. We deeply appreciate your trust, enthusiasm and support.

While this report talks about our work in 2023/2024, we cannot but reflect on these difficult times - the crisis in health and social care, the impact of the cost-of-living increases, and the lingering effect the coronavirus pandemic has had on people living with rare diseases. Such socio-economic and political events represent unprecedented challenges, and we continue to adapt to these changes.

With thanks from myself and the whole team at Myaware,

CEO's Report – Dr Heidi Harrison

Membership

Historic research publications have stated that there were approx. 12,000 people living with myasthenia in the UK. In December 2021 a research paper entitled Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019, written by Iain Carey was published outlining that this data is now estimated at 20,000 people in the UK.

Throughout 2024, Myaware's records showed that membership continued to grow steadily, reaching 2,750 members in March 2024. Over the year, Myaware was delighted to welcome hundreds of new members. Myaware appreciates that our members require the highest level of support at the beginning of and at crisis points in their Myasthenia journey and our active membership figures reflect this. Myaware began implementing lifetime memberships effective from January 2024 to ensure that members can continue to access information and support throughout their Myasthenia journey.







CEO's Report continued

Myaware national support services

Myaware members benefit from a range of online and telephone support and information services which guide individuals and their family members through diagnosis and beyond. Throughout 2023-24 Myaware continued to provide and enhance online services to ensure members had access to information, advice, and peer support. We have worked hard to implement the new national delivery model, with continued streamlining of services across the UK.

Online sessions and webinars

This year we successfully delivered weekly online support sessions, bringing our members together to discuss common issues and share valuable experiences. Our highly experienced National Support Co-ordinators and Benefits and Welfare Officer provided positive and empathetic updates regarding support, awareness and research, and imparted vital information on how to live well with Myasthenia. We also hosted our first webinars, a brand-new offer from Myaware. These webinars were presented by our Research and Partnerships Officer and Dr Katherine Dodd and facilitated by the Support Team. Myaware provides a combination of monthly online sessions for members who are new to the condition and to our organisation, along with Peer Support Sessions for our general membership, we also provide sessions specific to age and condition, with a new offer also introduced for carers encompassing welfare related topics. Our aim is to remove any sense of isolation by guiding members through the first few months of their diagnosis, and then keep members connected with others who may find themselves in a similar set of circumstances. We are delighted that over 1,030 members attended our online sessions this year and benefited from information and peer support.

> *"These are brilliant as the conversation is linked not just to MG but all other aspects that impact on MG. These sessions are imperative, online or in person."*

> *"Very interesting. I learnt a lot just by listening to others!"*

> *"Thank you for hosting this online session. It was very informative, and most importantly it made me feel less alone, as I try and learn how to navigate this condition."*

Peer support network and social media

Myaware facilitates and manages a variety of national social media closed groups, and this year we have connected over a thousand people living with Myasthenia and their family members. These groups provide a vital lifeline of peer support and a platform for Myaware to share updates and answer common questions. Our national peer support closed group caters for all members regardless of type of Myasthenia, age, or location. Our Myaware kids closed group is especially for parents of children who have been diagnosed with any form of Myasthenia, and our Young Generation closed group provided a platform for those aged between 18 and 39 where discussion can focus around education, employment or pregnancy and Myasthenia. And new this year, our much-needed closed group for carers.

> *"I have finally been officially diagnosed with CMS and I am in a bit of shock, it is bittersweet for sure... I am so grateful for the Myaware Facebook group, it has been such an encouragement."*

CEO's Report continued

Benefits and welfare advice service

The benefits system is complex, the rules can change, and when living with an unpredictable and sometimes debilitating condition like Myasthenia, it can be difficult to find the energy and time to fully research every opportunity to improve your quality of life. Myaware's dedicated Welfare Officer is here to help our members navigate the benefits system and check if they are entitled to any financial assistance, or support relating to transport, employment, or education.

This year Myaware has responded to 356 benefits and welfare enquiries. Amongst these were:

- Driving & Myasthenia enquiries
- Employment and Myasthenia enquiries
- Personal Independence Payment enquiries
- Attendance Allowance enquiries
- Blue Badge enquiries
- Appeals

Like all our support services this advice is available to all members in England, Scotland, Wales, and Northern Ireland. The service is provided by telephone (Monday-to Friday 9am-5pm), on the Myaware website, and via our online support sessions.

> *"You provided great assistance as ever and gave me confidence regarding upcoming PIP review."*
>
> *"Extremely helpful when I was applying for Attendance Allowance. Thank you so much."*
>
> *"More helpful than you could ever imagine, I just didn't know how to apply for help or even if I could."*

Telephone and email, support and information

Our dedicated Head Office and Support Teams are available to offer reassurance, advice and information. Whether members have a question they want answering or want to know more about Myaware objectives or services, our dedicated staff are here to help inform and guide members.

> *"It was lovely to speak to you last week, and to receive your very helpful email on Monday. Thank you so much, for taking the time to research the areas of concern that I have with the Ocular Myasthenia. It was very reassuring. Thank you to all of the team at Myaware, giving of your time to help Myasthenia patients like me. You are greatly appreciated."*

Emotional support service

People can have many reactions to Myasthenia, and for this reason our National Support Coordinators are here to listen and when needed can help point you to specialist support.

> *"Many thanks for your help and advice, it is massively appreciated. My sudden diagnosis and symptoms which have followed have been quite overwhelming and the information I've received from seeing neurologists about my MG had been limited - maybe in the most part being down to me not really knowing what to ask! The support I've received from Myaware and the help and advice from you all has been invaluable and made things a lot less daunting for me. Thanks again for everything. It's reassuring to know that with support from Myaware, there is help out there, and for me listening to others experiences in the support groups will be invaluable."*

CEO's Report continued

Myasthenia website, information, signposting and literary library

In an increasingly digital world, the Myaware website (found at www.myaware.org), is one of the most useful digital and communication tools the charity has. Our website exists to establish and maintain a relationship with the Myasthenia community, supporters, funders and the public. Our website helps us to provide information and advice, and deliver services to members, healthcare professionals, carers and a broad spectrum of stakeholders.

For those who prefer to learn about Myasthenia in print, Myaware provides a vast library of information booklets and leaflets aimed at different audiences, such as the:

- Myasthenia Gravis information leaflet
- LEMS information leaflet
- Health Care Professionals leaflet
- Ocular Myasthenia - a guide for medical professionals
- Ocular Myasthenia - a guide for patients
- Myasthenia and pregnancy factsheet
- Congenital Myasthenia - a guide for patients
- CMS Pregnancy leaflet - a guide for patients
- A variety of flyers promoting Myaware services

Myaware regularly provide large print version for members with visual impairments.

Together, the Myaware website and the charity's social media acts as a digital hub enabling us to share the fantastic stories of our members and how they have been empowered to understand their conditions, have greater say on the treatments and therapies available, and connect with other members who have Myasthenia related conditions via peer-to-peer support. Our website includes lots of helpful information including current research on Myasthenia, drugs to avoid, and places to find additional support. We also use our website to promote good news stories, fundraising events, and future online community sessions. The main objectives of the website are to provide advice and support for members and carers, to increase awareness in primary and acute medical audiences, as well as the general public, and to champion evidence-based research - enhancing medicines, surgical treatments and therapeutic interventions. In addition, users can access the charity's annual accounts, online shop, register for support events, and attain membership information. We urge anyone visiting our website to become a Myaware member, whether they have a Myasthenia diagnosis, are a relative, carer or a healthcare professional with an interest in the Myasthenias.

Our website operates the 'ReachDesk toolbar' which ensures visitors can access our content in a way that suits them best. Including text-to-speech, reading and translation support.

REPORT OF THE TRUSTEES

The Trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ending 31st March 2024 which are also prepared to meet requirements of the directors' reports and accounts for the Companies Act purposes.

The financial statements comply with the Charities Act 2011, The Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Articles of Association and Accounting and reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1st January 2019).

OBJECTIVES & ACTIVITIES OF THE CHARITY

We support people affected by Myasthenia and related conditions, raise awareness about the conditions and fund research to find new therapies to reduce their impact and ultimately find a cure.

We provide the following core support services:

- Telephone advice and information service.
- Support and information sessions delivered via online sessions covering research information, general support discussions and benefits and welfare advice.
- Monthly new members support sessions.
- Online sessions for condition type and age specific to support children up to the age of 18 and young people between the ages of 18 and 39.
- Information and support via the Myaware website.
- Our social media services include closed, secure groups for peer support for information and signposting.
- Welfare benefits and advice service.

We raise vital awareness of Myasthenia in the following ways:

- We represent our members via membership of umbrella organisations such as UK Neurological Alliances, Rare Disease UK and National Voices.
- Myaware provides specific information for our members and the general public via our website
- Myaware provides information packs for clinicians throughout the UK.

Myaware is committed to effectively and responsibly funding research projects in the following areas:

- Cause, cure, prevention, treatment and quality of life, in relation to Myasthenia and related conditions.
- Myaware is committed to training clinicians of the future in the field of Myasthenia.
- Myaware is committed to effectively communicating research project outcomes and future research opportunities with transparency to our members and general stake holders.

To support these aims we undertake a large variety of fundraising activities and as always are hugely grateful to the many people who have supported us with individual giving, community and event fundraising. As always, the challenge is to raise more unrestricted funds that can be used to finance the day to day running of the charity - postage, telephone, printing, online services and other core costs and we are particularly grateful to those who donate money that can be used in this way.

REPORT OF THE TRUSTEES

Grant making policy

The Charity may award grants to scientific research, specialist myasthenia nurses and training fellowships in support of its objective and activities.

Grants are awarded by the Board of Trustees when funds become available, and only when the reserves position of the charity mitigates the risk committing funds to projects running across several years.

Research grants are awarded following a rigorous peer review process under the control and supervision of the Myaware Medical Committee.

Public benefit

The charitable company has referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing its aims and objectives and in planning its future activities. In particular, the Trustees always consider how planned activities will contribute to the aims and objectives they have set.

ACHIEVEMENT AND PERFORMANCE

How we spend our money:

Support - £545,474

Research - £402,408

Awareness - £107,598

Fundraising - £12,655

REPORT OF THE TRUSTEES

Support of members

Our membership grew steadily during the financial year. Our data shows that we have welcomed hundreds of new members during the year, all of whom have received a 'newly diagnosed support pack'. This year we reviewed our membership renewal process and moved to lifetime membership, this will hopefully assist us in reaching and supporting more people affected by Myasthenia.

Newsletters continue to be sent to our members quarterly, providing news, support, encouragement and acknowledgement to those who have supported Myaware via donations and fundraising initiatives.

We continued to bring together specialist Myasthenia nurses from across the UK to facilitate the sharing of knowledge expertise across the sector.

In 2023, we introduced a carer only social media community group and online support sessions in recognition of the impact Myasthenia has on those with caring responsibilities. We facilitated our first sessions for carers and welcomed carer-members to this new support group.

We held our first Kids online sessions for parents of children with Myasthenia, this gave parents the opportunity to come together with other parents and share experiences and gain peer support from others in similar situations.

Myaware provided several online support sessions focused on Congenital Myasthenic Syndrome and Lambert Eaton Syndrome.

We also delivered our first webinars this year in May 2023 and February 2024. 524 people signed up to attend these events.

In total 672 members attended national online sessions and webinar sessions to access peer support, information, and friendship.

Over 1132 people used the carefully moderated Myaware member only closed social media groups, which provide a safe platform on which to share thoughts, concerns and experiences and receive information and support.

Telephone and email support are provided Monday to Friday, 9am to 5pm for members who need advice, information or someone to talk to. This service is delivered by our dedicated and caring Support Team and Head Office staff.

Benefits and Welfare advice was effectively and empathetically delivered to 356 members - giving financial and rights-based advice to support people living with Myasthenia and their families.

REPORT OF THE TRUSTEES

Research

The Research and Partnerships Officer (R&PO) oversaw the continued support of a variety of projects funded by Myaware. The R&PO also prepared and pursued the execution of contracts related to funding new projects within the research budget for the financial year 2023-2024. The details of these projects and contracts are as follows:

Professor Isabel Leite (University of Oxford): *The Establishment and Use of a UK Database for Myasthenic Disorders*:

Dr Ashraghi has applied for further funding to ensure population of the database with historical data. This funding will partially cover the employment of a Research Fellow who will apply for temporary contracts with NHS trusts to carry out data entry. The database coordinator is being funded by Myaware until September 2025. Dr Ashraghi will work with the coordinator to continue populating the database for this period and then reassess the need for further funding. During the period, Myaware will receive an annual summary of achievement.

Professor David Wraith and Professor Saiju Jacob (University of Birmingham): *Developing Antigen Specific Immunotherapy for Myasthenia*:

Dr San's project is looking to develop our understanding of antigen recognition in Myasthenia, and this work is continuing well. There has been a no-cost extension to the project that has been approved between the University of Birmingham and Myaware. Dr San has continued her clinical training with Professor Jacob while she carries out her lab work on this exciting project. Dr San has published two papers based on this work so far:

San, P.P. and Jacob, S. (2023) 'Role of complement in myasthenia gravis', Frontiers in Neurology, 14. Available at: https://doi.org/10.3389/fneur.2023.1277596.

San, P. P., & Jacob, S. (2023). Autoantibody-mediated neurological diseases. Medicine, 51(8), 558–568. https://doi.org/10.1016/j.mpmed.2023.05.00

Dr Katy Dodd (University of Manchester): *Optimising the Immunosuppressive Management of Myasthenia Gravis:*

Dr Dodd presented an overview of treatments in Myasthenia to the Myaware membership community in February and held an open discussion to hear where our community would like research to focus on going forward. Dr Dodd's T Cell work has helped identify interesting characteristics of T cells in both refractory patients and those with active and difficult to treat Myasthenia. Dr Dodd is looking to submit this work for publication in the near future and has presented it at national and international medical conferences.

REPORT OF THE TRUSTEES

Research - continued

Hayley Ramjattan (University of Oxford) - *CMS Monitoring*:

Hayley Ramjattan is a specialist neuromuscular physiotherapist who treats patients with Congenital Myasthenic Syndromes (CMS). At present, there are no validated outcome measures used to guide management, medication, and exercise for CMS patients. The aim of this project is to try and improve this and identify whether unvalidated tests used in managing Myasthenia Gravis patients (MG) could be effective. The data cut for the CMS project has been carried out, and Hayley has submitted her thesis for review and presented at the post graduate symposium at the University of Oxford. This data will be shared with the Myaware community after Hayley's research has been published.

Professor Isabel Leite (University of Oxford): *COVID-19 Vaccine Response in Myasthenia Gravis Patients:*

The funding agreement for this project has now been signed by the University of Oxford and countersigned by Myaware. Recruitment for an appropriate researcher to undertake this work is underway.

Partnerships

Myaware have successfully applied for introductory membership with the Association of Medical Research Council (AMRC). With this membership, Myaware will be able to improve its existing network within the research community. In addition, the R&PO is now able to attend workshops hosted by the AMRC and develop their own skills in writing research policy and different methods of getting involved in research from a patient organisation perspective.

The R&PO was additionally invited to the Rare Disease Connect in Neurology conference in Berlin in November 2023. At this conference, the R&PO was able to connect with representatives from other myasthenia-focused patient organisations from across the globe. Live translation software allowed all delegates to speak in their native languages to one another, creating a collaborative and welcoming experience for all. This meeting also involved healthcare professionals from a variety of countries, and there were opportunities to work together and discuss ways to improve Myasthenic care from an international perspective.

Finally, Myaware successfully applied for a funding grant amounting to £19,641.93 from the pharmaceutical company Merck. This grant will go towards several projects related to Myaware's core services, including the annual research impact report, annual member survey, and literature library refresh. We hope to continue this sponsorship with a new application to Merck for the next financial year.

REPORT OF THE TRUSTEES

Awareness

Myaware continued to bring together specialist Myasthenia nurses from across the UK to share knowledge and expertise. We plan to continue hosting these meetings to help contribute to a better understanding of the needs of people with Myasthenia amongst health care professionals.

We hosted our first webinars, a brand-new offer from Myaware. These webinars were presented by our Research and Partnerships Officer and focused on our Research Impact Report, which covered the last 10 years of research funded by Myaware, and Dr Katherine Dodd, who educated members on advances in research.

We attended the CMS Patient Day on 20th May. The specialist team in Oxford hold this event every year, with the aim to update patients on treatments and information and give those affected an opportunity to meet others affected by this rare condition.

In May 2023 we hosted My Awareness Month (MAM) and this year we focused on raising awareness of all the Myasthenia's with healthcare professionals. As we understand the difference having an early diagnosis, access to good health care and support can make to someone's life, and we wanted to do our best to ensure that more people experience this. We updated our Health Care Professional leaflet and encouraged members to share this with Health Care Professionals (HCPs) in their area.

We joined MDUK and other leading Myasthenia specialists for the 2023/2024 Virtual Information Seminar (Myasthenia Gravis) hosted by MDUK on the 15th February 2024.

The National Support Manager and Research and Partnerships Manager attended MG: Connects in October 2023 in Manchester. This day was organised by UCB (Union Chimique Belge) and designed to bring neurologists and specialist nurses together to better coordinate Myasthenia care. Myaware were invited to host a stall at the event where we provided HCPs with literature, information about the charity, and invited them to join as professional members. Myaware also had the opportunity to listen to several talks given by HCPs on the challenges in Myasthenia care.

Website performance

Myaware continues to offer an all-in-one digital inclusion solution called Reachdeck across our website. It helps us to ensure that our online content is accessible and usable to everyone by:

- **Improving the accessibility, readability and reach of our online content**
- **Protecting our communications, content and reputation**
- **Empowering our whole team to communicate with confidence**

Reachdeck allows all our web visitors to translate all content in over 100 languages, with the option to request read aloud content, increase or reduce text size and change font and background and text colours to increase readability for those who are visually impaired.

REPORT OF THE TRUSTEES

Review of Income Activities



Total £1,178,400

2023/24 continued to be a challenging year for fundraising. The ongoing impact of the cost-of-living crisis continued to make it difficult for our supporters to donate. Despite the challenges we are incredibly grateful to all those who were able to continue to support Myaware.

The Fundraising Team also faced challenges in recruiting a full Fundraising Team, and for the whole of 2023/24 functioned with a team of two, National Fundraising Manager and Individual Giving Fundraiser.

- During the year we were grateful to 23 people who remembered Myaware in the wills. Restricted bequests totalled £8,449, and unrestricted bequests totalled £847,605.

- We received £49,129 from Trusts and Grant giving organisations this year. An increase of 43% since last year. One of the donations for £11,787 was received from the Vitol Foundation. Other donations ranged from £200 to £5,000.

- Income received via Events decreased by 19% on the previous year and totalled £41,463, as there was no Events Fundraiser in place for the whole of the 2023/24. However, this has been rectified for 2025.

- During this financial year Myaware received £29,301 in In Memoriam donations and we are extremely grateful to those who have chosen to remember their loved ones by donating at Myaware.

REPORT OF THE TRUSTEES

Impact and Value

Myasthenia means muscle weakness. It affects the muscles that let you move but not the automatic ones like your heart that you don't have to think about. Your brain tells your muscles to work, but the message doesn't get through. Symptoms of Myasthenia include muscle weakness which makes day to day activities like walking, smiling and talking very difficult. When swallowing and breathing are affected, this can lead to a medical emergency.

Myaware works tirelessly to provide accessible support services and information to everyone who receives a Myasthenia diagnosis. We estimate there to be approximately 12,000 people in the UK with Myasthenia related conditions but there are currently no accurate published figures. Myaware supports approximately 25% of those who have received a Myasthenia diagnosis, and our aim is to raise more awareness to ensure that everyone who receives a diagnosis can access the support that they need to live well with Myasthenia.

A Myasthenia diagnosis can be life changing and we aim to make life easier for these people and their families in the following ways:

Accessible information and support online, on the telephone or via email

- 40 online support get-togethers this year providing support, information and advice.
- Several secure Facebook closed groups providing online peer support and advice.
- National Facebook, Twitter and Instagram pages offering information and signposting.
- Telephone and email support via our Support and Head Office Teams.
- Benefits and Welfare advice service.
- Online information for people living with Myasthenia their family members and healthcare professionals via our website.

Increased awareness amongst the public and healthcare professionals

- Comprehensive website offering accessible information on all aspects of living with Myasthenia.
- A range of detailed booklets on Myasthenia. It's symptoms and treatments.
- Newly diagnosed information packs and medical cards.
- Clinic awareness packs for GP surgeries, neurology clinics, dentists, optician and pharmacies.
- Representation of our members needs at Neurological Alliance, Rare Disease UK and National Voices.
- Representation of our members needs at annual MG Connects meeting for Neurologists.

Myaware is committed to effectively and responsibly funding research projects in the following areas:

- Cause
- Cure
- Prevention
- Treatment

Myaware is also committed to training clinicians of the future in the field of Myasthenia and effectively communicating outcomes regarding current and future research opportunities with transparency.

REPORT OF THE TRUSTEES

FUTURE DEVELOPMENTS, AMBITIONS AND LONG-TERM STRATEGIES

Meeting increasing demands of support from people affected by Myasthenia requires the charity to focus on developing future sustainable funding streams.

Following the pandemic, Myaware now provides a nationally focused Support Team who deliver support via online platforms, social media, telephone and email.

Myaware is committed to seeking member feedback via our annual member survey and short online surveys on our Social Media platforms, this assists with future services strategy.

Myaware is developing additional ways in which to allow our members to submit feedback regarding specific support that they have received. This will be via 'How did we do' short questionnaires.

Myaware will continue to develop the support and information provided via our website and improve our website user journey to ensure vital information is easily obtainable.

Myaware aims to improve access to our core services for those with accessibility challenges.

Myaware will continue to be committed to effective communication and engagement with our members.

Myaware will increase its work relating to raising awareness with healthcare professionals to improve accurate and timely diagnosis. This is planned via an External Medical Advisory Committee to assist with providing accurate and up-to-date medical information regarding the Myasthenias.

Myaware continues to be committed to representing our members at national forums such as Neurological Alliance and Rare Disease and to feedback updates and outcomes to our members.

Myaware is committed to effectively and responsibly utilising restricted research funding to support projects in the areas of cause, cure, prevention, treatment and general improvement of quality of life, in relation to Myasthenia and related conditions.

REPORT OF THE TRUSTEES

REFERENCE AND ADMINISTRATIVE DETAILS

Myaware is Company Limited by Guarantee

Registered Company Number in England and Wales: 3038358

Registered Charity Number in England and Wales: 1046443

Registered Charity Number on Scotland: SC044744

Registered Office
The College Business Centre
Uttoxeter New Road
Derby DE22 3WZ

Auditors
Johnson Tidsall Limited
Chartered Accountants
81 Burton Road, Derby DE1 1TJ

Chief Executive Officer
Dr Heidi Harrison

Company Secretary
Ben Bourne, Ellis-Fermor & Negus
also acts as solicitors to the charity:
Ellis-Fermor & Negus, 2 Devonshire Avenue, Beeston, Nottingham NG9 1BS

Bankers
Virgin Money
11 Smithy Row, Nottingham NG1 3EJ

Trustees
Trevor Ranson - Chair
Andrew Robinson - Treasurer
Jon Rio
Professor Bethan Peach
Professor Saiju Jacob
Maria Isabel Leite (resigned 09.02.24)
Huw Simmonds (resigned 31.03.24)
Tony Ferrari (resigned 08.07.24)
Rashmi Rungta
Penny Henrion
Fiona Norwood
Claire Wen (appointed 19.02.24)
Sara Jones (appointed 08.05.24)
Channa Hewanadduma (appointed 24.07.24)

More information regarding the Trustees can be found at:

https://www.myaware.org/pages/faqs/category/meet-the-board

REPORT OF THE TRUSTEES

STRUCTURE, GOVERNANCE AND MANAGEMENT

Myaware is a company limited by guarantee, incorporated on 27th March 1995 (number 3038358), a registered charity in England and Wales (number 1046443) and a charity registered in Scotland (number SC044744). It is governed by its Memorandum and Articles of Association adopted on 27th March 1995 and amended on 29th March 2018.

Subject to the provisions of the Companies Act 2006, the articles and to any directions given by special resolution, the business of the Company is managed by the Trustees who may exercise all the powers of the Company. No alteration of the articles and no such direction shall invalidate any prior act of the Trustees which would have been valid if that alteration had not been made or that direction had not been given. The powers given by this article shall not be limited by any special power given to the Trustees by the articles and a meeting of Trustees at which a quorum is present may exercise all the powers exercisable by the Trustees.

The pay and remuneration of the senior managers of Myaware is considered annually by the trustees. The board of Trustees meets during the budget setting process to review salary levels, increment payments and inflation rises. The Trustees consider benchmark information relating to similar posts in similar organisations within the charity sector to assist with their decision. We continue to work in partnership with other organisations with shared interest, including Neurological Alliance and Rare Disease UK.

Fundraising and data protection

Myaware operates within a strict fundraising policy and never uses telephone cold-calling; purchase address lists to write unsolicited letters, share the membership list to third parties or use any other methods or approaches that may be deemed as harassing or pressurising the recipient. We always respect the privacy of those who share their personal information with us.

Recruitment, appointment, induction and training of new Trustees

Only members of the charity may become Trustees.

The Articles of Association allow the Trustees to appoint candidates to become a Trustee (and Director), either to fill a vacancy, or the strengthen the Board. Candidates become known to the Board through personal knowledge or research of existing Trustees, by interested members of the organisation volunteering their services or, occasionally, as a result of advertising by the Board. Before appointing a new Trustee, the Board will consider any perceived weaknesses in the current Board in terms of special abilities or experience which they believe to be lacking. A potential candidate will then be approached by the Chair. Where possible the candidate will be invited to attend one or more meetings of the Board as a nonvoting observer. The candidate may then be appointed as a Trustee by a formal motion of the Board. The Chair takes care to ensure that new Trustees receive personal guidance on their responsibilities under the Charity's Articles, and Charity and Company law. They may also seek advice and assistance from the Treasurer and the Company Secretary.

REPORT OF THE TRUSTEES

Myaware Sub-committees

Medical Committee:

Professor Bethan Peach

Professor Saiju Jacob

Maria Isabel Leite (resigned February 2024)

Penny Henrion

Fiona Norwood

Charlotte Campbell – Research and Partnerships

Sarah Cuthell CEO (resigned July 2024)

Dr Heidi Harrison CEO (appointed July 2024)

Channa Hewanadduma (appointed July 2024)

Finance Committee:

Andrew Robinson (Treasurer)

Jon Rio

Rashmi Rungta

Jamie Caple - Finance Manager

Sarah Cuthell CEO (resigned July 2024)

Dr Heidi Harrison CEO (appointed July 2024)

The Chief Executive Officer (CEO) is appointed by the Trustees to manage the day-to-day operations of the charity. The CEO reports to the Chair as her line manager.

REPORT OF THE TRUSTEES

Risk Management

A risk review of the overall organisation takes place annually. The review took place in July 2023 and then in June 2024 when a committee of Trustees assessed the major risks. Subsequently, systems and procedures have been established to manage those risks.

An annual budget proposal covering anticipated income and expenditure is created by the CEO and Finance Committee and reviewed by the Trustees. Once agreed, this forms the basis of the financial reserve held by the charity to ensure that commitments can be met. The Finance Committee review performance against the agreed budget on a monthly basis and the full Board considers this quarterly.

The board consider any variation to budget and if necessary, implement changes to mitigate any risks identified.

FINANCIAL REVIEW

Financial Position

The organisation reported a total net surplus of £130,370 compared with a total net deficit of £395,713 in the previous year. This was due to several significant legacies gifted to the charity.

Unrestricted funds increased by £450,050 to £1,801,464

Restricted funds decreased by £319,680 to £339,486

Incoming Resources

Total incoming resources for the year were £1,178,400 up by £848,956 from the previous year.

This year we received £972,242 in donations, of which £856,054 relates to legacy gifts. We received £11,488 in restricted funds.

Income from other trading activities increased by £18,231 to £119,736.

Investment income has increased by £42,560 to £86,422.

REPORT OF THE TRUSTEES

Resources Expended

Total resources expended increased by £351,502 to £1,068,135 due to several large restricted research grants commitments.

Research costs were increased by £309,733 on previous year to £402,408 of which £329,515 was restricted.

Support costs were increased by £32,563 on previous year to £545,474 of which £26,998 was restricted.

Awareness costs increased by £6,341 to £107,598 of which £712 was restricted.

Fundraising costs were increased by £2,865 to £12,655.

Total funds stand as £2,140,950 compared with £2,010,580 last year.

Funds at the year-end were made up of unrestricted funds of £1,801,464 (2023: £1,351,414) and restricted funds of £339,486 (2023: £659,166).

Contingent Asset

During the year the charity was notified of a significant legacy of which Myaware is the sole beneficiary of the residual estate. The Trustees have been unable to obtain a reliable estimate of the amount due to Myaware and has therefore treated the legacy as a contingent asset. The rationale for recognition as a contingent asset is detailed in note 23 on page 42 of these financial statements.

REPORT OF THE TRUSTEES

Reserves Policy

Reserves are held to ensure that planned and committed expenditure over the next five years can be met. Unrestricted funds not invested in tangible and intangible fixed assets (the free reserves) are held to meet a minimum of twelve months budgeted expenditure and to enable the charity to fulfil its planned and committed expenditure over the next five years which are not covered by restricted funds.

As of 31st March 2024, the 12 month's budgeted unrestricted expenditure equates to £766,924 and the free reserves, which amount to £1,799,963 leaving a surplus of £1,033,039 available for future expenditure. The surplus reflects legacies bequeathed. The charity cannot predict its legacy income year on year, and this can vary significantly. The surplus on funds generated is helping to fund our current year.

Going Concern

The COVID-19 pandemic has had a negative effect on the charitable sector, and myaware is no exception to this. The Trustees have set a realistic budget for 2024/25 with a net deficit on unrestricted funds of £450,124. This has been calculated on a reduction in giving and no legacies receivable in the year.

Going concern is not considered an issue as the charity can utilise the surplus on unrestricted funds referred to in the above reserves policy. The liquidity position is monitored by the trustees on a monthly basis and the charity is continuing to operate within its reserves policy. On this basis the trustees consider the going concern basis for the preparation of these financial statements to be appropriate.

Principal Funding Sources

The charity benefitted during the year from a number of generous legacies amounting in total to £856,054.

Donations amounted to £86,887. Events fundraising generated £41,463 and In Memoriam donations raised £29,301.

Investment Policy and Objectives

Trustees agree on investments in compliance with the Articles of Association. The return on investment for the year was 4.1% (2023 2.0%). If the change in value of investments is included, the return is 5.1% (2023 1.6%). Note that these figures do not include interest earned on bank current accounts – such interest is identified in a line item in the notes to the accounts. The Trustees consider these results to be satisfactory in the current investment climate but aim to keep this under regular review.

REPORT OF THE TRUSTEES

Statement of Trustees Responsibilities

The Trustees (who are also the directors of Myaware Company Limited by Guarantee for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with the applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland.

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application resources, including the income and expenditure of the charitable company for that period. In preparing those financial statements, the trustees are required to:

- Select suitable accounting policies and they apply them consistently.
- Observe the methods and principles in the Charity SORP.
- Make judgements and estimates that are reasonable and prudent.
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006, The Charities and Trustees Investment Act (Scotland) 2005 and The Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

- There is no relevant audit information of which the charitable company's auditors are unaware; and
- The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

The report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

ON BEHALF OF THE BOARD:

Mr Trevor Ranson, Chair of the Board of Trustees

DATE: 24 January 2025

Opinion
We have audited the financial statements of Myaware (the 'charitable company') for the year ended 31 March 2024 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In our opinion the financial statements:
- give a true and fair view of the state of the charitable company's affairs as at 31 March 2024 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and Regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information
The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Report of the Trustees for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Trustees has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception
In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees.

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) requires us to report to you if, in our opinion:
- adequate and proper accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to take advantage of the small companies' exemption from the requirement to prepare a Strategic Report or in preparing the Report of the Trustees.

Responsibilities of trustees
As explained more fully in the Statement of Trustees' Responsibilities, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

In identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

-The nature and control environment of the charitable company

-Our discussions with management and governance including whether they had knowledge of any actual, suspected or alleged fraud

-The internal controls to mitigate the risks of fraud

Following our review, we have identified the following areas which are deemed to have the highest potential for fraud or material misstatement within the financial statements:

- The timing of revenue recognition
- The evaluation of estimates in respect of legacies
- The correct identification of restricted funds
- The timing and recognition of committed expenditure
- The risk of management override

We also considered any laws and regulations that were central to the operation of the charitable company including company law, charity law, employment law and health and safety.

The following procedures were undertaken in respect of the risks where we identified the potential for material misstatement:

Income from donations and legacies was considered a risk due to the volume and nature of these transactions. Income may be pledged but there may be a timing difference between commitment and receipt. The overall income of the charitable company could be materially understated.

Income transaction testing was performed to ensure completeness of income. Post year end donations and legacies were reviewed to ensure that income was recognised in the correct accounting period in accordance with the charitable company's accounting policy.

In respect of legacies, we also tested the accuracy of estimates by reviewing correspondence obtained from solicitors and executors which included the wills and statements of assets and liabilities of the deceased person's estate and where possible agreed to receipts after date.

Restricted funds in respect of income were tested to donor correspondence to ensure that the restrictions imposed were adhered to by the charitable company in expending those funds. This included vouching a sample of expenditure. In addition, we tested unrestricted income mindful of any non-recognition of restricted funds.

The testing of committed expenditure in relation to grants awarded by the charitable company in respect of research was tested by obtaining copies of the formal grant offer and agreeing the terms to the creditor provision in the financial statements. Trustees' board meeting minutes were reviewed, and all commitments noted in the year were agreed to the financial statements to ensure completeness.

A sample of journal entries were tested for appropriateness and enquiries made of management as to the procedures in place for posting journal entries. During our audit we considered any large, unusual journals or transactions outside the normal course of business which were highlighted as a result of our testing.

We reviewed the minutes of trustees' board meetings and controls put in place by the board of trustees including a review of their risk assessment.

At the planning stage we discussed with management any laws and regulations which were central to the operation of the charitable company.

The financial statements were reviewed alongside our disclosure checklists to identify any unusual or unexpected relationships or any areas of non-compliance. Discussions were held with management where it was considered additional disclosures were required.

We remained alert to any indications of fraud, material misstatement or non-compliance with laws and regulations throughout the audit including those relating to the financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and the trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

David Mellor FCA (Senior Statutory Auditor)
for and on behalf of Johnson Tidsall Limited
Chartered Accountants
& Statutory Auditor
Eligible to act as an auditor in terms of Section 1212 of the Companies Act 2006
81 Burton Road
Derby
Derbyshire
DE1 1TJ

Date: 25/11/2025

STATEMENT OF FINANCIAL ACTIVITIES
(INCORPORATING AN INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 MARCH 2024

	Notes	Unrestricted fund £	Restricted funds £	2024 Total funds £	2023 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	3	**960,754**	**11,488**	**972,242**	184,077
Other trading activities	4	**93,679**	**26,057**	**119,736**	101,505
Investment income	5	**86,422**	**-**	**86,422**	43,862
Total		**1,140,855**	**37,545**	**1,178,400**	329,444
EXPENDITURE ON					
Raising funds	6	**12,655**	**-**	**12,655**	9,790
Charitable activities	7				
Research		**72,893**	**329,515**	**402,408**	92,675
Support		**518,476**	**26,998**	**545,474**	512,911
Awareness		**106,886**	**712**	**107,598**	101,257
Total		**710,910**	**357,225**	**1,068,135**	716,633
Net gains/(losses) on investments		**20,105**	**-**	**20,105**	(8,524)
NET INCOME/(EXPENDITURE)		**450,050**	**(319,680)**	**130,370**	(395,713)
RECONCILIATION OF FUNDS					
Total funds brought forward		**1,351,414**	**659,166**	**2,010,580**	2,406,293
TOTAL FUNDS CARRIED FORWARD		**1,801,464**	**339,486**	**2,140,950**	2,010,580

The notes form part of these financial statements

MYAWARE
COMPANY NUMBER 3038358
BALANCE SHEET
31 MARCH 2024

	Notes	Unrestricted fund £	Restricted funds £	2024 Total funds £	2023 Total funds £
FIXED ASSETS					
Intangible assets	14	-	-	-	3,023
Tangible assets	15	1,501	-	1,501	1,742
Investments	16	241,379	-	241,379	221,273
		242,880	-	242,880	226,038
CURRENT ASSETS					
Stocks	17	4,162	-	4,162	3,486
Debtors	18	838,534	-	838,534	116,707
Cash at bank and in hand		751,258	844,997	1,596,255	2,034,264
		1,593,954	844,997	2,438,951	2,154,457
CREDITORS					
Amounts falling due within one year	19	(35,370)	(202,079)	(237,449)	(252,596)
NET CURRENT ASSETS		1,558,584	642,918	2,201,502	1,901,861
TOTAL ASSETS LESS CURRENT LIABILITIES		1,801,464	642,918	2,444,382	2,127,899
CREDITORS					
Amounts falling due after more than one year	20	-	(303,432)	(303,432)	(117,319)
NET ASSETS		1,801,464	339,486	2,140,950	2,010,580
FUNDS	21				
Unrestricted funds				1,801,464	1,351,414
Restricted funds				339,486	659,166
TOTAL FUNDS				2,140,950	2,010,580

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies' regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 24 January 2025 and were signed on its behalf by:

.....

Mr T Ranson - Trustee

The notes form part of these financial statements

CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 MARCH 2024

	Notes	2024 £	2023 £
Cash flows from operating activities			
Cash generated from operations	1	(522,431)	(102,628)
Net cash used in operating activities		(522,431)	(102,628)
Cash flows from investing activities			
Purchase of tangible fixed assets		(2,000)	-
Interest received		86,422	43,862
Net cash provided by investing activities		84,422	43,862
Change in cash and cash equivalents in the reporting period		(438,009)	(58,766)
Cash and cash equivalents at the beginning of the reporting period		2,034,264	2,093,030
Cash and cash equivalents at the end of the reporting period		1,596,255	2,034,264

The notes form part of these financial statements

NOTES TO THE CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 MARCH 2024

1. RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2024 £	2023 £
Net income/(expenditure) for the reporting period (as per the Statement of Financial Activities)	**130,370**	(395,713)
Adjustments for:		
Depreciation charges	**5,264**	6,974
(Gain)/losses on investments	**(20,105)**	8,524
Interest received	**(86,422)**	(43,862)
(Increase)/decrease in stocks	**(676)**	878
(Increase)/decrease in debtors	**(721,827)**	460,892
Increase/(decrease) in creditors	**170,965**	(140,321)
Net cash used in operations	**(522,431)**	(102,628)

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1/4/23 £	Cash flow £	At 31/3/24 £
Net cash			
Cash at bank and in hand	**2,034,264**	**(438,009)**	**1,596,255**
	2,034,264	**(438,009)**	1,596,255
Total	**2,034,264**	**(438,009)**	**1,596,255**

The notes form part of these financial statements

1. STATUTORY INFORMATION

Myaware is a charitable company, registered in England and Wales and Scotland. The charitable company's registered company number, registered charity numbers, registered office address and business address can be found in the reference and administrative details of the Report of the Trustees.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', the Companies Act 2006 and the Charities and Trustee Investment (Scotland) Act 2005. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

The currency basis for the preparation of these financial statements is pound sterling (£).

Going concern
The trustees regularly monitor the charity's reserves policy and risk assessment. A realistic budget for 2024/25 has been prepared. Liquid funds and cash flow are monitored on a monthly basis. To date, no material uncertainties exist that would affect the preparation of the financial statements on a going concern basis.

Significant judgements and estimates
The following judgements (apart from those involving estimates) have been made in the process of applying the charitable company's accounting policies that have had the most significant effect on amounts recognised in the financial statements:

Legacies - when calculating amounts due on legacies, management considers the wills of the deceased, executors accounts and notifications received from executors. At 31 March 2024 there is a legacy debtor, included in other debtors, of £779,560.

Grants - when calculating grant commitments, management considers the nature of the grants as being within the charity's objectives and the possible future benefits for people affected by myasthenia.

Income
All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received, and the amount can be measured reliably.

Donated services and goods are recognised as income when the charity has control over them, the economic benefit is probable and can be measured reliably. In accordance with the Charities SORP (FRS102), the volunteer time of Support Groups is not recognised. Information about their contribution is provided in the Trustees' Annual Report.

For donations to be recognised the charity will have been notified of the amounts and the settlement date. If there are conditions attached to the donation and this requires a level of performance before entitlement can be obtained, then income is deferred until those conditions are fully met or the fulfilment of those conditions is within the control of the charity, and it is probable that they will be fulfilled.

For legacies, entitlement is the earlier of the charity being notified of an impending distribution or the legacy being received. At this point income is recognised.

Income from trading activities includes income earned from fundraising events and trading activities to raise funds for the charity. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred.

Investment income is earned through holding assets for investment purposes such as shares and bank deposit accounts. It includes dividends and interest. It is included when the amount can be measured reliably.

2. ACCOUNTING POLICIES - continued

Income - continued
Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the charity will comply with conditions attaching to them and the grants will be received using the accrual model.

Debtors
Other debtors are recognised at the settlement amount due. Prepayments are valued at the amount prepaid.

Expenditure
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings, they have been allocated to activities on a basis consistent with the use of resources.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Allocation and apportionment of support costs and governance
Resources expended are allocated to the particular activity where the cost relates directly to that activity. However, the cost of overall direction and administration on each activity, including the salary and overhead costs of the general office and regional staff, is apportioned on the following bases which are an estimate, based on staff time, of the amount attributable to each activity:

	Percentage allocation
Research	11%
Support	74%
Awareness	15%

Intangible fixed assets
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:

Computer software - over 3 years straight line

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 20% on cost
Computer equipment	- 33% on cost

Tangible fixed assets are stated at cost or deemed costs less accumulated depreciation. Cost includes costs directly attributable to making the asset capable of operating as intended.

Individual fixed assets costing £500 or more are capitalised at cost.

Investments
Investments are valued at market value which is deemed to be fair value. Movements in market value are reflected in the statement of financial activities as a net gain/(loss).

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Stock is valued on a first in first out basis.

2. ACCOUNTING POLICIES - continued

Taxation
The charity is exempt from corporation tax on its charitable activities.

Fund accounting
The charitable company has both restricted and unrestricted funds. All funds are used to benefit and promote its charitable objects.

Restricted funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose and the restriction means that the funds can only be used for specific projects or activities.

When donors specify that donations and grants are for particular purposes which do not amount to pre-conditions regarding entitlement, this income is included in incoming resources of restricted funds when receivable. The relevant expenditure is then matched as restricted expenditure.

Unrestricted funds are general funds that are available for use at the trustees' discretion in furtherance of any objectives of the charity.

Designated funds are unrestricted funds set aside at the discretion of the trustees for specific purposes.

Pension costs and other post-retirement benefits
The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Operating lease agreements
Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged to the SOFA on a straight line basis over the period of the lease.

Reserves
The charitable company maintains a level of reserves required to fulfil its objectives. The trustees monitor reserves at regular meetings.

Financial instruments
Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

3. DONATIONS AND LEGACIES

	2024	2023
	£	£
Donations	**86,887**	85,679
Legacies	**856,054**	63,470
In Memoriam	**29,301**	34,928
	972,242	184,077

The charity benefits greatly from the involvement of many helpers and volunteers, details of which are given in our annual report. In accordance with FRS102 and the Charities SORP (FRS102), the economic contribution of volunteers is not recognised in these financial statements.

4. OTHER TRADING ACTIVITIES

	2024	2023
	£	£
Affinity programmes	2,069	2,739
Appeals	11,782	6,678
Collections	2,825	1,497
Corporate	4,946	3,875
Grants	31,629	(3,838)
Lotteries	3,147	3,114
National events	15,063	24,033
Regional events	26,400	27,367
Sales of merchandise	4,375	3,700
Trusts	17,500	32,340
	119,736	101,505

During the 2022 year management implemented changes to the charity's fundraising structure. This restructure was an outcome of Covid and Myaware's inability to continue to provide face to face support services. The regional fundraising structure was deemed unfit for current and future purpose and a new national fundraising team structure was implemented.

As a result of this, certain restricted grants applied for on a regional basis in previous years were repaid as the criteria for the grants could no longer be met. This also affected the 2023 year.

5. INVESTMENT INCOME

	2024	2023
	£	£
Deposit account interest	76,693	33,771
Current account interest	3,234	3,620
Dividends on shares and other investments	6,495	6,471
	86,422	43,862

6. RAISING FUNDS

Raising donations and legacies

	2024	2023
	£	£
Merchandise	3,308	2,910
Events	6,454	4,250
Appeal mailings	1,331	1,150
Lottery	1,562	1,480
	12,655	9,790

7. CHARITABLE ACTIVITIES COSTS

	Direct Costs (see note 8)	Support costs (see note 9)	Totals
	£	£	£
Research	**383,040**	**19,368**	**402,408**
Support	**415,169**	**130,305**	**545,474**
Awareness	**81,184**	**26,414**	**107,598**
	879,393	**176,087**	**1,055,480**

8. DIRECT COSTS OF CHARITABLE ACTIVITIES

	2024	2023
	£	£
Staff costs	**520,898**	489,872
Medical research	**317,424**	18,981
Medical care	**7,682**	2,245
Travel and miscellaneous	**28,626**	20,970
MyNews & member communications	**3,669**	3,768
Meetings and conferences	**1,094**	1,056
	879,393	536,892

Grants payable during the year were as follows:

	2024	2023
	£	£
Commitments as at 1 April 2023	356,612	500,446
Commitments made in the year	316,970	18,981
Commitments released in the year	-	-
Grants paid during the year	(168,071)	(162,815)
Commitments as at 31 March 2024	505,511	356,612

9. SUPPORT COSTS

	Management	Governance costs	Totals
	£	£	£
Research	**17,239**	**2,129**	**19,368**
Support	**115,982**	**14,323**	**130,305**
Awareness	**23,511**	**2,903**	**26,414**
	156,732	**19,355**	**176,087**

9. SUPPORT COSTS - continued

Support costs, included in the above, are as follows:

Management

	Research	Support	Awareness	2024 Total activities	2023 Total activities
	£	£	£	£	£
Rental of premises	1,644	11,062	2,242	14,948	15,500
Utilities and insurance	2,023	13,609	2,759	18,391	17,339
Office equipment	307	2,067	419	2,793	2,860
Printing, postage and stationery	1,057	7,106	1,440	9,603	8,994
Photocopier costs	91	611	123	825	910
Support website	2,746	18,473	3,745	24,964	21,418
IT support & software	5,902	39,706	8,049	53,657	49,053
H R costs	2,119	14,268	2,894	19,281	15,145
General expenses	635	4,270	866	5,771	7,900
Bank charges	136	914	185	1,235	1,372
Amortisation of intangible fixed assets	333	2,237	453	3,023	4,686
Depreciation of tangible and heritage assets	246	1,659	336	2,241	2,288
	17,239	115,982	23,511	156,732	147,465

Governance costs

	Research	Support	Awareness	2024 Total activities	2023 Total activities
	£	£	£	£	£
Trustees' expenses	499	3,357	681	4,537	1,809
Auditors' remuneration	969	6,520	1,321	8,810	8,965
Legal and professional fees	661	4,446	901	6,008	11,712
	2,129	14,323	2,903	19,355	22,486

10. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2024	2023
	£	£
Auditors' remuneration	8,810	8,965
Depreciation - owned assets	2,241	2,288
Computer software amortisation	3,023	4,686

11. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 March 2024 nor for the year ended 31 March 2023.

Trustees' expenses

	2024	2023
	£	£
Trustees' expenses	4,537	1,809

During the year 4 trustees (2023: 2) received reimbursement of their expenses for attending meetings totalling £497 (2023: £360).

The charge for 2024 includes accommodation for trustee meetings of £1,277 (2023: £981) and trustee courses of £2,763 (2023: £468).

12. STAFF COSTS

	2024	2023
	£	£
Wages and salaries	456,502	431,117
Social security costs	37,158	34,059
Other pension costs	27,238	24,696
	520,898	489,872

The average number of full time equivalent employees during the year was 13 (2023: 13).

The average monthly number of employees during the year was as follows:

	2024	2023
Fundraising, support and awareness	13	13
Management and operations of the charity	4	4
	17	17

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2024	2023
£60,001 - £70,000	1	1

Wages and salaries include redundancy costs of £ nil (2023: £8,328).

The key management personnel of the charity comprises the Chief Executive Officer. The total employee benefits of the key management personnel of the charity amounted to £74,658, including pension contributions (2023: £70,396).

13. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	176,917	7,160	184,077
Other trading activities	98,703	2,802	101,505
Investment income	43,862	-	43,862
Total	319,482	9,962	329,444
EXPENDITURE ON			
Raising funds	9,790	-	9,790
Charitable activities			
Research	77,326	15,349	92,675
Support	500,767	12,144	512,911
Awareness	99,658	1,599	101,257
Total	687,541	29,092	716,633
Net gains/(losses) on investments	(8,524)	-	(8,524)
NET INCOME/(EXPENDITURE)	(376,583)	(19,130)	(395,713)
RECONCILIATION OF FUNDS			
Total funds brought forward	1,727,997	678,296	2,406,293
TOTAL FUNDS CARRIED FORWARD	1,351,414	659,166	2,010,580

14. INTANGIBLE FIXED ASSETS

	Computer software £
COST	
At 1 April 2023 and 31 March 2024	**95,007**
AMORTISATION	
At 1 April 2023	**91,984**
Charge for year	**3,023**
At 31 March 2024	**95,007**
NET BOOK VALUE	
At 31 March 2024	-
At 31 March 2023	3,023

15. TANGIBLE FIXED ASSETS

	Fixtures and fittings £	Computer equipment £	Totals £
COST			
At 1 April 2023	**13,247**	**45,208**	**58,455**
Additions	**-**	**2,000**	**2,000**
Disposals	**(7,771)**	**(31,701)**	**(39,472)**
At 31 March 2024	**5,476**	**15,507**	**20,983**
DEPRECIATION			
At 1 April 2023	**13,247**	**43,466**	**56,713**
Charge for year	**-**	**2,241**	**2,241**
Eliminated on disposal	**(7,771)**	**(31,701)**	**(39,472)**
At 31 March 2024	**5,476**	**14,006**	**19,482**
NET BOOK VALUE			
At 31 March 2024	**-**	**1,501**	**1,501**
At 31 March 2023	-	1,742	1,742

16. FIXED ASSET INVESTMENTS

	Listed investments £
MARKET VALUE	
At 1 April 2023	**221,273**
Revaluations	**20,106**
At 31 March 2024	**241,379**
NET BOOK VALUE	
At 31 March 2024	**241,379**
At 31 March 2023	221,273

There were no investment assets outside the UK.

Cost or valuation at 31 March 2024 is represented by:

	Listed investments £
Valuation in 2022	**229,797**
Valuation in 2023	**(8,524)**
Valuation in 2024	**20,106**
	241,379

17. STOCKS

	2024	2023
	£	£
Finished goods	4,162	3,486

18. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2024	2023
	£	£
Other debtors	807,264	84,243
Prepayments and accrued income	31,270	32,464
	838,534	116,707

19. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2024	2023
	£	£
Other creditors	26,007	3,964
Committed grants	202,079	239,293
Accruals and deferred income	9,363	9,339
	237,449	252,596

20. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

	2024	2023
	£	£
Committed grants	303,432	117,319

21. MOVEMENT IN FUNDS

	At 1/4/23	Net movement in funds	At 31/3/24
	£	£	£
Unrestricted funds			
General fund	1,351,414	450,050	1,801,464
Restricted funds			
Research	563,262	(311,993)	251,269
Support	93,758	(26,617)	67,141
Awareness	2,146	18,930	21,076
	659,166	(319,680)	339,486
TOTAL FUNDS	2,010,580	130,370	2,140,950

21. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	**1,140,855**	**(710,910)**	**20,105**	**450,050**
Restricted funds				
Research	**17,522**	**(329,515)**	**-**	**(311,993)**
Support	**381**	**(26,998)**	**-**	**(26,617)**
Awareness	**19,642**	**(712)**	**-**	**18,930**
	37,545	**(357,225)**	**-**	**(319,680)**
TOTAL FUNDS	**1,178,400**	**(1,068,135)**	**20,105**	**130,370**

Comparatives for movement in funds

	At 1/4/22 £	Net movement in funds £	At 31/3/23 £
Unrestricted funds			
General fund	1,727,997	(376,583)	1,351,414
Restricted funds			
Research	572,818	(9,556)	563,262
Support	101,733	(7,975)	93,758
Awareness	3,745	(1,599)	2,146
	678,296	(19,130)	659,166
TOTAL FUNDS	2,406,293	(395,713)	2,010,580

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	319,482	(687,541)	(8,524)	(376,583)
Restricted funds				
Research	5,793	(15,349)	-	(9,556)
Support	4,169	(12,144)	-	(7,975)
Awareness	-	(1,599)	-	(1,599)
	9,962	(29,092)	-	(19,130)
TOTAL FUNDS	329,444	(716,633)	(8,524)	(395,713)

21. MOVEMENT IN FUNDS - continued

Restricted funds
Restricted funds comprise:

Research
Restricted funds in this class will be applied to:

a. Scientific and clinical research into the causes, disease mechanisms, diagnosis and epidemiology of Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndrome and other similar disorders of the Neuro-Muscular Junction.

b. The provision of equipment and facilities to support (a).

c. Provision of specialist medical facilities (including staff) where the Trustees consider that such provision has a significant impact on the effectiveness of (a).

Support
Restricted funds in this class will be applied to:

d. Development of new support groups of the charity, to foster the health and welfare of myasthenics and their families and carers.

e. Organisation of Regional Conferences to encourage mutual support between members, myasthenics, and support groups.

f. In exceptional circumstances - provision of specialist medical facilities (including staff) where the Trustees consider that such provision would have a major impact on the health and welfare of myasthenics, and alternative funding cannot be obtained.

Awareness
Restricted funds in this class will be applied to:

g. Preparation, publication and distribution of information about Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndrome and other similar disorders of the Neuro-Muscular Junction. (Including information on their causes, diagnosis and treatment, and issues concerning the lifestyle and quality-of-life of patients with these disorders). Publication and distribution include development and maintenance of the association's internet websites.

h. Publicity and promotion of events to foster awareness, in the general public, national and local government, and other bodies, of these disorders, and the problems experienced by patients and their families and carers.

i. Activities to foster awareness in the medical profession of these disorders, and the problems experienced by patients and their families and carers.

j. Activities to foster awareness in the medical profession of the current state of best medical practice in the diagnosis and treatment of these disorders.

k. Regional and national events to disseminate information about these disorders to myasthenics, their families and carers (including information about current and planned future medical and scientific research).

For presentation purposes all restricted income receivable is allocated to one of the above three categories that best describes its restriction.

A detailed breakdown of the income and expenditure allocated to these categories is available on request.

22. EMPLOYEE BENEFIT OBLIGATIONS

The total contribution paid to Personal Pension Plans in the year for certain employees amounted to £27,238 (2023: £24,696).

23. CONTINGENT ASSET

During the year the charity was notified of a significant unrestricted legacy of which Myaware is the sole beneficiary of the residual estate. Probate was granted on 21 November 2023.

Initial reports indicated that the net estate at date of death amounted to £6,953,855, with a residual value to the charity of around £3.5m. The residual value due to Myaware is after specific bequests to beneficiaries including property and chattels which are granted free of inheritance tax.

The trustees recognise the charity's entitlement to the legacy but there is uncertainty as to the amount of payment due to Myaware in respect of its residual interest in the estate. This uncertainty arises due to:

- No information has been received from the executors' solicitors regarding the realisation of the estate which would provide us with a reasonable estimate of the residuary amount due to the charity.

- No distributions on account have been received to date.

- We have not received notification that the inheritance tax liability has been settled on the specific bequests.

- The estate at date of death includes a listed shares portfolio of around £5.3m. The timing of the realisation of this portfolio could have a significant effect on the value to be distributed.

After due consideration, the trustees are of the opinion that the interest of the charity in this significant residual legacy cannot be measured reliably and therefore should be disclosed as a contingent asset until the criteria for income recognition are met.

24. OTHER FINANCIAL COMMITMENTS

At the year end the charity had financial commitments in respect of rent amounting to £14,049 (2023: £14,049) and other leases amounting to £2,904 (2023: £2,904).

25. RELATED PARTY DISCLOSURES

During the year the charity paid a salary, benefits and expenses reimbursement totalling £21,585 (2023: £21,378) to an employee who is the spouse of a trustee.

26. ULTIMATE CONTROLLING PARTY

The charity is controlled by its Board of Trustees.

MYAWARE

England & Wales - Charity number 1046443

Accounts

myaware
Fighting Myasthenia Together

Myaware Report of the Trustees and Financial Statements For The Year 31st March 2023

Myaware is a Registered Charity No. England & Wales 1046443. Scotland SC044744. Company Limited by Guarantee No. 3038358 (England & Wales)

Contents

- Chairman's Report 1
- CEO's Report 2
- Report of the Trustees
  - Objectives & Activities of the Charity 6
  - Achievement and Performance 7
  - Future Developments 14
  - Reference and Administrative Details 15
  - Structure Governance and Management 16
  - Financial Review 18
  - Statement of Trustees Responsibilities 20
- Report of the Independent Auditors 21
- Statement of Financial Activities 25
- Balance Sheet 26
- Notes to the financial statements 27
- Detailed Statement of Financial Activities 40

Myaware Report of the Trustees and Financial Statements Year End 31st March 2023

Chairman's Report – Trevor Ranson

Myaware is committed to providing support to over 2500 members from across the UK. In the last year we have welcomed and supported 672 members to 44 online Zoom support sessions, sent 18,390 support communications and answered 59 generic medical questions relating to myasthenia.

In addition, we have assisted 349 members with enquiries relating to benefits and welfare, an increase of 16% compared to the previous year. 29.5% of these enquires relate to Personal Independence Payments to help with extra living costs incurred when living with a long-term condition diagnosis, 20% are general welfare enquiries and 13% of enquiries relate to advice required regarding driving with a myasthenia diagnosis. 76 counselling sessions were delivered to approx. 13 members, a reduction of 60% compared to last financial year.

We continue to review and evaluate our support services with the help of our members who kindly complete myaware's annual member survey. We have increased the number of Zoom sessions provided this year by 63% to meet the need of our members, deliver vital information, support and provide a platform on which our members can meet and share experience and information. Additional peer support services include myaware's secure Facebook groups for members only. We manage three closed groups: All members, parents' group and Young Generation group for 18 – 39-year-olds. These groups provide a safe lifeline and connection to the UK myasthenia community, on which members can chat, share experience and ask important questions related to myasthenia.

This year, myaware and our members have benefited from the new Research and Partnerships role, which exists to manage the funding of vital research into the myasthenias, as well as providing an essential link to partner, umbrella support and sister myasthenia organisation around the globe. This role also facilitates collaborative work with NICE in relation to the appraisal of new myasthenia treatments, ensuring that our members are kept up to date with developments in this area and the opportunity to be involved in patient focus groups to help shape the future of myasthenia medications.

Myaware continues to address the fundraising challenges which have arisen since the beginning of the pandemic. We are increasingly vigilant, to ensure that we spend the funds that we receive in a cost effective and responsible way. With this in mind, we continue to periodically review our services and objectives to ensure sustainability for the future.

Despite changes to our support service delivery in the last few years, we are delighted to be able to continue to reach and support so many people living with myasthenia in the UK and their families.

On behalf of myself, the board of trustees and the team at myaware, I'd like to take this opportunity to pass on my sincere and heartfelt thanks to all our donors and supporters, without whom, myaware would not be able to continue to support the UK myasthenia community.

CEO's Report – Sarah Cuthell

Membership

Historic research publications have stated that there were approx. 12,000 people living with myasthenia in the UK. In December 2021 a research paper entitled *Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019*, written by Iain Carey was published outlining that this data is now estimated at 20,000 people in the UK.

In April 2022, myaware's records showed that active membership had reduced by 3.4% from 2775 to 2681 during the period of the financial year. During the same period, myaware welcomed 594 brand new members. However, 920 members failed to renew membership on anniversary of joining. Myaware appreciates that our members require the highest level of support at the beginning of and at crisis points of their myasthenia journey and our active membership figures reflect this. Myaware is working to encourage our members to continue with their membership regardless of status of their condition, to ensure that they can continue to access information and support throughout their myasthenia journey, without interruption.







CEO's Report continued

Myaware national support services

Myaware members benefit from a range of online and telephone support and information services which guide individuals and their family members through diagnosis and beyond. Throughout 2022-23 myaware continued to provide and enhance online services to ensure members had access to information, advice, and peer support. We moved fully to a national delivery model, streamlining services across the UK to make the best use out of our resources.

Zoom sessions

This year we delivered 44 online Zoom sessions, bringing our members together to discuss common issues and share valuable experiences. Our highly experienced National Support Co-ordinators and Benefits and Welfare Officer have delivered positive and empathetic updates regarding support, awareness and research, and imparted vital information on how to live well with myasthenia. We are delighted that over 672 members attended these Zoom sessions throughout the year and benefited from information and peer support. Myaware provides a combination of monthly Zoom sessions for members who are new to the condition and to our organisation, along with Peer Support Sessions for our general membership, we also provide sessions specific to age and condition. Our aim is to remove any sense of isolation by guiding members through the first few months of their diagnosis, and then we aim to keep members connected with others who find themselves in a similar set of circumstances. Other zoom sessions have included, bringing together parents and carers, and a presentation about living with myasthenia.

"Thank you so much for organising these extremely fantastic sessions which are very reassuring and helpful. Look forward to the next session!"

"I have had Myasthenia Gravis for around 18 years and after suffering a deterioration in my symptoms over the last few months, it was really lovely to be able to catch up with others. You all do amazing work, and these sessions are a wonderful support for everyone."

Peer support network via social media

Myaware facilitates and manages three national Facebook closed groups and this year we have connected 972 people living with myasthenia and their family members. These groups provide a vital 24/7 lifeline of peer support and a platform for myaware to share updates and answer common questions. Our national peer support closed group caters for all members regardless of type of myasthenia, age, or location. Our myaware kids closed group is especially for parents of children who have been diagnosed with any form of Myasthenia, and our Young Generation closed group provided a platform for those aged between 18 and 39 where discussion can focus around education, employment or pregnancy and myasthenia.

"I want to say a huge thank you to those that offered me reassurance and advice through this group. Not only did it mean the world to me, but genuinely helped a lot. Other people, including my family told me it would be ok, but I trusted your words more as I knew many of you had been through it."

CEO's Report continued

Benefits and welfare advice service

The benefits system is complex, the rules can change, and when living with an unpredictable and sometimes debilitating condition like myasthenia, it can be difficult to find the energy and time to fully research every opportunity to improve your quality of life. Myaware's dedicated benefits and welfare officer is here to help our members navigate the benefits system and check if they are entitled to any financial assistance, or support relating to transport, employment, or education.

This year myaware has responded to 349 benefits and welfare enquiries. This is an 18% increase on the number of enquiries answered last year.
Amongst these were:

- 45 driving & myasthenia enquiries
- 32 employment and myasthenia enquiries
- 103 Personal Independence Payment enquiries
- 25 Attendance Allowance enquiries
- 31 Blue Badge enquiries

Like all our support services this advice is available to all members in England, Scotland, Wales, and Northern Ireland. The service is provided by telephone, on the myaware website and via our Zoom sessions, and is available Monday to Friday, 9am to 5pm.

"Just to say thank you all at myaware for all your help and advice with coming to terms Myasthenia Gravis. It has been very hard, as up till 4 months ago I didn't take any medication and now I have to take 18 tablets a day. I have had a few bad days, but with all the help I have been given by the people at myaware I have been able to get though them. I'm now back at work and I have been able to carry on driving with the help and advice from myaware. I would just like to say a very big thank you all, keep the good work up. Many Thanks!"

Telephone and Email, Support and Information

Our team are available Monday to Friday 9am to 5pm by telephone and email. Whether members have a question they want answering or want to know more about myaware objectives or services, our dedicated Head Office and the Support Team members are here to help inform and guide our members.

"Thank you so much for being there! You guys have been so supportive, the myaware charity is one of the reasons I'm still here! Please pass on our thanks to the whole team."

Emotional support service

People can have many reactions to myasthenia, including strong reactions to changes to their body or being anxious about treatment, and some people find it difficult to cope with the feeling of loss of control. It can sometimes help to talk through these feelings with someone outside of their friends and family, and for this reason, members of myaware have had access to our free, confidential counselling service, delivered via an accredited counsellor with many years of experience supporting people with long-term conditions. In 2022-23 we saw a reduction in the number of people accessing this service, with less than 1% of the membership utilising it. Across the year we only delivered 76 sessions, equating to only thirteen members accessing counselling and a decrease in uptake of 60%.

CEO's Report continued

Myasthenia Literature Library

For those who prefer to learn about myasthenia in print, myaware provides a vast library of information booklets, leaflets, and fliers for those living with myasthenia and healthcare professionals,
this includes information booklets and PDF's covering the following:

- A medical Guide for Patients with Myasthenia Gravis
- Ocular Myasthenia – a guide for the medical professionals
- A medical Guide for Patients with LEMS
- Myasthenia and pregnancy factsheet
- Myasthenia for Complete Beginners Who am I? Booklet
- Congenital Myasthenia – a guide
- Ocular Myasthenia – a guide for patients
- A variety of flyers promoting myaware services

Myaware regularly provides large print version for members with visual impairments.

Website information and signposting

The myaware website; www.myaware.org exists to provide an online library of information about the organisation and our objectives, the different types of myasthenia and vital information about how to live well with myasthenia. During the course of the year, our website pages have received 426,575 views, with users viewing an average of 2 pages per session. The pages most visited continue to include information on 'drugs to avoid,' 'extraocular muscles' and Pyridostigmine information'. Most searched for words during this period on our website were 'steroids', 'Covid' and 'Drugs to avoid' indicating that the most important subject matter relates to myasthenia treatments. Our data shows that the average time spent on each webpage is 1.3 seconds and that 62% of users access our website using a mobile phone. This information along with other web analytics have prompted a review of our web page content, structure and web user journey to ensure that our users can access the required information as quickly as possible and that the information and layout translates effectively for mobile phone use.

Myaware utilises our website to share a variety of information about our three objectives of Support, Awareness and Research. In addition, users can access member's stories, annual accounts, fundraising activities, online shop, register for online support events and membership information. We urge anyone visiting our website to become a myaware member, where they have a myasthenia diagnosis, are a relative, carer or a healthcare professional with an interest in the myasthenias.

Our website hosts ReachDesk toolbar which ensures that our visitors can access our content in a way that suits them best. Including text-to-speech, reading and translation support.

REPORT OF THE TRUSTEES

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 March 2023 which are also prepared to meet requirements of the directors' reports and accounts for the Companies Act purposes.

The financial statements comply with the Charities Act 2011, The Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Articles of Association and Accounting and reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES OF THE CHARITY

We support people affected by myasthenia and related conditions, raise awareness about the conditions and fund research to find new therapies to reduce their impact and ultimately find a cure.

We provide the following core support services:

- Support and information sessions delivered via Zoom covering research information, general support discussion and benefits and welfare advice
- Monthly new members support sessions via Zoom
- Zoom sessions for condition type and age specific to support to children up to the age of 18 and young people between the ages of 18 and 39.
- Information and support via the myaware website
- Our social media services include closed, secure groups for peer support and pages for information and signposting
- Telephone and online welfare and benefits advice service

We raise vital awareness of myasthenia in the following ways:

- We represent our members via membership of umbrella organisations such as UK Neurological Alliances, Rare Disease UK and National Voices
- Myaware provides specific information for our members and the general public via our website
- Myaware provides information packs for clinicians throughout the UK

Myaware is committed to effectively and responsibly funding research projects in the following areas:

Cause, Cure, Prevention, Treatment and Quality of life, in relation to myasthenia and related conditions.

- Myaware is committed to training clinicians of the future in the field of myasthenia.
- Myaware is committed to effectively communicating research project outcomes and future research opportunities with transparency to our members and general stake holders.

To support these aims we undertake fundraising activities and as always are hugely grateful to the many people who have supported us financially and of course our team of volunteers who support us with support and fundraising activities. As always, the challenge is to raise more unrestricted funds that can be used to finance the day to day running of the charity – postage, telephone, printing, on-line services and other core costs and we are particularly grateful to those who donate money that can be used in this way.

REPORT OF THE TRUSTEES

Grant Making Policy

The Charity may award grants to scientific research, specialist myasthenia nurses and training fellowships in support of its objective and activities.

Grants are awarded by the Board of Trustees when funds become available, and only when the reserves position of the charity mitigates the risk committing funds to projects running across several years.

Research grants are awarded following a rigorous peer review process under the control and supervision of the myaware Medical Committee.

Public Benefit

The charitable company has referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing its aims and objectives and in planning its future activities. In particular, the trustees always consider how planned activities will contribute to the aims and objectives they have set.

ACHIEVEMENT AND PERFORMANCE

How we spend our money:

Support - £512,911

Research - £92,675

Awareness - £101,257

Fundraising - £9790



REPORT OF THE TRUSTEES

Support of Members

- Our membership reduced by 3.4% to 2,681 during the financial year. Our data shows that we have welcomed 594 new members during the year, all of whom have received a 'newly diagnosed information pack'. The continuing reduction in member renewals highlights a need to review our membership process and continue to engage with our members via annual member survey and short online surveys.

- Newsletters continue to be sent to our members quarterly, providing news, support, encouragement and acknowledgement to those who have supported myaware via donations and fundraising initiatives.

- We brought together specialist myasthenia nurses from across the UK in May and September 2022 and March 2023 to facilitate the sharing of knowledge expertise across the sector.

- In August 22 we hosted a carer's support session via zoom as part of my awareness month.

- Our Young Generation members who are aged 18-39, benefited from three support Zoom sessions during the year.

- We held two Zoom support sessions for parents of children with myasthenia, this gave parents the opportunity to come together with other parents and share experiences and gain peer support from others in similar situations.

- Myaware provided one Zoom support session focused on Congenital Myasthenic Syndrome.

- In October 2022 we hosted a Zoom support session focused on living with myasthenia.

- 672 members attended national Zoom sessions to access peer support, information, and friendship.

- Over 972 people used the carefully moderated myaware member only closed Facebook groups, which provide a safe platform on which to share thoughts, concerns and experiences and receive information and support.

- Telephone and email support are provided Monday to Friday, 9am to 5pm for members who need advice, information or someone to talk to. This service is delivered by our dedicated support team and head office staff.

- Benefits and Welfare advice was effectively and empathetically delivered to 349 members, this increased by 16% from last year

- The myaware Counsellor was available by phone to help members with the emotional impact of living with a long-term condition – this service delivered 76 counselling sessions during the year but saw a 60% decrease in service demand compared to the previous year.

REPORT OF THE TRUSTEES

Research

The Oxford Myasthenia Patient Sample Store – Dr Sarosh Irani (NDCN, Oxford)

Dr Sarosh Irani applied to myaware for funding to secure purchase of a new tank for storing frozen cells over liquid nitrogen and replacement of an existing -20°C freezer. This grant was originally granted by myaware however, it became apparent that the grant funding would be used to cover ongoing maintenance costs for the biobank. In light of this, it was seen that the most appropriate way forward was for myaware to withdraw the offer of funding and advise the applicant that if they wished to re-apply for funding with the express interest of myaware supporting maintenance of the biobank than they were to do so by the end of October 22 or by the end of January 23. No application was received.

Deep Phenotyping Study – Professor Paul Maddison, Professor Sarosh Irani, and Dr Phil Ambrose (Nottingham and Oxford University Hospitals NHS Trust)

Following Dr Ambrose's return to the fellowship in the Summer of 2021, he completed his study focusing on a way in which a set of available drugs may be able to modulate the function of immune cells in patients with myasthenia gravis. He did so using a rare collection of immune cells donated by untreated old and young myasthenia gravis patients who worked with Professor Paul Maddison in Nottingham. Dr Ambrose focused on T cells in this regard, cells which are normally responsible for producing autoantibodies and this is done incorrectly in myasthenia gravis. The aim of this was to identify if available drugs were able to block T cell activation. This work is important for the future of tailored therapies for individuals with myasthenia gravis. Dr Ambrose's work finished February 2023 and he filed his final report with myaware.

National Myasthenia Database – Dr Mohammed Ashraghi (University of Oxford)

The development of the first national myasthenia database is nearing completion under the care of Dr Mohammed Ashraghi. The database has been designed to be user-friendly, web-based, and be able to cope with real-time data entry validation. The database has been signed off by IT, information compliance, and legal teams to ensure all data remains safe. The research ethics committee has completed their review of the project and approved the database for five years. The database will initially be based at Oxford but will begin recruiting at other hospitals around the UK once it goes live. The project team are currently working on recruiting a database coordinator who will help oversee this. Currently, there are ongoing discussions on how best to ensure the longevity and funding of this database, as well as the best method of entering the first wave of patient data.

REPORT OF THE TRUSTEES

Research continued

Optimising the Immunosuppressive Management of Myasthenia Gravis – Dr Katy Dodd (University of Manchester)

This is a short-term project that forms part of Dr Dodd's PhD studies at the University of Manchester. In Dr Dodd's project, flow cytometry will be used to analyse blood samples from different patients with varying severities of myasthenia gravis, altering sub-type (early and late onset), as well as patients who are being treated with various immunosuppressive medications. Dr Dodd presented data at the Association of British Neurologists conference and is working towards publishing her work on T cells.

Developing Antigen-Specific Immunotherapy in MG – Dr Pyae Phyo San (University of Birmingham)

This fellowship has been undertaken by Dr Pyae Phyo San, a neurology speciality trainee at West Midlands Deanery. This stat of this grant of £316,971, was delayed until 2023/2024. Dr Pyae Phyo San is working under the supervision of Professor Saiju Jacob. This project builds on the previous success of antigen specific immunotherapy in treating other autoimmune conditions such as multiple sclerosis and Graves' disease. Dr San has effectively recruited 45 patients to her and Professors Jacob and Wraith's immunotherapy study. Their initial screening data has helped them identify peptides that show an intense response in their patient group, and they are continuing now with more tests to identify the strongest candidate peptide in the project. This final, best peptide will hopefully be used to explore selective suppression of the immune system in myasthenia gravis patients. Meanwhile, Dr San has been attending Professor Jacob's neuroimmunology clinics twice a week and developing her lab skills with immunologists in Professor Wraith's group.

COVID-19 Vaccine Response in Myasthenia Gravis Patients – Professor Maria Isabel Leite (University of Oxford)

Professor Maria Isabel Leite of the University of Oxford has been granted funding by myaware to answer those very questions. In this project, the responses of T cells and antibodies in patients who have received COVID-19 vaccines will be investigated. In addition to this, the database software REDCap will enable conclusions to be drawn on the influence certain patient and disease characteristics have on the response to vaccination. A final aim of this study is to estimate the rate and severity of MG exacerbations, if any. Currently, myaware is awaiting the final signature from the financial department at University of Oxford.

Instrumented Walking Test and Physical Activity with Congenital Myasthenia Syndrome – Hayley Ramjattan (University of Oxford Hospitals)

Hayley Ramjattan is a clinical specialist neuromuscular physiotherapist at Oxford University Hospitals. Currently, there are no validated outcome measures for use in CMS. Hayley is looking to discover to what extent is there a relationship between instrumented walking test and physical activity in the community for individuals with Congenital Myasthenic Syndrome. This project is expected to carry out a data cut shortly and analysis thereafter.

REPORT OF THE TRUSTEES

Awareness

Myaware continues to work with umbrella organisations such as Neurological Alliance and Rare Disease UK to ensure that our member's views and needs are presented. This year our Rare Disease Day appeal in February 2023 raised £1,960. This appeal raised the awareness of the challenges faced by those living with myasthenia and shared the story of Zainab who was diagnosed at the age of 15.

Myaware continues to raise awareness of the myasthenia's amongst healthcare professionals by providing information packs to GP and neurology clinics across the UK as well as ophthalmologists, dentists and pharmacists with the aim of reducing diagnosis time.

Website performance

	2021/2022	2022/2023
Visitors to the website	151,29	161,100
Pages most visited	• Drugs to avoid • Extraocular muscles • Pyridostigmine	• Drugs to avoid • Extraocular muscles • Pyridostigmine
Average session length	1.46 seconds	1.23 seconds
Bounce back rate	72.6%	71.4%
Number of pages viewed during each session	2.12	1.7

Myaware continues to offer an all-in-one digital inclusion solution called Reachdeck across our whole website. It helps us to ensure that our online content is accessible and usable to everyone by:

- **Improving the accessibility, readability and reach of our online content**
- **Protecting our communications, content and reputation**
- **Empowering our whole team to communicate with confidence**

Reachdeck allows all our web visitors to translate all content in over 100 languages, with the option to request read aloud content, increase or reduce text size and change font and background and text colours to increase readability for those who are visually impaired.

From October to December 2022 myaware engaged our members in a survey regarding life with myasthenia. We received over 1000 responses via post and Survey Monkey. This survey data was then used to update and educate neurologists and clinicians from all over the UK at MG Connects, a national myasthenia conference for healthcare professionals and to help myaware shape the future of our objectives and services.

Unfortunately, we were unable to hold 'My Awareness Month in May 2022. However, MAM was reinstated in May 2023 when the focus was on raising awareness amongst General Practitioners. Our awareness appeal in the month of May 22 raised £3,157. This appeal was centred around Lisa's story and the great challenges she faced in obtaining a myasthenia diagnosis and the impacts these delays had on her life and the lives of her family members. Sharing experiences like Lisa's helps myaware to raise vital awareness amongst the general public and healthcare professionals to ensure that timely diagnosis can be achieved and vital treatments can be offered to improve quality of life for those living with myasthenia.

REPORT OF THE TRUSTEES

Review of Fundraising Activities



Total £329,444

2022/2023 continued to be a challenging year for fundraising. The ongoing impact of Covid-19 along with unfavourable economic times, continued to make face to face fundraising a challenge for many of our supporters. Despite these challenges we are incredibly grateful to all those who were able to continue to support myaware.

- During the year we were grateful to twelve people who remembered myaware in their wills. One bequest for £5,000 was restricted for research purposes. With eleven further bequests without restriction totalling £58,470.

- Donations have decreased by 10% since last year to £85,679.

- Corporate donations and affinity programmes have raised £6,614 during the period.

- We received £28,502 from trusts and grant giving organisations this year. A decrease of 29% since last year. This is due in part to having no dedicated Trust Fundraiser in post during 2022/23.

- Income received via events decreased by 6% on the previous year and totalled £51,400. A dedicated Events Fundraiser was only in place for four months of the year. Highlights of the events income include participants in the London Marathon October 2022 and Great North Run September 2022 raising a total of £24,578 making up 48% of all events income for the year.

- During this financial year myaware received £34,928 in In Memoriam donations and we are extremely grateful to those who have chosen to remember their loved ones by donating to myaware.

REPORT OF THE TRUSTEES

Impact and Value

Myasthenia means muscle weakness. It affects the muscles that let you move but not the automatic ones like your heart that you don't have to think about. Your brain tells your muscles to work, but the message doesn't get through. Symptoms of myasthenia include muscle weakness which makes day to day activities like walking, smiling and talking very difficult. When swallowing and breathing are affected, this can lead to a medical emergency.

Myaware works tirelessly to provide accessible support services and information to everyone who receives a myasthenia diagnosis. We think there are approximately 12,000 people in the UK with myasthenia but there are currently no accurate published figures. Myaware supports approximately 25% of those who have received a myasthenia diagnosis and our aim is to raise more awareness to ensure that everyone who receives a diagnosis can access the support that they need to live well with myasthenia.

A myasthenia diagnosis can be life changing and we aim to make life easier for these people and their families in the following ways:

• Accessible information and support online, on the telephone or via email

- 44 online support get-togethers this year providing support, information and advice
- Three secure Facebook closed groups providing 24/7 online peer support and advice
- National Facebook, Twitter and Instagram pages offering information and signposting
- Telephone and email support via our support and head office teams
- Skype/telephone counselling service
- Benefits and Welfare advice service
- Online information for people living with myasthenia their family members and healthcare professionals via our website

• Increased awareness amongst the public and healthcare professionals

- Vast website offering accessible information on all aspects of living with myasthenia
- A range of detailed information booklets on myasthenia, it's symptoms and treatments
- Newly diagnosed information packs
- Clinic awareness packs for GP surgeries, neurology clinics, dentists, optician and pharmacies
- Representation of our members needs at Neurological Alliance, Rare Disease UK and National Voices.
- Representation of our members needs at annual MG Connects meeting for Neurologists

• Myaware is committed to effectively and responsibly funding research projects in the following areas:

- Cause
- Cure
- Prevention
- Treatment

Myaware is also committed to training clinicians of the future in the field of myasthenia and effectively communicating outcomes regarding current and future research opportunities with transparency

REPORT OF THE TRUSTEES

FUTURE DEVELOPMENTS, AMBITIONS AND LONG-TERM STRATEGIES

Meeting increasing demands of support from people affected by myasthenia requires the charity to maintain its tight focus on cost control.

During the financial year myaware has been continuing to work hard to comply with the General Data Protection Regulation 2018.

Following the pandemic, myaware now provides a nationally focused support team who deliver support via online platforms such as Zoom, social media, telephone and email.

Myaware is committed to seeking member feedback via our annual member survey and short online surveys on our Social Media platforms, this assists with future services strategy.

Myaware is developing additional ways in which to allow our members to submit feedback regarding specific support that they have received. This will be via 'How did we do' short questionnaires.

Myaware will continue to develop the support and information provided via our website and improve our web user journey to ensure ease of access to vital information.

Myaware aims to improve access to our core services for those with accessibility challenges.

Myaware will continue to be committed to effective communication and engagement with our members.

Myaware will increase its work relating to raising awareness with healthcare professionals to improve accurate and timely diagnosis. This is planned via a new External Medical Advisory Committee to assist with providing accurate and up-to-date medical information regarding the myasthenias.

Myaware continues to be committed to representing our members at national forums such as Neurological Alliance and Rare Disease and to feedback updates and outcomes to our members.

Myaware is committed to effectively and responsibly utilising restricted research funding to support projects in the areas of cause, cure, prevention, treatment and general improvement of quality of life, in relation to myasthenia and related conditions.

REPORT OF THE TRUSTEES

REFERENCE AND ADMINISTRATIVE DETAILS

Myaware is a company limited by guarantee

Registered Company Number in England and Wales: 3038358

Registered Charity Number in England and Wales: 1046443

Registered Charity Number on Scotland: SC044744

Registered Office
The College Business Centre
Uttoxeter New Road
Derby DE22 3WZ

Auditors
Johnson Tidsall Limited
Chartered Accountants
81 Burton Road, Derby DE1 1TJ

Chief Executive Officer
Ms Sarah Cuthell

Company Secretary
Ben Bourne, Ellis-Fermor & Negus
also acts as solicitors to the charity:
Ellis-Fermor & Negus, 2 Devonshire
Avenue, Beeston, Nottingham
NG9 1BS

Bankers
Virgin Money
28 St Peter's Square, Derby, DE1 1SL

Trustees
Trevor Ranson – Chairman
Andrew Robinson – Treasurer
Jon Rio
Prof Bethan Peach
Saiju Jacob
Maria Isabel Leite
Huw Simmonds
Tony Ferrari
Rashmi Rungta
Penny Henrion
Bruce McColl (resigned 18.01.23)
Fiona Norwood (joined 18.01.23)

More information regarding the Trustees can be found at:

https://www.myaware.org/Pages/FAQs/Category/meet-the-board

REPORT OF THE TRUSTEES

STRUCTURE GOVERNANCE AND MANAGEMENT

Myaware is a company limited by guarantee, incorporated on 27th March 1995 (number 3038358), a registered charity in England and Wales (number 1046443) and a charity registered in Scotland (number SCO44744). It is governed by its Memorandum and Articles of Association adopted on 27th March 1995 and amended on 29th March 2018.

Subject to the provisions of the Companies Act 2006, the articles and to any directions given by special resolution, the business of the Company is managed by the trustees who may exercise all the powers of the Company. No alteration of the articles and no such direction shall invalidate any prior act of the trustees which would have been valid if that alteration had not been made or that direction had not been given. The powers given by this article shall not be limited by any special power given to the trustees by the articles and a meeting of trustees at which a quorum is present may exercise all the powers exercisable by the trustees.

The pay and remuneration of the senior managers of myaware is considered annually by the Trustees. The board of Trustees meets during the budget setting process to review salary levels, increment payments and inflation rises. The Trustees consider benchmark information relating to similar posts in similar organisations with the charity sector to assist with their decision. We continue to work in partnership with other organisations with shared interest, including Neurological Alliance and Rare Disease UK.

Fundraising and Data Protection

Myaware operates within a strict fundraising policy and never uses telephone cold-calling; purchase address lists to write unsolicited letters, share the membership list to third parties or use any other methods or approaches that may be deemed as harassing or pressurising the recipient. We always respect the privacy of those who share their personal information with us.

Recruitment, appointment, induction and training of new trustees

Only members of the charity may become Trustees.

The Articles of Association allow the Trustees to appoint candidates to become a Trustee (and Director), either to fill a vacancy, or to strengthen the Board. Candidates become known to the Board through the personal knowledge or research of existing Trustees, by interested members of the organisation volunteering their services or, occasionally, as a result of advertising by the Board. Before appointing a new Trustee, the Board will consider any perceived weaknesses in the current Board in terms of special abilities or experience which they believe to be lacking. A potential candidate will then be approached by the Chairman. Where possible the candidate will be invited to attend one or more meetings of the Board as a nonvoting observer. The candidate may then be appointed as a Trustee by a formal motion of the Board.

At present the Board does not operate a formal scheme for the training of Trustees. The Chairman takes care to ensure that they receive personal guidance on their responsibilities under the Charity's Articles, and Charity and Company law. They may also seek advice and assistance from the Treasurer and the Company Secretary. The Board will keep under review the need for a formal training process, which must be consistent with the Charity's financial and personal resources.

REPORT OF THE TRUSTEES

Myaware Sub-committees

Medical Committee:

Prof Bethan Peach

Prof Saiju Jacob

Maria Isabel Leite

Penny Henrion

Fiona Norwood (appointed September 2023)

Charlotte Campbell (appointed March 2023)

Sarah Cuthell CEO

Finance Committee:

Andrew Robinson (Treasurer)

Bruce McColl (resigned February 2023)

Jon Rio

Rashmi Rungta

Jamie Caple (appointed March 2023)

Sarah Cuthell CEO

The Chief Executive Officer (CEO) is appointed by the Trustees to manage the day-to-day operations of the charity. The CEO reports to the Chair as her line manager.

Risk Management

A risk review of the overall organisation takes place annually. The review took place in July 2022 and then in July 2023 when a committee of trustees assessed the major risks. Subsequently, systems and procedures have been established to manage those risks.

An annual budget proposal covering anticipated income and expenditure is created by the CEO and Finance Committee and reviewed by the Trustees. Once agreed, this forms the basis of the financial reserve held by the charity to ensure that commitments can be met. The Finance Committee review performance against the agreed budget on a monthly basis and the full Board considers this quarterly.

The board consider any variation to budget and if necessary, implement changes to mitigate any risks identified.

REPORT OF THE TRUSTEES

FINANCIAL REVIEW

Financial Position

The organisation reported a total net deficit of £395,713 compared with a total net deficit of £296,756 in the previous year due to reduced fundraising income and legacy gifts.

Unrestricted funds decreased by £376,583 to £1,351,414.

Restricted funds decreased by £19,130 to £659,166.

Incoming Resources

• Total incoming resources for the year were £329,444 down by £377,460 from the previous year.

• This year we received £184,077 in unrestricted donations, of which £63,470 relates to legacy gifts. We received £9,962 in restricted funds.

• Income from other trading activities increased by £43,399 to £101,505.

• Investment income has increased by £36,030 to £43,862.

Resources Expended

• Total resources expended reduced by £305,520 to £716,633, due to the delay in finalisation of large restricted research grants commitments in 2023/2024 and a reduction in payroll costs.

• Research costs were reduced by £273,913 on previous year to £92,675 of which £15,349 was restricted.

• Support costs were reduced by £27,922 on previous year to £512,911 of which £12,144 was restricted.

• Awareness costs reduced by £3,976 to £101,257 of which £1,599 was restricted.

• Fundraising costs were increased by £291 to £9,790.

• Total funds stand at £2,010,580 compared with £2,406,293 last year.

• Funds at the year-end were made up of unrestricted funds of £1,351,414 (2022: £1,727,997) and restricted funds of £659,166 (2022: £678,296).

REPORT OF THE TRUSTEES

Reserves Policy

Reserves are held to ensure that planned and committed expenditure over the next five years can be met. Unrestricted funds not invested in tangible and intangible fixed assets (the free reserves) are held to meet a minimum of twelve months budgeted expenditure and to enable the charity to fulfil its planned and committed expenditure over the next five years which are not covered by restricted funds.

As of 31st March 2023, the 12 month's budgeted unrestricted expenditure equates to £823,113 and the free reserves, which amount to £1,346,649 leaving a surplus of £523,536 available for future expenditure. The surplus reflects legacies bequeathed. The charity cannot predict its legacy income year on year, and this can vary significantly. The surplus on funds generated is helping to fund our current year.

Going concern

The COVID-19 pandemic has had a negative effect on the charitable sector, and myaware is no exception to this. The Trustees have set a realistic budget for 2023/24 with a net deficit on unrestricted funds of £536,067. This has been calculated on a reduction in giving and no legacies receivable in the year.

Going concern is not considered an issue as the charity can utilise the surplus on unrestricted funds referred to in the above reserves policy. The liquidity position is monitored by the trustees on a monthly basis and the charity is continuing to operate within its reserves policy. On this basis the trustees consider the going concern basis for the preparation of these financial statements to be appropriate.

Principal Funding Sources

The charity benefitted during the year from a number of generous legacies amounting in total to £63,470.

Donations amounted to £85,679. Events fundraising generated £51,400 and In Memoriam donations raised £34,928

Investment Policy and Objectives

Trustees agree on investments in compliance with the Articles of Association. The return on investment for the year was 2.0% (2022 0.4%). If the change in value of investments is included, the return is 1.6% (2022 1.3%). Note that these figures do not include interest earned on bank current accounts – such interest is identified in a line item in the notes to the accounts. The Trustees consider these results to be satisfactory in the current investment climate but aim to keep this under regular review.

REPORT OF THE TRUSTEES

Statement of Trustees Responsibilities

The Trustees (who are also the directors of myaware Company Limited by Guarantee for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with the applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland.

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application resources, including the income and expenditure of the charitable company for that period. In preparing those financial statements, the trustees are required to:

- Select suitable accounting policies and they apply them consistently.
- Observe the methods and principles in the Charity SORP.
- Make judgements and estimates that are reasonable and prudent.
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006, The Charities and Trustees Investment Act (Scotland) 2005 and The Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

- There is no relevant audit information of which the charitable company's auditors are unaware; and
- The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

The report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

ON BEHALF OF THE BOARD:

Mr Trevor Ranson, Chairman of the Board of Trustees

DATE: 15/12/2023

REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES AND MEMBERS OF MYAWARE

Opinion
We have audited the financial statements of Myaware (the 'charitable company') for the year ended 31 March 2023 which comprise the Statement of Financial Activities, the Balance Sheet and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In our opinion the financial statements:
- give a true and fair view of the state of the charitable company's affairs as at 31 March 2023 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and Regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information
The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Report of the Trustees for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Trustees has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception
In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees.

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) requires us to report to you if, in our opinion:

- adequate and proper accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to take advantage of the small companies' exemption from the requirement to prepare a Strategic Report or in preparing the Report of the Trustees.

Responsibilities of trustees
As explained more fully in the Statement of Trustees' Responsibilities, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

In identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

-The nature and control environment of the charitable company

-Our discussions with management and governance including whether they had knowledge of any actual, suspected or alleged fraud

-The internal controls to mitigate the risks of fraud

Following our review, we have identified the following areas which are deemed to have the highest potential for fraud or material misstatement within the financial statements:

- The timing of revenue recognition
- The evaluation of estimates in respect of legacies
- The correct identification of restricted funds
- The timing and recognition of committed expenditure
- The risk of management override

We also considered any laws and regulations that were central to the operation of the charitable company including company law, charity law, employment law and health and safety.

The following procedures were undertaken in respect of the risks where we identified the potential for material misstatement:

Income from donations and legacies was considered a risk due to the volume and nature of these transactions. Income may be pledged but there may be a timing difference between commitment and receipt. The overall income of the charitable company could be materially understated.

Income transaction testing was performed to ensure completeness of income. Post year end donations and legacies were reviewed to ensure that income was recognised in the correct accounting period in accordance with the charitable company's accounting policy.

In respect of legacies, we also tested the accuracy of estimates by reviewing correspondence obtained from solicitors and executors which included the wills and statements of assets and liabilities of the deceased person's estate and where possible agreed to receipts after date.

Restricted funds in respect of income were tested to donor correspondence to ensure that the restrictions imposed were adhered to by the charitable company in expending those funds. This included vouching a sample of expenditure. In addition, we tested unrestricted income mindful of any non-recognition of restricted funds.

The testing of committed expenditure in relation to grants awarded by the charitable company in respect of research was tested by obtaining copies of the formal grant offer and agreeing the terms to the creditor provision in the financial statements. Trustees' board meeting minutes were reviewed, and all commitments noted in the year were agreed to the financial statements to ensure completeness.

A sample of journal entries were tested for appropriateness and enquiries made of management as to the procedures in place for posting journal entries. During our audit we considered any large, unusual journals or transactions outside the normal course of business which were highlighted as a result of our testing.

We reviewed the minutes of trustees' board meetings and controls put in place by the board of trustees including a review of their risk assessment.

At the planning stage we discussed with management any laws and regulations which were central to the operation of the charitable company.

The financial statements were reviewed alongside our disclosure checklists to identify any unusual or unexpected relationships or any areas of non-compliance. Discussions were held with management where it was considered additional disclosures were required.

We remained alert to any indications of fraud, material misstatement or non-compliance with laws and regulations throughout the audit including those relating to the financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and the trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

David Mellor FCA (Senior Statutory Auditor)
for and on behalf of Johnson Tidsall Limited
Chartered Accountants
& Statutory Auditor
Eligible to act as an auditor in terms of Section 1212 of the Companies Act 2006
81 Burton Road
Derby
Derbyshire
DE1 1TJ

Date: 15/12/23

MYAWARE

STATEMENT OF FINANCIAL ACTIVITIES
(INCORPORATING AN INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 MARCH 2023

	Notes	Unrestricted fund £	Restricted funds £	2023 Total funds £	2022 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	3	**176,917**	**7,160**	**184,077**	640,966
Other trading activities	4	**98,703**	**2,802**	**101,505**	58,106
Investment income	5	**43,862**	**-**	**43,862**	7,832
Total		**319,482**	**9,962**	**329,444**	706,904
EXPENDITURE ON					
Raising funds	6	**9,790**	**-**	**9,790**	9,499
Charitable activities	7				
Research		**77,326**	**15,349**	**92,675**	366,588
Support		**500,767**	**12,144**	**512,911**	540,833
Awareness		**99,658**	**1,599**	**101,257**	105,233
Total		**687,541**	**29,092**	**716,633**	1,022,153
Net gains/(losses) on investments		**(8,524)**	**-**	**(8,524)**	18,493
NET INCOME/(EXPENDITURE)		**(376,583)**	**(19,130)**	**(395,713)**	(296,756)
RECONCILIATION OF FUNDS					
Total funds brought forward		**1,727,997**	**678,296**	**2,406,293**	2,703,049
TOTAL FUNDS CARRIED FORWARD		**1,351,414**	**659,166**	**2,010,580**	2,406,293

The notes form part of these financial statements

MYAWARE

BALANCE SHEET
31 MARCH 2023

	Notes	Unrestricted fund £	Restricted funds £	2023 Total funds £	2022 Total funds £
FIXED ASSETS					
Intangible assets	14	**3,023**	-	**3,023**	7,709
Tangible assets	15	**1,742**	-	**1,742**	4,030
Investments	16	**221,273**	-	**221,273**	229,797
		226,038	-	**226,038**	241,536
CURRENT ASSETS					
Stocks	17	**3,486**	-	**3,486**	4,364
Debtors	18	**116,707**	-	**116,707**	577,599
Cash at bank and in hand		**1,018,497**	**1,015,767**	**2,034,264**	2,093,030
		1,138,690	**1,015,767**	**2,154,457**	2,674,993
CREDITORS					
Amounts falling due within one year	19	**(13,314)**	**(239,282)**	**(252,596)**	(210,480)
NET CURRENT ASSETS		**1,125,376**	**776,485**	**1,901,861**	2,464,513
TOTAL ASSETS LESS CURRENT LIABILITIES		**1,351,414**	**776,485**	**2,127,899**	2,706,049
CREDITORS					
Amounts falling due after more than one year	20	-	**(117,319)**	**(117,319)**	(299,756)
NET ASSETS		**1,351,414**	**659,166**	**2,010,580**	2,406,293
FUNDS	21				
Unrestricted funds				**1,351,414**	1,727,997
Restricted funds				**659,166**	678,296
TOTAL FUNDS				**2,010,580**	2,406,293

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies' regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 15/12/2023 and were signed on its behalf by:

.....
Mr T Ranson - Trustee

The notes form part of these financial statements

1. STATUTORY INFORMATION

Myaware is a charitable company, registered in England and Wales and Scotland. The charitable company's registered company number, registered charity numbers, registered office address and business address can be found in the reference and administrative details of the Report of the Trustees.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', the Companies Act 2006 and the Charities and Trustee Investment (Scotland) Act 2005. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

The currency basis for the preparation of these financial statements is pound sterling (£).

Going concern
The trustees regularly monitor the charity's reserves policy and risk assessment. A realistic budget for 2023/24 has been prepared. Liquid funds and cash flow are monitored on a monthly basis. To date, no material uncertainties exist that would affect the preparation of the financial statements on a going concern basis.

Significant judgements and estimates
The following judgements (apart from those involving estimates) have been made in the process of applying the charitable company's accounting policies that have had the most significant effect on amounts recognised in the financial statements:

Legacies - when calculating amounts due on legacies, management considers the wills of the deceased, executors accounts and notifications received from executors.

Grants - when calculating grant commitments, management considers the nature of the grants as being within the charity's objectives and the possible future benefits for people affected by myasthenia.

Income
All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received, and the amount can be measured reliably.

Donated services and goods are recognised as income when the charity has control over them, the economic benefit is probable and can be measured reliably. In accordance with the Charities SORP (FRS102), the volunteer time of Support Groups is not recognised. Information about their contribution is provided in the Trustees' Annual Report.

For donations to be recognised the charity will have been notified of the amounts and the settlement date. If there are conditions attached to the donation and this requires a level of performance before entitlement can be obtained, then income is deferred until those conditions are fully met or the fulfilment of those conditions is within the control of the charity, and it is probable that they will be fulfilled.

For legacies, entitlement is the earlier of the charity being notified of an impending distribution or the legacy being received. At this point income is recognised.

Income from trading activities includes income earned from fundraising events and trading activities to raise funds for the charity. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred.

Investment income is earned through holding assets for investment purposes such as shares and bank deposit accounts. It includes dividends and interest. It is included when the amount can be measured reliably.

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the charity will comply with conditions attaching to them and the grants will be received using the accrual model.

2. ACCOUNTING POLICIES - continued

Debtors
Other debtors are recognised at the settlement amount due. Prepayments are valued at the amount prepaid.

Expenditure
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Allocation and apportionment of support costs and governance
Resources expended are allocated to the particular activity where the cost relates directly to that activity. However, the cost of overall direction and administration on each activity, including the salary and overhead costs of the general office and regional staff, is apportioned on the following bases which are an estimate, based on staff time, of the amount attributable to each activity:

	Percentage allocation
Research	11%
Support	74%
Awareness	15%

Intangible fixed assets
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:

Computer software - over 3 years straight line

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 20% on cost
Computer equipment	- 33% on cost

Tangible fixed assets are stated at cost or deemed costs less accumulated depreciation. Cost includes costs directly attributable to making the asset capable of operating as intended.

Individual fixed assets costing £500 or more are capitalised at cost.

Investments
Investments are valued at market value which is deemed to be fair value. Movements in market value are reflected in the statement of financial activities as a net gain/(loss).

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Stock is valued on a first in first out basis.

Taxation
The charity is exempt from corporation tax on its charitable activities.

2. ACCOUNTING POLICIES - continued

Fund accounting
The charitable company has both restricted and unrestricted funds. All funds are used to benefit and promote its charitable objects.

Restricted funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose and the restriction means that the funds can only be used for specific projects or activities.

When donors specify that donations and grants are for particular purposes which do not amount to pre-conditions regarding entitlement, this income is included in incoming resources of restricted funds when receivable. The relevant expenditure is then matched as restricted expenditure.

Unrestricted funds are general funds that are available for use at the trustees' discretion in furtherance of any objectives of the charity.

Designated funds are unrestricted funds set aside at the discretion of the trustees for specific purposes.

Pension costs and other post-retirement benefits
The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Operating lease agreements
Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged to the SOFA on a straight line basis over the period of the lease.

Reserves
The charitable company maintains a level of reserves required to fulfil its objectives. The trustees monitor reserves at regular meetings.

Financial instruments
Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

3. DONATIONS AND LEGACIES

	2023	2022
	£	£
Donations	**85,679**	95,583
Legacies	**63,470**	490,115
Grants	**-**	9,218
In Memoriam	**34,928**	46,050
	184,077	640,966

The charity benefits greatly from the involvement of many helpers and volunteers, details of which are given in our annual report. In accordance with FRS102 and the Charities SORP (FRS102), the economic contribution of volunteers is not recognised in these financial statements.

Grants received, included in the above, are as follows:

	2023	2022
	£	£
Coronavirus job retention scheme	**-**	9,218

4. OTHER TRADING ACTIVITIES

	2023	2022
	£	£
Affinity programmes	2,739	1,890
Appeals	6,678	7,370
Collections	1,497	468
Corporate	3,875	7,339
Grants	(3,838)	(53,847)
Lotteries	3,114	4,334
National events	24,033	17,906
Regional events	27,367	36,813
Sales of merchandise	3,700	4,928
Trusts	32,340	30,905
	101,505	58,106

During the 2022 year management implemented changes to the charity's fundraising structure. This restructure was an outcome of Covid and myaware's inability to continue to provide face to face support services. The regional fundraising structure was deemed unfit for current and future purpose and a new national fundraising team structure was implemented.

As a result of this, certain restricted grants applied for on a regional basis in previous years were repaid as the criteria for the grants could no longer be met.

5. INVESTMENT INCOME

	2023	2022
	£	£
Deposit account interest	33,771	908
Current account interest	3,620	538
Dividends on shares and other investments	6,471	6,386
	43,862	7,832

6. RAISING FUNDS

Raising donations and legacies

	2023	2022
	£	£
Merchandise	2,910	2,173
Events	4,250	3,098
Appeal mailings	1,150	996
Lottery	1,480	3,232
	9,790	9,499

7. CHARITABLE ACTIVITIES COSTS

	Direct Costs (see note 8)	Support costs (see note 9)	Totals
	£	£	£
Research	**74,026**	**18,649**	**92,675**
Support	**387,454**	**125,457**	**512,911**
Awareness	**75,412**	**25,845**	**101,257**
	536,892	**169,951**	**706,843**

8. DIRECT COSTS OF CHARITABLE ACTIVITIES

	2023	2022
	£	£
Staff costs	**489,872**	528,511
Medical research	**18,981**	291,025
Medical care	**2,245**	1,529
Travel and miscellaneous	**20,970**	6,829
MyNews & member communications	**3,768**	4,098
Meetings and conferences	**1,056**	1,055
	536,892	833,047

Grants payable during the year were as follows:

	2023	2022
	£	£
Commitments as at 1 April 2022	500,446	421,705
Commitments made in the year	18,981	323,919
Commitments released in the year	-	(32,894)
Grants paid during the year	(162,815)	(212,284)
Commitments as at 31 March 2023	356,612	500,446

A research grant budgeted for in 2022/23 totalling £316,971 was formally committed in the first quarter of the year ended 31 March 2024 once agreement by both parties had been received.

9. SUPPORT COSTS

	Management	Governance costs	Totals
	£	£	£
Research	**16,176**	**2,473**	**18,649**
Support	**108,817**	**16,640**	**125,457**
Awareness	**22,472**	**3,373**	**25,845**
	147,465	**22,486**	**169,951**

9. SUPPORT COSTS - continued

Support costs, included in the above, are as follows:

Management

	Research	Support	Awareness	2023 Total activities	2022 Total activities
	£	£	£	£	£
Rental of premises	1,705	11,470	2,325	15,500	23,755
Utilities and insurance	1,889	12,709	2,741	17,339	18,177
Office equipment	315	2,116	429	2,860	3,845
Printing, postage and stationery	990	6,655	1,349	8,994	9,977
Photocopier costs	100	674	136	910	1,299
Support website	2,356	15,849	3,213	21,418	23,933
IT support & software	5,368	36,115	7,570	49,053	47,084
H R costs	1,666	11,207	2,272	15,145	10,356
General expenses	869	5,846	1,185	7,900	6,825
Bank charges	151	1,015	206	1,372	1,497
Amortisation of intangible fixed assets	515	3,468	703	4,686	15,525
Depreciation of tangible fixed assets	252	1,693	343	2,288	3,076
	16,176	108,817	22,472	147,465	165,349

Governance costs

	Research	Support	Awareness	2023 Total activities	2022 Total activities
	£	£	£	£	£
Trustees' expenses	199	1,339	271	1,809	233
Auditors' remuneration	986	6,634	1,345	8,965	7,268
Legal and professional fees	1,288	8,667	1,757	11,712	6,757
	2,473	16,640	3,373	22,486	14,258

10. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2023	2022
	£	£
Auditors' remuneration	8,965	7,268
Depreciation - owned assets	2,288	3,076
Computer software amortisation	4,686	15,525

11. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 March 2023 nor for the year ended 31 March 2022.

Trustees' expenses

	2023	2022
	£	£
Trustees' expenses	1,809	233

During the year 2 trustees (2022: 2) received reimbursement of their expenses for attending meetings totalling £360.

The charge for 2023 includes accommodation for trustee meetings of £981 and trustee courses £468.

12. STAFF COSTS

	2023	2022
	£	£
Wages and salaries	431,117	462,259
Social security costs	34,059	32,710
Other pension costs	24,696	33,542
	489,872	528,511

The average number of full time equivalent employees during the year was 13 (2022: 15).

The average monthly number of employees during the year was as follows:

	2023	2022
Fundraising, support and awareness	13	15
Management and operations of the charity	4	4
	17	19

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2023	2022
£60,001 - £70,000	1	1

Wages and salaries include redundancy costs of £ 8,328 (2022: £16,327).

The key management personnel of the charity comprises the Chief Executive Officer. The total employee benefits of the key management personnel of the charity amounted to £70,396 including pension contributions (2022: £67,090).

13. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	635,330	5,636	640,966
Other trading activities	118,908	(60,802)	58,106
Investment income	7,832	-	7,832
Total	762,070	(55,166)	706,904
EXPENDITURE ON			
Raising funds	9,499	-	9,499
Charitable activities			
Research	75,563	291,025	366,588
Support	520,538	20,295	540,833
Awareness	104,441	792	105,233
Total	710,041	312,112	1,022,153
Net gains on investments	18,493	-	18,493
NET INCOME/(EXPENDITURE)	70,522	(367,278)	(296,756)
Transfers between funds	16,715	(16,715)	-
Net movement in funds	87,237	(383,993)	(296,756)
RECONCILIATION OF FUNDS			
Total funds brought forward	1,640,760	1,062,289	2,703,049
TOTAL FUNDS CARRIED FORWARD	1,727,997	678,296	2,406,293

14. INTANGIBLE FIXED ASSETS

	Computer software £
COST	
At 1 April 2022 and 31 March 2023	**95,007**
AMORTISATION	
At 1 April 2022	**87,298**
Charge for year	**4,686**
At 31 March 2023	**91,984**
NET BOOK VALUE	
At 31 March 2023	**3,023**
At 31 March 2022	7,709

15. TANGIBLE FIXED ASSETS

	Fixtures and fittings £	Computer equipment £	Totals £
COST			
At 1 April 2022 and 31 March 2023	**13,247**	**45,208**	**58,455**
DEPRECIATION			
At 1 April 2022	**13,247**	**41,178**	**54,425**
Charge for year	**-**	**2,288**	**2,288**
At 31 March 2023	**13,247**	**43,466**	**56,713**
NET BOOK VALUE			
At 31 March 2023	**-**	**1,742**	**1,742**
At 31 March 2022	-	4,030	4,030

16. FIXED ASSET INVESTMENTS

	Listed investments £
MARKET VALUE	
At 1 April 2022	**229,797**
Revaluations	**(8,524)**
At 31 March 2023	**221,273**
NET BOOK VALUE	
At 31 March 2023	**221,273**
At 31 March 2022	229,797

There were no investment assets outside the UK.

Cost or valuation at 31 March 2023 is represented by:

	Listed investments £
Valuation in 2022	**229,797**
Valuation in 2023	**(8,524)**
	221,273

17. STOCKS

	2023	2022
	£	£
Finished goods	3,486	4,364

18. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023	2022
	£	£
Other debtors	84,243	568,640
Prepayments and accrued income	32,464	8,959
	116,707	577,599

19. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023	2022
	£	£
Other creditors	3,964	1,039
Committed grants	239,293	200,690
Accruals and deferred income	9,339	8,751
	252,596	210,480

20. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

	2023	2022
	£	£
Committed grants	117,319	299,756

21. MOVEMENT IN FUNDS

	At 1/4/22	Net movement in funds	At 31/3/23
	£	£	£
Unrestricted funds			
General fund	1,727,997	(376,583)	1,351,414
Restricted funds			
Research	572,818	(9,556)	563,262
Support	101,733	(7,975)	93,758
Awareness	3,745	(1,599)	2,146
	678,296	(19,130)	659,166
TOTAL FUNDS	2,406,293	(395,713)	2,010,580

21. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	**319,482**	**(687,541)**	**(8,524)**	**(376,583)**
Restricted funds				
Research	**5,793**	**(15,349)**	**-**	**(9,556)**
Support	**4,169**	**(12,144)**	**-**	**(7,975)**
Awareness	**-**	**(1,599)**	**-**	**(1,599)**
	9,962	**(29,092)**	**-**	**(19,130)**
TOTAL FUNDS	**329,444**	**(716,633)**	**(8,524)**	**(395,713)**

Comparatives for movement in funds

	At 1/4/21 £	Net movement in funds £	Transfers between funds £	At 31/3/22 £
Unrestricted funds				
General fund	1,640,760	70,522	16,715	1,727,997
Restricted funds				
Research	860,312	(287,494)	-	572,818
Support	198,440	(79,992)	(16,715)	101,733
Awareness	3,537	208	-	3,745
	1,062,289	(367,278)	(16,715)	678,296
TOTAL FUNDS	2,703,049	(296,756)	-	2,406,293

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	762,070	(710,041)	18,493	70,522
Restricted funds				
Research	3,531	(291,025)	-	(287,494)
Support	(59,697)	(20,295)	-	(79,992)
Awareness	1,000	(792)	-	208
	(55,166)	(312,112)	-	(367,278)
TOTAL FUNDS	706,904	(1,022,153)	18,493	(296,756)

21. MOVEMENT IN FUNDS - continued

Restricted funds
Restricted funds comprise:

Research
Restricted funds in this class will be applied to:

a. Scientific and clinical research into the causes, disease mechanisms, diagnosis and epidemiology of Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndrome and other similar disorders of the Neuro-Muscular Junction.

b. The provision of equipment and facilities to support (a).

c. Provision of specialist medical facilities (including staff) where the Trustees consider that such provision has a significant impact on the effectiveness of (a).

Support
Restricted funds in this class will be applied to:

d. Development of new support groups of the charity, to foster the health and welfare of myasthenics and their families and carers.

e. Organisation of Regional Conferences to encourage mutual support between members, myasthenics, and support groups.

f. In exceptional circumstances - provision of specialist medical facilities (including staff) where the Trustees consider that such provision would have a major impact on the health and welfare of myasthenics, and alternative funding cannot be obtained.

Awareness
Restricted funds in this class will be applied to:

g. Preparation, publication and distribution of information about Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndrome and other similar disorders of the Neuro-Muscular Junction. (Including information on their causes, diagnosis and treatment, and issues concerning the lifestyle and quality-of-life of patients with these disorders). Publication and distribution include development and maintenance of the associationÆs internet websites.

h. Publicity and promotion of events to foster awareness, in the general public, national and local government, and other bodies, of these disorders, and the problems experienced by patients and their families and carers.

i. Activities to foster awareness in the medical profession of these disorders, and the problems experienced by patients and their families and carers.

j. Activities to foster awareness in the medical profession of the current state of best medical practice in the diagnosis and treatment of these disorders.

k. Regional and national events to disseminate information about these disorders to myasthenics, their families and carers (including information about current and planned future medical and scientific research).

For presentation purposes all restricted income receivable is allocated to one of the above three categories that best describes its restriction.

A detailed breakdown of the income and expenditure allocated to these categories is available on request.

22. EMPLOYEE BENEFIT OBLIGATIONS

The total contribution paid to Personal Pension Plans in the year for certain employees amounted to £24,696 (2022: £33,542).

23. OTHER FINANCIAL COMMITMENTS

At the year end the charity had financial commitments in respect of rent amounting to £14,049 (2022: £23,760) and other leases amounting to £2,904 (2022: £3,960).

24. RELATED PARTY DISCLOSURES

During the year the charity paid a salary, benefits and expenses reimbursement totalling £21,378 (2022: £19,750) to an employee who is the spouse of a trustee.

The charity also paid £1,121 (2022: £403) for legal services performed by Andrew Lutley, Company Secretary until 31 December 2022.

25. ULTIMATE CONTROLLING PARTY

The charity is controlled by its Board of Trustees.

MYAWARE

DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2023

	2023 £	2022 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	**85,679**	95,583
Legacies	**63,470**	490,115
Grants	**-**	9,218
In Memoriam	**34,928**	46,050
	184,077	640,966
Other trading activities		
Affinity programmes	**2,739**	1,890
Appeals	**6,678**	7,370
Collections	**1,497**	468
Corporate	**3,875**	7,339
Grants	**(3,838)**	(53,847)
Lotteries	**3,114**	4,334
National events	**24,033**	17,906
Regional events	**27,367**	36,813
Sales of merchandise	**3,700**	4,928
Trusts	**32,340**	30,905
	101,505	58,106
Investment income		
Deposit account interest	**33,771**	908
Current account interest	**3,620**	538
Dividends on shares and other investments	**6,471**	6,386
	43,862	7,832
Total incoming resources	**329,444**	706,904
EXPENDITURE		
Raising donations and legacies		
Merchandise	**2,910**	2,173
Events	**4,250**	3,098
Appeal mailings	**1,150**	996
Lottery	**1,480**	3,232
	9,790	9,499
Charitable activities		
Wages	**431,117**	462,259
Social security	**34,059**	32,710
Pensions	**24,696**	33,542
Medical research	**18,981**	291,025
Medical care	**2,245**	1,529
Travel and miscellaneous	**20,970**	6,829
Carried forward	**532,068**	827,894

MYAWARE

DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2023

	2023 £	2022 £
Charitable activities		
Brought forward	**532,068**	827,894
MyNews & member communications	**3,768**	4,098
Meetings and conferences	**1,056**	1,055
	536,892	833,047
Support costs		
Management		
Rental of premises	**15,500**	23,755
Utilities and insurance	**17,339**	18,177
Office equipment	**2,860**	3,845
Printing, postage and stationery	**8,994**	9,977
Photocopier costs	**910**	1,299
Support website	**21,418**	23,933
IT support & software	**49,053**	47,084
H R costs	**15,145**	10,356
General expenses	**7,900**	6,825
Bank charges	**1,372**	1,497
Amortisation of intangible fixed assets	**4,686**	15,525
Depreciation of tangible fixed assets	**2,288**	3,076
	147,465	165,349
Governance costs		
Trustees' expenses	**1,809**	233
Auditors' remuneration	**8,965**	7,268
Legal and professional fees	**11,712**	6,757
	22,486	14,258
Total resources expended	**716,633**	1,022,153
Net expenditure before gains and losses	**(387,189)**	(315,249)
Realised recognised gains and losses		
Realised gains/(losses) on fixed asset investments	**(8,524)**	18,493
Net expenditure	**(395,713)**	(296,756)

MYAWARE

England & Wales - Charity number 1046443

Accounts

myaware

Fighting Myasthenia Together

Myaware Report of the Trustees and Financial Statements For The Year 31st March 2022

Myaware is a Registered Charity No. England & Wales 1046443. Scotland SC044744.
Company Limited by Guarantee No. 3038358 (England & Wales)

Contents

- Chairman's Report 1
- CEO's Report 2 - 5
- Report of the Trustees
  - Objectives and Activities of the Charity 6
  - Achievement and Performance 7
  - Future Developments 14
  - Reference and Administrative Details 15
  - Structure Governance and Management 15
  - Financial Review 17
  - Statement of Trustees Responsibilities 19
- Report of the Independent Auditors 20
- Statement of Financial Activities 24
- Balance Sheet 25
- Cash Flow Statement 26
- Notes to the Cash Flow Statement 27
- Notes to the Financial Statement 28
- Detailed Statement of Financial Accounts 42

Myaware Report of the Trustees and Financial Statements Year Ended 31st March 2022

Chairman's Report – Trevor Ranson



At the start of this financial year, we had experienced twelve months of living with the effects of the Coronavirus pandemic and the continued inability to provide ourprevious face to face support services and awareness raising activities. This resulted in a drastic reduction in workload within the organisation, which subsequently resulted in placing 35% of our staff on furlough leave whilst utilising the Government's Coronavirus job retention scheme (CJRS). After five months of continued reduction in workload, the time had come to consider the long-term adjustments that would be necessary to ensure sustainability for the future of myaware and security of support services for our members.

After much deliberation, in July 2021 myaware implemented a new structure of operation. It was at this point that four members of the myaware team took voluntary redundancy. I would like to extend my heartfelt thanks to those members of staff and our remaining team for their long-standing dedication and support of our members and fundraising supporters.

The new operational structure has resulted in a step away from our previous 'regional' approach to support service delivery and now focuses on a national approach. Since July 2021 myaware's three National Support Co-ordinators and head office team have extended a listening ear, delivered information and signposted all of our members via telephone, online Zoom sessions and social media. Our benefits and welfare advice and emotional support services were unaffected and continue to be provided via telephone and Skype.

Our previous fundraising structure relied on fundraising events and activities out in the community which also proved to be non-existent or difficult throughout the first year of the pandemic and well into the second year. Following necessary changes to the ensure effective and safe fundraising, our regional fundraisers became focused on specific types of fundraising, such as individual giving, events and applications to trusts and grant giving organisations on a national level. Despite the unknown and difficult times which we have all been through, myaware is exceptionally grateful to those donors and supporters who have continued to give what they can and continued to find new and creative ways in which to raise vital funds. Your help and support have kept myaware afloat during the most exceptional times in recent history.

I am delighted to report that despite necessary changes to our remote delivery of support services, they have thrived this year. Myaware has delivered 27 Zoom sessions which have benefited 620 myaware members. These sessions have included updates on myaware funded research projects, drop-in sessions for general chat. Discussion sessions on frequently asked questions and myasthenia subjects, monthly new member sessions. Myaware has also delivered Zoom sessions dedicated specifically to the different types of myasthenia and age categories, which demand information on more specific subjects such as education, employment and pregnancy but to name a few.

As many people turn to social media and web to find the information and networks required to live well with myasthenia, our social media closed groups and information pages continue to thrive and provide essential peer support and vital lifeline.

CEO's Report – Sarah Cuthell

It is estimated that there are approximately 12,000 people living with myasthenia in the UK, at the end of March 2022 myaware had 2775 active members, a reduction of 3% for the same period last year. During this financial year 644 new members have signed up to myaware membership. This clearly identifies that myaware continues to struggle to retain members who have thankfully traversed through the difficult first year of diagnosis and stabilised to such a degree that urgent support is no longer required and so myaware will be concentrating on improving our services for every day living with myasthenia.

Myaware provides support to individuals across the UK, the following data is for members in each of the devolved nations:

- England – 83%
- Northern Ireland – 3%
- Scotland – 9%
- Wales – 5%

ACTIVE MEMBERS



MEMBERSHIP TYPE



Furthermore, our year end data clearly shows that the majority of our members (69%) have been diagnosed with general myasthenia and 15% of our membership are relatives of those who have been diagnosed with any type of myasthenia.

There have been no radical changes to the age demographic of our members during this financial year:

- 11% of members are aged between 18 and 39
- 49% of members are aged between 40 and 69
- 39% of members are aged over 70
- 1% of members have not shared their age



However, our member survey conducted in December 21 and January 22 shows that the average diagnosis age regardless of type is 53 years old.

CEO's Report

Myaware national support services

Myaware members benefit from our range of online and telephone support and information services which guide individuals and their family members through diagnosis and beyond. Since March 2020, myaware has been unable to provide our previous face to face support such as local support groups and annual region conferences due to the risks associated with Covid-19 for our members who are immunocompromised.

Connecting our members online

- **Zoom sessions**

This year we have delivered 27 online Zoom sessions bringing our members together to discuss common issues and share valuable experience. Our highly experienced National Support Co-ordinators and our Benefits and Welfare Officer have delivered positive and empathetic updates regarding support, awareness and research and imparted vital information on how to live well with myasthenia. We are delighted that over 620 members have attended these Zoom sessions throughout the year and benefited from information and peer support. Myaware provides a monthly Zoom session for members who are new to the condition and to our organisation. Our aim is to remove any sense of isolation by guiding newly diagnosed members through the first few months and connecting them with others who find themselves in a similar set of circumstances.

> *"I am writing to thank you for running the Zoom session for new members. I found it a very useful and interesting experience. The follow-up email has a lot of helpful detail and I thank you for that, too. I have been very impressed by the range of information and help which myaware offers. Thank you."*

Our other Zoom sessions include updates and presentations regarding myaware funded research projects. Discussions regarding first aid, medications and treatments, and collaboration with other support organisations like Age UK. Our regular drop-in sessions are for those who simply wish to have a chat and connect with fellow members.

> *"I joined the Zoom research session last night - fascinating and so exciting and a really worthwhile research project."*

- **Peer support network via social media**

Myaware facilitates and manages three national Facebook closed groups and this year we have connected 771 people living with myasthenia and their family members. These groups provide a vital 24/7 lifeline of peer support and a platform for myaware to share updates and answer common questions. Our national peer support closed group caters for all members regardless of type of myasthenia, age, or location. Our myaware kids closed group is especially for parents of children who have been diagnosed with any form of myasthenia and our Young Generation closed group provided a platform for those aged between 18 and 39 where discussion can focus around education, employment or pregnancy and myasthenia.

> *"I know how overwhelming and daunting it can be, so anyone on this thread please message me if you want to. I got so much strength from the wonderful support network on here so want to pay it forward xx."*

CEO's Report

Telephone support and information

Accessing services online can be difficult for some and so our team are available Monday to Friday 9am to 5pm by telephone. Whether members have a burning question or simply need to chat or want to know more about myaware objectives or services, our dedicated Head Office and Support Team members are here to help inform and guide our members.

> *"Thank you so much for listening and understanding my situation, frustration etc. I am generally a very private person and surprised myself that I have chatted about 'things' like I have. Your total understanding is exactly what I need at this time."*

Website information and signposting

The myaware website; www.myaware.org exists to provide an online library of information about the organisation and our objectives, the different types of myasthenia and vital information about how to live well with myasthenia. During the course of the year, we have had over 151,000 visitors to the website. The pages most visited include information on 'drugs to avoid,' 'extraocular muscles' and Pyridostigmine information'.

Myaware utilises our website to showcase our members blogs so that others can feel reassured that they are not alone. Our 'Coronavirus' page has informed our members of key support available during the pandemic both from myaware and external support organisations and the government. Our 'benefits and welfare' page has informed our members of what they are eligible for and ways in which to make life with myasthenia easier, via hidden disability lanyards, RADAR keys for disabled toilets and assistance on public transport.

Our website hosts ReachDesk toolbar which ensures that our visitors can access our content in a way that suits them best. Including text-to-speech, reading and translation support.

Emotional support service

People have many reactions to myasthenia. Our members may have strong reactions to changes to their body or be anxious about treatment. Some people find it difficult to cope with the feeling of loss of control. It can help to talk through any of these issues and feelings with someone outside of their friends and family. Members of myaware can access our confidential one-to-one counselling service, delivered via our accredited counsellor who have many years of experience with people with long-term conditions.

Our emotional support service provides a confidential counselling service by telephone or Skype to members of myaware and their immediate family and carers.

This service allows our members to discuss anything that is worrying them emotionally in complete confidence and without judgement. One of the key triggers of myasthenia is stress and often talking things through is a great way to alleviate stress.

This year the demand for emotional support has increased by 43% compared to last year and myaware has provided 191 counselling sessions to meet this demand.

CEO's Report

Benefits and welfare advice service

The benefits system is complex, and the rules often change and when living with an unpredictable and sometimes debilitating condition like myasthenia, it can be difficult to find the energy and time to fully research every opportunity to improve your quality of life. Myaware's dedicated benefits and welfare officer is here to help our members navigate the benefits system and check if they are entitled to any financial support, support relating to transport, employment, or education.

This year myaware has responded to 295 benefits and welfare enquiries. Amongst these were:

- 41 driving & myasthenia enquiries
- 59 employment and myasthenia enquiries
- 75 Personal Independence Payment enquiries
- 22 Attendance Allowance enquiries
- 21 Blue Badge enquiries

Like all of our support services this advice is available to all members in England, Scotland, Wales, and Northern Ireland and is provided by telephone, on the myaware website and via our Zoom sessions and is available Monday to Friday, 9am to 5pm.

BENEFITS & WELFARE ENQUIRIES



> *"I would just like to take this opportunity to thank myaware for your invaluable advice throughout my PIP claim. My advice to others is don't forget to get all the advice you can from myaware."*

Myasthenia Literature Library

For those who prefer to learn about myasthenia in hard copy print, myaware provides a vast library of information booklets, leaflets, and fliers for those living with myasthenia and healthcare professionals, including the following:

Information booklets	
A medical Guide for Patients with Myasthenia Gravis	Ocular Myasthenia – a guide for the medical professionals
A medical Guide for Patients with LEMS	Myasthenia and pregnancy factsheet
Myasthenia for Complete Beginners	Who am I? Booklet (myasthenia simplified)
Congenital Myasthenia – a guide	Variety of flyers promoting myaware services
Ocular Myasthenia – a guide for patients	

Myaware regularly provide large print version for members with visual impairments.

Myasthenia is a rare condition, and it is therefore very important that we raise vital awareness amongst healthcare professionals. Due to grants from trusts and grant giving organisations, we have been able to provide clinical awareness packs to GP surgeries, pharmacists, dentists, ophthalmologists and neurology clinics.

REPORT OF THE TRUSTEES

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 March 2022 which are also prepared to meet requirements of the directors' reports and accounts for the Companies Act purposes.

The financial statements comply with the Charities Act 2011, The Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Articles of Association and Accounting and reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES OF THE CHARITY

We support people affected by myasthenia and related conditions, raise awareness about the conditions and fund research to find new therapies to reduce their impact and ultimately find a cure.

We provide the following core support services:

- Support and information sessions delivered via Zoom covering research information, general support discussion and benefits and welfare advice
- Monthly new members support sessions via Zoom
- Zoom sessions for condition type and age specific to support to children up to the age of 18 and young people between the ages of 18 and 39.
- Information and support via the myaware website
- Our social media services include closed, secure groups for peer support and pages for information and signposting
- Skype/Telephone counselling service
- Telephone and online welfare and benefits advice service

We raise vital awareness of myasthenia in the following ways:

- We represent our members via membership of umbrella organisations such as UK Neurological Alliances, Rare Disease UK and National Voices
- Myaware provides specific information for our members and the general public via our website
- Myaware provides information packs for clinicians throughout the UK

Myaware is committed to effectively and responsibly funding research projects in the following areas:

Cause, Cure, Prevention, Treatment and Quality of life, in relation to myasthenia and related conditions.

- Myaware is committed to training clinicians of the future in the field of myasthenia.
- Myaware is committed to effectively communicating research project outcomes and future research opportunities with transparency to our members and general stake holders.

To support these aims we undertake fundraising activities and as always are hugely grateful to the many people who have supported us financially and of course our team of volunteers who support us with support and fundraising activities. As always, the challenge is to raise more unrestricted funds that can be used to finance the day to day running of the charity – postage, telephone, printing, on-line services and other core costs and we are particularly grateful to those who donate money that can be used in this way.

REPORT OF THE TRUSTEES

Grant Making Policy

The Charity may award grants to scientific research, specialist myasthenia nurses and training fellowships in support of its objective and activities.

Grants are awarded by the Board of Trustees when funds become available, and only when the reserves position of the charity mitigates the risk committing funds to projects running across several years.

Research grants are awarded following a rigorous peer review process under the control and supervision of the myaware Medical Committee.

Public Benefit

The charitable company has referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing its aims and objectives and in planning its future activities. In particular, the trustees always consider how planned activities will contribute to the aims and objectives they have set.

ACHIEVEMENT AND PERFORMANCE

How we spend our money

Support	£540,833
Research	£366,588
Awareness	£105,233
Fundraising	£9,499

REPORT OF THE TRUSTEES

Support of Members

- Our membership reduced by 3% to 2,775 during the financial year. Our data shows that we have welcomed 644 new members during the year, all of whom have received a 'newly diagnosed support pack'. The reduction in general membership numbers shows that we have a great opportunity to improve our services for members who find themselves in a positive and stable situation by providing more appealing and relevant support for ongoing life with myasthenia.

- Last financial year our support costs reduced by 11% due to inability to deliver face to face support services. This year our support costs have reduced again by 15% as a result of reorganising the organisation to deliver national telephone and online services.

- Newsletters continue to be sent to our members quarterly, providing news, support, encouragement and acknowledgement to those who have supported myaware via donations and fundraising initiatives.

- Our Young Generation members who are aged 18-39, benefited from support Zoom sessions in September 2021.

- Myaware provided two Zoom sessions focused on Congenital Myasthenic Syndrome. These sessions covered subjects relating to physiotherapy, research and treatments and benefited 32 of 52 members who have a CMS diagnosis.

- 456 members attended national Zoom sessions to access peer support, information and friendship

- 164 members attended monthly new member Zoom sessions for an introduction to myaware and an opportunity to meet other newly diagnosed members.

- Over 771 people used the carefully moderated myaware member only closed Facebook groups, which provide a safe platform on which to share thoughts, concerns and experiences and receive information and support

- Telephone and email support are provided Monday to Friday, 9am to 5pm for members who need advice, information or someone to talk to. This service is delivered by our dedicated support team and head office staff

- Benefits and Welfare advice was effectively and empathetically delivered to 295 members

- The myaware Counsellor is available by Skype or 'phone to help members with the emotional impact of living with a long-term condition – this service has delivered 191 counselling sessions, helping our members to prioritise their mental health.

REPORT OF THE TRUSTEES

Research

During this financial year myaware has funded five main research projects relating to myasthenia and the board are currently in the process of reviewing a further three future projects:

The Covid - 19 pandemic has seriously impacted on all research in the United Kingdom with many of our researchers having their immediate focus on helping the NHS to fight the pandemic. However, the situation is slowly returning to normal and research projects are beginning to start up again.

Deep Phenotyping Study

Professor Paul Maddison, Prof Sarosh Irani, Dr Phil Ambrose (Nottingham and Oxford University Hospitals NHS Trust).

Dr Ambrose took 15 months away from his research to return to Nottingham NHS during the pandemic; he returned to his fellowship in the summer of 2021. Dr Ambrose writes:

We have been continuing to follow the journey of patients with myasthenia gravis from first diagnosis since 2014 and now have follow-up data on over 200 patients at 3 years into their diagnosis and around 50 patients over 5 years into their diagnosis. The pandemic has made it hard to get some of the blood samples that we were collecting so a few safely planned home visits have had to be made to continue the banking of blood samples throughout the patients' journeys. We have been looking at immune system pathways that might tell us if the immune system is regulated differently in myasthenia gravis compared to people without the illness. There is also new work which aims to find new ways to isolate the specific immune cells (B cells) that might be causing production of antibodies in myasthenia gravis. This work will help us understand more about the disease-causing B cells and what the development process is leading to the formation of the antibodies.

Dr Sui Wong (Moorfields Eye Hospital NHS Foundation Trust).

Dr Sui Wong has been involved in two myaware-funded projects

Prognostic outcomes of Ocular Myasthenia Gravis: Dr Wong is preparing the data for analysis on the long term (i.e., greater than 2 years) outcome of people with Ocular Myasthenia Gravis (OMG), looking to see how many go onto develop Generalised Myasthenia Gravis. She has initiated a Systematic Review on the characteristics of OMG, in line with the recent TRIPOD (transparent reporting of a multivariable prediction model for individual prognosis or diagnosis) reporting guidelines. This will help identify risk factors which can be assessed by testing in a prediction model designed to determine the risk of developing Generalised Myasthenia Gravis in people who first develop ocular (only) symptoms.

Understanding the pathophysiology of Ocular Myasthenia Gravis through Video Oculography:

Visual Oculography is a non-invasive, video-based method of quantifying movements of the eyes (eye tracking) using a head-mounted mask equipped with small camera. Classifying the subtypes of OMG according to eye movement deficit and antibody levels can begin to shed light on differences which will be relevant to both clinical outcome of the disease and the possibility of more targeted treatments. Dr Wong reports that pleasingly the recruitment targets were reached despite the challenges of COVID - 19. The very complex data collected is now being prepared for analysis, which will take a few months.

National Myasthenia Database (Dr Mohammed Ashraghi (University of Oxford):

This project is a myaware-funded research fellow and is working on the national database for patients with myasthenia, in conjunction with Dr Isabel Leite. Over the summer you may have "met", Dr Ashraghi as he spoke at several virtual myaware meetings describing the project and answering member's questions, which was found to be very helpful and informative. The database is now fully functional and security protocols are now in place to ensure the data security. Currently this is being reviewed by an independent assessor. Once completed and any queries satisfied, the paperwork will be submitted to the health research authority and research ethics committee for final approval. We hope this will not take too long and data collection should start very soon.

REPORT OF THE TRUSTEES

Developing antigen specific Immunotherapy in Myasthenia Gravis (Dr Pyae Phyo San - University of Birmingham)

Dr Pyae Phyo San commenced a myaware-funded Clinical Research Fellowship in August 2021 under the supervision of Professors David Wraith and Saju Jacob, and so is just starting the research journey. The project "Developing Antigen Specific Immunotherapy in Myasthenia Gravis" is funded for three years.

Dr San is currently learning all the laboratory techniques and protocols required. This project will be one of the first studies in Myasthenia to explore the use of disease-specific immunotherapy, which will minimise the potential side effects of currently used non-specific immunosuppressive medications and should yield very exciting results in the future. As well as carrying out the research, Dr San has started seeing myasthenia gravis outpatients twice a week at Queen Elizabeth Hospital Birmingham.

In addition to these five ongoing projects, myaware has also agreed to fund two other smaller projects.

Myaware have agreed to fund a study (subject to contract) which will investigate the effectiveness of the Covid - 19 vaccinations in patients with myasthenia in Oxford. This project will look in detail at the magnitude and duration of the immune response to the vaccine including antibody and T cell responses and should provide invaluable information on the effectiveness of the vaccine protocol in patients with immunosuppressed myasthenia patients. We will share more details on this project in due course.

Finally, a small grant has been made available to Dr Katy Dodds (University of Manchester), working with Dr J Sussman, to enable her to carry out a side project in her main PhD project looking at how the effects of immune checkpoint and complement regulators on T cells differ in patients with myasthenia gravis. Immune checkpoint regulators are control points in the regulation of the immune system and are crucial for self-tolerance and help prevent the immune system from attacking cells indiscriminately. Information on these molecules should help physicians to predict a way to optimise treatment protocols for individual patients.

As always, myaware is only able to fund all these exciting and extremely important projects through the generosity of our members and their families. All the clinicians, scientists and fellows involved in the myaware research programme have asked us to pass on their heartfelt thanks to everyone who has helped fund this invaluable research.

REPORT OF THE TRUSTEES

Awareness

Myaware continues to work with umbrella organisations such as Neurological Alliance and Rare Disease UK to ensure that our member's views and needs are presented. This year our Rare Disease Day appeal in February 2021 raised £4,545. This appeal raised the awareness of the challenges faced by carers of those living with myasthenia and shared the story of Georgina who cares for her husband Peter.

Myaware continues to raise awareness of the myasthenia's amongst healthcare professionals by providing information packs to GP and neurology clinics across the UK as well as ophthalmologists, dentists and pharmacists with the aim of reducing diagnosis time.

This year we reviewed the structure of our website, simplifying menu options and page contents to improve the web user journey. We continue to review all medical content and improve the user journey further. We have implemented a brand-new fundraising subsite, giving valuable instant support to our donors and fundraisers.

Website performance

	2020/2021	2021/2022
Visitors to the website:	157,717	151,229
Pages most visited:	• Drugs to avoid • Pyridostigmine information • Coronavirus information	• Drugs to avoid • Extraocular muscles • Pyridostigmine information
Averages session length	1.41 seconds	1.46 seconds
Bounce back rate:	74.09%	72.65%
Number of pages viewed during each session	2.02	2.12

Myaware offers an all-in-one digital inclusion solution called Reachdeck across our whole website. It helps us to ensure that our online content is accessible and usable to everyone by:

- Improving the accessibility, readability and reach of our online content
- Protecting our communications, content and reputation
- Empowering our whole team to communicate with confidence

Reachdeck allows all of our web visitors to translate all content in over 100 languages, with the option to request read aloud content, increase or reduce text size and change font and background and text colours to increase readability for those who are visually impaired.

In December 2021 myaware engaged our members in a survey regarding living with myasthenia. We received over 900 responses via post and Survey Monkey. This survey data was then used to update and educate neurologists and clinicians from all over the UK at MG Connects, a national myasthenia conference for healthcare professionals.

Unfortunately, we were unable to hold 'My Awareness Month in May 2021 due to the impacts of the pandemic on our service delivery and staff. We look forward to reinstating this in May 2023. However, our appeal in the month of May 21 raised £1,105. This raised awareness of the impacts of the pandemic on those living with myasthenia including feelings of vulnerability, isolation and the risk of job loss impacts on household finances.

REPORT OF THE TRUSTEES

Review of Fundraising Activities

How we raised the money



Total £706,904

The second year of the pandemic continued to pose challenges to our supporters, most of who are living with myasthenia or are relatives or friends of. Extra consideration has been required to protect those who are vulnerable against the Covid-19 virus, making face to face fundraising an ongoing challenge.

- Despite these challenges we are very grateful to all those who were able to continue to support myaware.

- During the year we were grateful to 22 people who remembered myaware in their wills. These bequests total £490,115

- Donations have increased by 14% since last year to £95,583.

- Corporate donations and affinity programmes have raised £9229 during the period.

- We received £40,123 from trusts and grant giving organisation this year. However, post pandemic we were forced to return a total of £53,847 to trusts who had restricted their grants to face to face activity in the year previous (20/21). This was due to myaware's ongoing inability to deliver face to face support services post pandemic.

- Income received via events increased by 20% in the previous year and totalled £54,719. This income is a direct result of myaware's dedicated supporters who took part in virtual runs and other events despite the challenges of the pandemic.

- During this financial year myaware received £46,050 in In Memoriam donations and we are extremely grateful to those who have chosen to remember their loved ones by donating to myaware.

REPORT OF THE TRUSTEES

Impact and Value

Myasthenia means muscle weakness. It affects the muscles that let you move but not the automatic ones like your heart that you don't have to think about. Your brain tells your muscles to work, but the message doesn't get through. Symptoms of myasthenia include muscle weakness which makes day to day activities like walking, smiling and talking very difficult. When swallowing and breathing are affected, this can lead to a medical emergency.

Myaware works tirelessly to provide accessible support services and information to everyone who receives a myasthenia diagnosis. We think there are approximately 12,000 people in the UK with myasthenia but there are currently no accurate published figures. Myaware supports approximately 25% of those who have received a myasthenia diagnosis and our aim is to raise more awareness to ensure that everyone who receives a diagnosis can access the support that they need to live well with myasthenia.

A myasthenia diagnosis can be life changing and we aim to make life easier for these people and their families in the following ways:

- Accessible information and support online, on the telephone or via skype
  - 27 online support get-togethers this year providing support, information and advice
  - Three secure Facebook closed groups providing 24/7 online peer support and advice
  - National Facebook, Twitter and Instagram pages offering information and signposting
  - Telephone support via our support and head office teams
  - Skype/telephone counselling service
  - Benefits and Welfare advice service
  - Online information for people living with myasthenia their family members and healthcare professionals via our website

- Increased awareness amongst the public and healthcare professionals
  - Vast website offering accessible information on all aspects of living with myasthenia
  - A range of detailed information booklets on myasthenia, it's symptoms and treatments
  - Newly diagnosed information packs
  - Clinic awareness packs for GP surgeries, neurology clinics, dentists, optician and pharmacies
  - Representation of our members needs at Neurological Alliance and Rare Disease UK

- Myaware is committed to effectively and responsibly funding research projects in the following areas:
  - Cause
  - Cure
  - Prevention
  - Treatment

  Myaware is also committed to training clinicians of the future in the field of myasthenia and effectively communicating outcomes regarding current and future research opportunities with transparency.

FUTURE DEVELOPMENTS, AMBITIONS AND LONG-TERM STRATEGIES

Meeting increasing demands of support from people affected by myasthenia requires the charity to maintain its tight focus on cost control.

During the financial year myaware has been continuing to work hard to comply with the General Data Protection Regulations (GDPR).

In light of pandemic impacts on face-to-face support delivery, myaware has reorganised the structure of our support delivery. We now provide a nationally focused support team who deliver support via online platforms such as Zoom, social media and Telephone.

Myaware is committed to seeking member feedback regarding if and when to resume face-to-face support and shared a myaware member survey in December 2021 to assist with future services strategy.

Myaware will continue to develop the support and information provided via our website and social media pages and groups.

Myaware aims to improve the awareness of our personal wellbeing services such as counselling and benefits & welfare advice to ensure our members are able to access with ease.

Myaware will continue to be committed to effective communication and engagement with our members.

Myaware will increase its work relating to raising awareness with healthcare professionals to improve accurate and timely diagnosis.

Myaware continues to be committed to representing our members at national forums such as Neurological Alliance and Rare Disease and to feedback updates and outcomes to our members.

Myaware is committed to effectively and responsibly utilising restricted research funding to support projects in the areas of cause, cure, prevention, treatment and general improvement of quality of life, in relation to myasthenia and related conditions.

REFERENCE AND ADMINISTRATIVE DETAILS

Myaware is a company limited by guarantee

Registered Company Number in England and Wales: 3038358

Registered Charity Number in England and Wales: 1046443

Registered Charity Number in Scotland: SC044744

Registered Office
The College Business Centre
Uttoxeter New Road
Derby DE22 3WZ

Chief Executive Officer
Ms Sarah Cuthell

Bankers
Yorkshire Bank
28 St Peter's Square, Derby, DE1 1SL

Auditors
Johnson Tidsall Limited
Chartered Accountants
81 Burton Road, Derby DE1 1TJ

Company Secretary
Andrew Lutley
A J Lutley also acts as solicitors to the charity: A J Lutley Solicitors, Springfield Rookery Hill, Ashtead Park,
Ashtead KT21 1HY

Trustees

Trevor Ranson – Chairman	Maria Isabel Leite
Andrew Robinson – Treasurer	Penny Henrion
Bruce McColl	Rashmi Rungta
Jon Rio	Huw Simmonds
Saiju Jacob	Liz McSheehy (resigned 30.08.21)
Prof Bethan Peach	Stuart Mann (resigned 09.10.21)

More information regarding Trustees can be found at:

www.myaware.org/Pages/FAQs/Category/meet-the-board

STRUCTURE GOVERNANCE AND MANAGEMENT

Myaware is company limited by guarantee, incorporated on 27th March 1995 (number 3038358), a registered charity in England and Wales (number 1046443) and a charity registered in Scotland (number SCO44744). It is governed by its Memorandum and Articles of Association adopted on 27th March 1995 and amended on 29th March 2018.

Subject to the provisions of the Companies Act 2006, the articles and to any directions given by special resolution, the business of the Company is managed by the trustees who may exercise all the powers of the Company. No alteration of the articles and no such direction shall invalidate any prior act of the trustees which would have been valid if that alteration had not been made or that direction had not been given. The powers given by this article shall not be limited by any special power given to the trustees by the articles and a meeting of trustees at which a quorum is present may exercise all the powers exercisable by the trustees.

REPORT OF THE TRUSTEES

The pay and remuneration of the senior managers of myaware is considered annually by the Trustees. The board of Trustees meets during the budget setting process to review salary levels, increment payments and inflation rises. The Trustees consider benchmark information relating to similar posts in similar organisations with the charity sector to assist with their decision.

We continue to work in partnership with other organisations with shared interest, including Neurological Alliance and Rare Disease UK.

Fundraising and Data Protection

Myaware operates within a strict fundraising policy and never uses telephone cold-calling; purchase address lists to write unsolicited letters, share the membership list to third parties or use any other methods or approaches that may be deemed as harassing or pressurising the recipient. We always respect the privacy of those who share their personal information with us.

Recruitment, appointment, induction and training of new trustees

Only members of the charity may become Trustees.

The Articles of Association allow the Trustees to appoint candidates to become a Trustee (and Director), either to fill a vacancy, or to strengthen the Board. Candidates become known to the Board through the personal knowledge or research of existing Trustees, by interested members of the organisation volunteering their services or, occasionally, as a result of advertising by the Board. Before appointing a new Trustee, the Board will consider any perceived weaknesses in the current Board in terms of special abilities or experience which they believe to be lacking. A potential candidate will then be approached by the Chairman. Where possible the candidate will be invited to attend one or more meetings of the Board as a nonvoting observer. The candidate may then be appointed as a Trustee by a formal motion of the Board.

At present the Board does not operate a formal scheme for the training of Trustees. The Chairman takes care to ensure that they receive personal guidance on their responsibilities under the Charity's Articles, and Charity and Company law. They may also seek advice and assistance from the Treasurer and the Company Secretary. The Board will keep under review the need for a formal training process, which must be consistent with the Charity's financial and personal resources.

Medical Committee:	**Finance Committee:**
Prof Bethan Peach	Andrew Robinson (Treasurer)
Saiju Jacob	Bruce McColl
Maria Isabel Leite	Jon Rio
Liz McSheehy (resigned 30.08.21)	Stuart Mann (resigned 09.10.21)
Sarah Cuthell (CEO)	Sarah Cuthell (CEO)

The Chief Executive Officer (CEO) is appointed by the Trustees to manage the day-to-day operations of the charity. The CEO reports to the Chair as her line manager.

REPORT OF THE TRUSTEES

Risk Management

A risk review of the overall organisation takes place annually. The review took place in October 2020 and then July 2022 when the trustees assessed the major risks. Subsequently, systems and procedures have been established to manage those risks.

An annual budget proposal covering anticipated income and expenditure is created by the CEO and Finance Committee and reviewed by the Trustees. Once agreed, this forms the basis of the financial reserve held by the charity to ensure that commitments can be met. The Finance Committee review performance against the agreed budget on a monthly basis and the full Board considers this quarterly.

The board consider any variation to budget and if necessary, implement changes to mitigate any risks identified.

FINANCIAL REVIEW

Financial Position

The organisation reported a total net deficit of £296,756 compared with a total net deficit of £23,835 in the previous year due to reduced fundraising income and legacy gifts.

Unrestricted funds were increased by £87,237 to £1,727,997

Restricted funds decreased by £383,993 to £678,296

Incoming Resources

- Total incoming resources for the year were £706,904, down by £285,895 from the previous year.
- This year we received £635,330 in unrestricted donations, of which £490,115 relates to legacy gifts. We received £5636 in restricted funds.
- Income from other trading activities dropped by £248,812 to £58,106. The decrease reflects the inability to fundraise in the community and the changing donor trends in light of uncertainty, even 12 to 24 months after the first outbreak of the pandemic.
- Investment income has decreased by £2228 to £7832

Resources Expended

- Total resources expended reduced by £30,264 to £1,022,153.
- Research costs were reduced by £40,545 on previous year to £366,588 of which £291,025 was restricted.
- Support costs were reduced by £94,709 on previous year to £540,833 of which £20,295 was restricted.
- Awareness costs increased by £24,730 to £105,233. £792 of which was restricted.
- Fundraising costs were reduced by £830 to £9499
- Total funds stand at £2,406,293 compared with £2,703,049 last year.
- Funds at the year-end were made up of unrestricted funds of £1,727,997 (2021: £1,640,760) and restricted funds of £678,296 (2021: £1,062,289).

REPORT OF THE TRUSTEES

Reserves Policy

Reserves are held to ensure that planned and committed expenditure over the next five years can be met. Unrestricted funds not invested in tangible and intangible fixed assets (the free reserves) are held to meet a minimum of twelve months budgeted expenditure and to enable the charity to fulfil its planned and committed expenditure over the next five years which are not covered by restricted funds.

As of 31st March 2022, the 12 month's budgeted unrestricted expenditure equates to £580,046 and the free reserves, which amount to £1,716,258 leave a surplus of £1,136,212 available for future expenditure. The surplus reflects legacies bequeathed. The charity cannot predict its legacy income year on year, and this can vary significantly. The surplus on funds generated is helping to fund our current year.

Going concern

COVID-19

The pandemic has had a negative effect on the charitable sector, and myaware is no exception to this. The Trustees have set a realistic budget for 2022/23 with a net deficit on unrestricted funds of £596,730. This has been calculated on a reduction in giving and no legacies receivable in the year.

Going concern is not considered an issue as the charity can utilise the surplus on unrestricted funds referred to in the above reserves policy. The liquidity position is monitored by the trustees on a monthly basis and the charity is continuing to operate within its reserves policy. On this basis the trustees consider the going concern basis for the preparation of these financial statements to be appropriate.

Principal Funding Sources

The charity benefitted during the year from a number of generous legacies amounting in total to £490,115

Donations amounted to £95,583. Events fundraising generated £54,719 and In Memoriam donations raised £46,050

Investment Policy and Objectives

Trustees agree on investments in compliance with the Articles of Association. The return on investment for the year was 0.4% (2021 0.5%). If the change in value of investments is included, the return is 1.3% (2021 2.4%). Note that these figures do not include interest earned on bank current accounts – such interest is identified in a line item in the notes to the accounts. The Trustees consider these results to be satisfactory in the current investment climate but aim to keep this under regular review.

REPORT OF THE TRUSTEES

Statement of Trustees Responsibilities

The Trustees (who are also the directors of myaware Company Limited by Guarantee for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with the applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland.

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application resources, including the income and expenditure of the charitable company for that period. In preparing those financial statements, the trustees are required to:

- Select suitable accounting policies and they apply them consistently.
- Observe the methods and principles in the Charity SORP.
- Make judgements and estimates that are reasonable and prudent.
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006, The Charities and Trustees Investment Act (Scotland) 2005 and The Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

- There is no relevant audit information of which the charitable company's auditors are unaware; and
- The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

The report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

ON BEHALF OF THE BOARD:

Mr Trevor Ranson Chairman – Chairman of the Board of Trustees

DATE: 13/12/22

REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES AND MEMBERS OF MYAWARE

Opinion
We have audited the financial statements of Myaware (the 'charitable company') for the year ended 31 March 2022 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In our opinion the financial statements:
- give a true and fair view of the state of the charitable company's affairs as at 31 March 2022 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and Regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information
The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Report of the Trustees for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Trustees has been prepared in accordance with applicable legal requirements.

REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES AND MEMBERS OF MYAWARE

Matters on which we are required to report by exception
In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees.

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) requires us to report to you if, in our opinion:
- adequate and proper accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to take advantage of the small companies exemption from the requirement to prepare a Strategic Report or in preparing the Report of the Trustees.

Responsibilities of trustees
As explained more fully in the Statement of Trustees' Responsibilities, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

In identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

-The nature and control environment of the charity

-Our discussions with management and governance including whether they had knowledge of any actual, suspected or alleged fraud

-The internal controls to mitigate the risks of fraud

Following our review, we have identified the following areas which are deemed to have the highest potential for fraud or material misstatement within the financial statements:

- The timing of revenue recognition
- The evaluation of estimates in respect of legacies
- The correct identification of restricted funds
- The timing and recognition of committed expenditure
- The risk of management override

We also considered any laws and regulations that were central to the operation of the charity including charity law, employment law and health and safety.

The following procedures were undertaken in respect of the risks where we identified the potential for material misstatement:

Income from donations and legacies was considered a risk due to the volume and nature of these transactions. Income may be pledged but there may be a timing difference between commitment and receipt. The overall income of the charity could be materially understated.

Income transaction testing was performed to ensure completeness of income. Post year end donations and legacies were reviewed to ensure that income was recognised in the correct accounting period in accordance with the charity's accounting policy.

In respect of legacies, we also tested the accuracy of estimates by reviewing correspondence obtained from solicitors and executors which included the wills and statements of assets and liabilities of the deceased person's estate and where possible agreed to receipts after date.

Restricted funds in respect of income were tested to donor correspondence to ensure that the restrictions imposed were adhered to by the charity in expending those funds. This included vouching a sample of expenditure. In addition, we tested unrestricted income mindful of any non-recognition of restricted funds.

The testing of committed expenditure in relation to grants awarded by the charity in respect of research was tested by obtaining copies of the formal grant offer and agreeing the terms to the creditor provision in the financial statements. Trustees' board meeting minutes were reviewed, and all commitments noted in the year were agreed to the financial statements to ensure completeness.

A sample of journal entries were tested for appropriateness and enquiries made of management as to the procedures in place for posting journal entries. During our audit we considered any large, unusual journals or transactions outside the normal course of business which were highlighted as a result of our testing.

We reviewed the minutes of trustees' board meetings and controls put in place by the board of trustees including a review of their risk assessment.

At the planning stage we discussed with management any laws and regulations which were central to the operation of the charity.

The financial statements were reviewed alongside our disclosure checklists to identify any unusual or unexpected relationships or any areas of non-compliance. Discussions were held with management where it was considered additional disclosures were required.

We remained alert to any indications of fraud, material misstatement or non-compliance with laws and regulations throughout the audit including those relating to the financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report
This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees, as a body, in accordance with section 44 (1) (c) of the Charities and Trustee Investment Scotland Act 2005 and Regulation 10 of the Charities Accounts (Scotland) Regulations 2006 (as amended). Our audit work has been undertaken so that we might state to the charitable company's members and the trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

David Mellor FCA (Senior Statutory Auditor)
for and on behalf of Johnson Tidsall Limited
Chartered Accountants
& Statutory Auditor
81 Burton Road
Derby
Derbyshire
DE1 1TJ

Date: 13/12/2022

MYAWARE

STATEMENT OF FINANCIAL ACTIVITIES
(INCORPORATING AN INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 MARCH 2022

	Notes	Unrestricted fund £	Restricted funds £	2022 Total funds £	2021 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	3	**635,330**	**5,636**	640,966	675,821
Other trading activities	4	**118,908**	**(60,802)**	**58,106**	306,918
Investment income	5	**7,832**	**-**	**7,832**	10,060
Total		762,070	(55,166)	706,904	992,799
EXPENDITURE ON					
Raising funds	6	9,499	-	9,499	10,329
Charitable activities	7				
Research		**75,563**	**291,025**	**366,588**	326,043
Support		**520,538**	**20,295**	**540,833**	635,542
Awareness		**104,441**	792	**105,233**	80,503
Total		**710,041**	**312,112**	**1,022,153**	1,052,417
Net gains on investments		**18,493**	**-**	**18,493**	35,783
NET INCOME/(EXPENDITURE)		**70,522**	**(367,278)**	**(296,756)**	(23,835)
Transfers between funds	21	**16,715**	**(16,715)**	**-**	-
Net movement in funds		**87,237**	**(383,993)**	**(296,756)**	(23,835)
RECONCILIATION OF FUNDS					
Total funds brought forward		**1,640,760**	**1,062,289**	**2,703,049**	2,726,884
TOTAL FUNDS CARRIED FORWARD		**1,727,997**	**678,296**	**2,406,293**	2,703,049

MYAWARE
COMPANY NUMBER 1046443
BALANCE SHEET
31 MARCH 2022

	Notes	Unrestricted fund £	Restricted funds £	2022 Total funds £	2021 Total funds £
FIXED ASSETS					
Intangible assets	14	**7,709**	**-**	**7,709**	23,477
Tangible assets	15	**4,030**	**-**	**4,030**	3,661
Investments	16	**229,797**	**-**	**229,797**	211,304
		241,536	**-**	**241,536**	238,442
CURRENT ASSETS					
Stocks	17	**4,364**	**-**	**4,364**	2,138
Debtors	18	**577,599**	**-**	**577,599**	859,595
Cash at bank and in hand		**914,288**	**1,178,742**	**2,093,030**	2,040,174
		1,496,251	**1,178,742**	**2,674,993**	2,901,907
CREDITORS					
Amounts falling due within one year	19	(9,790)	(200,690)	**(210,480)**	(273,400)
NET CURRENT ASSETS		**1,486,461**	**978,052**	**2,464,513**	2,628,507
TOTAL ASSETS LESS CURRENT LIABILITIES		**1,727,997**	**978,052**	2,706,049	2,866,949
CREDITORS					
Amounts falling due after more than one year	20	**-**	**(299,756)**	**(299,756)**	(163,900)
NET ASSETS		**1,727,997**	**678,296**	**2,406,293**	2,703,049
FUNDS	21				
Unrestricted funds				**1,727,997**	1,640,760
Restricted funds				**678,296**	1,062,289
TOTAL FUNDS				**2,406,293**	2,703,049

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies' regime.

The financial statements were approved by the Board of Trustees and authorised for issue on ..... and were signed on its behalf by:

.....
Mr T Ranson - Trustee

MYAWARE

CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 MARCH 2022

	Notes	2022 £	2021 £
Cash flows from operating activities			
Cash generated from operations	1	**48,226**	195,137
Net cash provided by operating activities		**48,226**	195,137
Cash flows from investing activities			
Purchase of intangible fixed assets		**-**	(14,759)
Purchase of tangible fixed assets		**(3,445)**	(2,768)
Sale of intangible fixed assets		**243**	-
Interest received		**7,832**	10,060
Net cash provided by/(used in) investing activities		**4,630**	(7,467)
Change in cash and cash equivalents in the reporting period		**52,856**	187,670
Cash and cash equivalents at the beginning of the reporting period		**2,040,174**	1,852,504
Cash and cash equivalents at the end of the reporting period		**2,093,030**	2,040,174

MYAWARE

NOTES TO THE CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 MARCH 2022

1. RECONCILIATION OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2022 £	2021 £
Net expenditure for the reporting period (as per the Statement of Financial Activities)	**(296,756)**	(23,835)
Adjustments for:		
Depreciation charges	**18,601**	31,643
Gain on investments	**(18,493)**	(35,783)
Interest received	**(7,832)**	(10,060)
(Increase)/decrease in stocks	**(2,226)**	1,491
Decrease in debtors	**281,996**	3,802
Increase in creditors	**72,936**	227,879
Net cash provided by operations	**48,226**	195,137

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1/4/21 £	Cash flow £	At 31/3/22 £
Net cash			
Cash at bank and in hand	**2,040,174**	**52,856**	**2,093,030**
	2,040,174	**52,856**	**2,093,030**
Total	**2,040,174**	**52,856**	**2,093,030**

1. STATUTORY INFORMATION

Myaware is a charitable company, registered in England and Wales and Scotland. The charitable company's registered company number, registered charity numbers, registered office address and business address can be found in the reference and administrative details of the Report of the Trustees.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

The currency basis for the preparation of these financial statements is pound sterling (£).

Going concern
The trustees regularly monitor the charity's reserves policy and risk assessment. A realistic budget for 2022/23 has been prepared. Liquid funds and cash flow are monitored on a monthly basis. To date, no material uncertainties exist that would affect the preparation of the financial statements on a going concern basis.

Significant judgements and estimates
The following judgements (apart from those involving estimates) have been made in the process of applying the charitable company's accounting policies that have had the most significant effect on amounts recognised in the financial statements:

Legacies - when calculating amounts due on legacies, management considers the wills of the deceased, executors accounts and notifications received from executors.

Grants - when calculating grant commitments, management considers the nature of the grants as being within the charity's objectives and the possible future benefits for people affected by myasthenia.

Income
All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received, and the amount can be measured reliably.

Donated services and goods are recognised as income when the charity has control over them, the economic benefit is probable and can be measured reliably. In accordance with the Charities SORP (FRS102), the volunteer time of Support Groups is not recognised. Information about their contribution is provided in the Trustees' Annual Report.

For donations to be recognised the charity will have been notified of the amounts and the settlement date. If there are conditions attached to the donation and this requires a level of performance before entitlement can be obtained, then income is deferred until those conditions are fully met or the fulfilment of those conditions is within the control of the charity, and it is probable that they will be fulfilled.

For legacies, entitlement is the earlier of the charity being notified of an impending distribution or the legacy being received. At this point income is recognised.

Income from trading activities includes income earned from fundraising events and trading activities to raise funds for the charity. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred.

Investment income is earned through holding assets for investment purposes such as shares and bank deposit accounts. It includes dividends and interest. It is included when the amount can be measured reliably.

2. ACCOUNTING POLICIES - continued

Income – continued
Grants
Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the charity will comply with conditions attaching to them and the grants will be received using the accrual model.

Debtors
Other debtors are recognised at the settlement amount due. Prepayments are valued at the amount prepaid.

Expenditure
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Allocation and apportionment of support costs and governance
Resources expended are allocated to the particular activity where the cost relates directly to that activity. However, the cost of overall direction and administration on each activity, including the salary and overhead costs of the general office and regional staff, is apportioned on the following bases which are an estimate, based on staff time, of the amount attributable to each activity:

	Percentage allocation
Research	11%
Support	74%
Awareness	15%

Intangible fixed assets
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:

Computer software - over 3 years straight line

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 20% on cost
Computer equipment	- 33% on cost

Tangible fixed assets are stated at cost or deemed costs less accumulated depreciation. Cost includes costs directly attributable to making the asset capable of operating as intended.

Individual fixed assets costing £500 or more are capitalised at cost.

Investments
Investments are valued at market value which is deemed to be fair value. Movements in market value are reflected in the statement of financial activities as a net gain/(loss).

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Stock is valued on a first in first out basis.

Taxation
The charity is exempt from corporation tax on its charitable activities.

2. ACCOUNTING POLICIES - continued

Fund accounting
The charitable company has both restricted and unrestricted funds. All funds are used to benefit and promote its charitable objects.

Restricted funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose and the restriction means that the funds can only be used for specific projects or activities.

When donors specify that donations and grants are for particular purposes which do not amount to pre-conditions regarding entitlement, this income is included in incoming resources of restricted funds when receivable. The relevant expenditure is then matched as restricted expenditure.

Unrestricted funds are general funds that are available for use at the trustees' discretion in furtherance of any objectives of the charity.

Designated funds are unrestricted funds set aside at the discretion of the trustees for specific purposes.

Pension costs and other post-retirement benefits
The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Operating lease agreements
Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged to the SOFA on a straight line basis over the period of the lease.

Reserves
The charitable company maintains a level of reserves required to fulfil its objectives. The trustees monitor reserves at regular meetings.

Financial instruments
Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

3. DONATIONS AND LEGACIES

	2022	2021
	£	£
Donations	**95,583**	83,601
Legacies	**490,115**	519,560
Grants	**9,218**	29,355
In Memoriam	**46,050**	43,305
	640,966	675,821

The charity benefits greatly from the involvement of many helpers and volunteers, details of which are given in our annual report. In accordance with FRS102 and the Charities SORP (FRS102), the economic contribution of volunteers is not recognised in these financial statements.

Grants received, included in the above, are as follows:

	2022	2021
	£	£
Coronavirus Job Retention Scheme	**9,218**	29,355

4. OTHER TRADING ACTIVITIES

	2022	2021
	£	£
Affinity programmes	**1,890**	623
Appeals	**7,370**	15,978
Collections	**468**	921
Corporate	**7,339**	7,065
Grants	**(53,847)**	140,428
Lotteries	**4,334**	5,382
National events	**17,906**	9,225
Regional events	**36,813**	36,263
Sales of merchandise	**4,928**	4,686
Trusts	**30,905**	86,347
	58,106	306,918

During the year management implemented changes to the charity's fundraising structure. This restructure was an outcome of Covid and myaware's inability to continue to provide face to face support services. The regional fundraising structure was deemed unfit for current and future purpose and a new national fundraising team structure was implemented.

As a result of this, certain restricted grants totalling £71,683 applied for on a regional basis in previous years were repaid as the criteria for the grants could no longer be met.

5. INVESTMENT INCOME

	2022	2021
	£	£
Deposit account interest	**908**	3,815
Current account interest	**538**	150
Dividends on shares and other investments	**6,386**	6,095
	7,832	10,060

6. RAISING FUNDS

Raising donations and legacies

	2022	2021
	£	£
Merchandise	**2,173**	2,976
Events	**3,098**	3,357
Appeal mailings	**996**	349
Lottery	**3,232**	3,647
	9,499	10,329

7. CHARITABLE ACTIVITIES COSTS

	Direct Costs (see note 8)	Support costs (see note 9)	Totals
	£	£	£
Research	**347,451**	**19,137**	**366,588**
Support	**407,124**	**133,709**	**540,833**
Awareness	**78,472**	**26,761**	**105,233**
	833,047	**179,607**	**1,012,654**

8. DIRECT COSTS OF CHARITABLE ACTIVITIES

	2022	2021
	£	£
Staff costs	**528,511**	580,867
Medical research	**291,025**	267,677
Medical care	**1,529**	-
Travel and miscellaneous	**6,829**	5,600
MyNews & member communications	**4,098**	7,158
Meetings and conferences	**1,055**	1,427
	833,047	862,729

Grants payable during the year were as follows:

	2022	2021
	£	£
Commitments as at 1 April 2021	421,705	184,343
Commitments made in the year	323,919	275,772
Commitments released in the year	(32,894)	(8,095)
Grants paid during the year	(212,284)	(30,315)
Commitments as at 31 March 2022	500,446	421,705

9. SUPPORT COSTS

	Management	Governance costs	Totals
	£	£	£
Research	**17,568**	**1,569**	**19,137**
Support	**123,158**	**10,551**	**133,709**
Awareness	**24,623**	**2,138**	**26,761**
	165,349	**14,258**	**179,607**

9. SUPPORT COSTS - continued

Support costs, included in the above, are as follows:

Management

	Research	Support	Awareness	2022 Total activities	2021 Total activities
	£	£	£	£	£
Rental of premises	**2,613**	**17,579**	**3,563**	**23,755**	**23,760**
Utilities and insurance	**1,999**	**13,451**	2,727	**18,177**	**17,255**
Office equipment	**-**	**3,845**	**-**	**3,845**	**2,315**
Printing, postage and stationery	**1,097**	**7,383**	**1,497**	**9,977**	**11,680**
Photocopier costs	**143**	**961**	**195**	**1,299**	**1,009**
Support website	**2,633**	**17,710**	**3,590**	**23,933**	**30,461**
IT support & software	**4,982**	**34,642**	**7,460**	**47,084**	**38,773**
H R costs	**1,140**	**7,663**	**1,553**	**10,356**	**5,044**
General expenses	**751**	**5,050**	**1,024**	**6,825**	**1,131**
Bank charges	**165**	**1,108**	224	**1,497**	**1,573**
Amortisation of intangible fixed assets	**1,707**	**11,489**	**2,329**	**15,525**	**25,363**
Depreciation of tangible fixed assets	**338**	**2,277**	**461**	**3,076**	**6,280**
	17,568	**123,158**	**24,623**	**165,349**	**164,644**

Governance costs

	Research	Support	Awareness	2022 Total activities	2021 Total activities
	£	£	£	£	£
Trustees' expenses	**26**	**172**	**35**	**233**	**-**
Auditors' remuneration	**800**	**5,379**	**1,089**	**7,268**	**7,941**
Legal and professional fees	**743**	**5,000**	**1,014**	**6,757**	6,774
	1,569	**10,551**	**2,138**	**14,258**	**14,715**

10. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2022	2021
	£	£
Auditors' remuneration	**7,268**	7,941
Depreciation - owned assets	**3,076**	6,280
Computer software amortisation	**15,525**	25,363

11. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 March 2022 nor for the year ended 31 March 2021.

Trustees' expenses

	2022	2021
	£	£
Trustees' expenses	**233**	-

During the year 2 trustees (2021: 0) received reimbursement of their expenses for attending meetings.

12. STAFF COSTS

	2022	2021
	£	£
Wages and salaries	**463,558**	509,640
Social security costs	**34,490**	36,906
Other pension costs	**30,463**	34,321
	528,511	580,867

The average number of full time equivalent employees during the year was 15 (2021: 19).

The average monthly number of employees during the year was as follows:

	2022	2021
Fundraising, support and awareness	**15**	20
Management and operations of the charity	**4**	4
	19	24

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2022	2021
£60,001 - £70,000	**1**	-

Wages and salaries include redundancy costs of £16,327.

The key management personnel of the charity comprises the Chief Executive Officer. The total employee benefits of the key management personnel of the charity amounted to £67,090. including pension contributions (2021: £61,158).

13. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund	Restricted funds	Total funds
	£	£	£
INCOME AND ENDOWMENTS FROM			
Donations and legacies	673,194	2,627	675,821
Other trading activities	125,725	181,193	306,918
Investment income	10,060	-	10,060
Total	808,979	183,820	992,799
EXPENDITURE ON			
Raising funds	10,329	-	10,329
Charitable activities			
Research	54,506	271,537	326,043
Support	432,395	203,147	635,542
Awareness	80,503	-	80,503
Total	577,733	474,684	1,052,417
Net gains on investments	35,783	-	35,783
NET INCOME/(EXPENDITURE)	267,029	(290,864)	(23,835)
Transfers between funds	73,908	(73,908)	-
Net movement in funds	340,937	(364,772)	(23,835)
RECONCILIATION OF FUNDS			
Total funds brought forward	1,299,823	1,427,061	2,726,884
TOTAL FUNDS CARRIED FORWARD	1,640,760	1,062,289	2,703,049

14. INTANGIBLE FIXED ASSETS

	Computer software £
COST	
At 1 April 2021	**95,736**
Disposals	**(729)**
At 31 March 2022	**95,007**
AMORTISATION	
At 1 April 2021	**72,259**
Charge for year	**15,525**
Eliminated on disposal	**(486)**
At 31 March 2022	**87,298**
NET BOOK VALUE	
At 31 March 2022	**7,709**
At 31 March 2021	23,477

15. TANGIBLE FIXED ASSETS

	Fixtures and fittings £	Computer equipment £	Totals £
COST			
At 1 April 2021	**13,247**	**41,763**	**55,010**
Additions	**-**	**3,445**	**3,445**
At 31 March 2022	**13,247**	**45,208**	**58,455**
DEPRECIATION			
At 1 April 2021	**13,247**	**38,102**	**51,349**
Charge for year	**-**	**3,076**	**3,076**
At 31 March 2022	**13,247**	**41,178**	**54,425**
NET BOOK VALUE			
At 31 March 2022	**-**	**4,030**	**4,030**
At 31 March 2021	-	3,661	3,661

16. FIXED ASSET INVESTMENTS

	Listed investments £
MARKET VALUE	
At 1 April 2021	**211,304**
Revaluations	**18,493**
At 31 March 2022	**229,797**
NET BOOK VALUE	
At 31 March 2022	**229,797**
At 31 March 2021	211,304

16. FIXED ASSET INVESTMENTS - continued

There were no investment assets outside the UK.

The historical cost of fixed asset investments as at 31 March 2022 was £89,858 (2021: £89,858).

17. STOCKS

	2022 £	2021 £
Finished goods	**4,364**	2,138

18. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022 £	2021 £
Other debtors	**568,640**	848,353
Prepayments and accrued income	**8,959**	11,242
	577,599	859,595

19. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022 £	2021 £
Other creditors	**1,039**	6,864
Committed grants	**200,690**	257,805
Accruals and deferred income	**8,751**	8,731
	210,480	273,400

20. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

	2022 £	2021 £
Committed grants	**299,756**	163,900

21. MOVEMENT IN FUNDS

	At 1/4/21 £	Net movement in funds £	Transfers between funds £	At 31/3/22 £
Unrestricted funds				
General fund	**1,640,760**	**70,522**	**16,715**	**1,727,997**
Restricted funds				
Research	**860,312**	**(287,494)**	**-**	**572,818**
Support	**198,440**	(79,992)	**(16,715)**	**101,733**
Awareness	**3,537**	**208**	**-**	**3,745**
	1,062,289	**(367,278)**	**(16,715)**	**678,296**
TOTAL FUNDS	**2,703,049**	**(296,756)**	**-**	**2,406,293**

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	**762,070**	**(710,041)**	**18,493**	**70,522**
Restricted funds				
Research	**3,531**	**(291,025)**	**-**	**(287,494)**
Support	**(59,697)**	**(20,295)**	**-**	(79,992)
Awareness	**1,000**	(792)	**-**	**208**
	(55,166)	**(312,112)**	**-**	**(367,278)**
TOTAL FUNDS	**706,904**	**(1,022,153)**	**18,493**	**(296,756)**

Comparatives for movement in funds

	At 1/4/20 £	Net movement in funds £	Transfers between funds £	At 31/3/21 £
Unrestricted funds				
General fund	1,299,823	267,029	73,908	1,640,760
Restricted funds				
Research	1,204,757	(270,537)	(73,908)	860,312
Support	220,117	(21,677)	-	198,440
Awareness	2,187	1,350	-	3,537
	1,427,061	(290,864)	(73,908)	1,062,289
TOTAL FUNDS	2,726,884	(23,835)	-	2,703,049

21. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	808,979	(577,733)	35,783	267,029
Restricted funds				
Research	1,000	(271,537)	-	(270,537)
Support	181,470	(203,147)	-	(21,677)
Awareness	1,350	-	-	1,350
	183,820	(474,684)	-	(290,864)
TOTAL FUNDS	992,799	(1,052,417)	35,783	(23,835)

A current year 12 months and prior year 12 months combined position is as follows:

	At 1/4/20 £	Net movement in funds £	Transfers between funds £	At 31/3/22 £
Unrestricted funds				
General fund	1,299,823	337,551	90,623	1,727,997
Restricted funds				
Research	1,204,757	(558,031)	(73,908)	572,818
Support	220,117	(101,669)	(16,715)	101,733
Awareness	2,187	1,558	-	3,745
	1,427,061	(658,142)	(90,623)	678,296
TOTAL FUNDS	2,726,884	(320,591)	-	2,406,293

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	1,571,049	(1,287,774)	54,276	337,551
Restricted funds				
Research	4,531	(562,562)	-	(558,031)
Support	121,773	(223,442)	-	(101,669)
Awareness	2,350	(792)	-	1,558
	128,654	(786,796)	-	(658,142)
TOTAL FUNDS	1,699,703	(2,074,570)	54,276	(320,591)

21. MOVEMENT IN FUNDS - continued

Restricted funds
Restricted funds comprise:

Research
Restricted funds in this class will be applied to:

a. Scientific and clinical research into the causes, disease mechanisms, diagnosis and epidemiology of Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndrome and other similar disorders of the Neuro-Muscular Junction.

b. The provision of equipment and facilities to support (a).

c. Provision of specialist medical facilities (including staff) where the Trustees consider that such provision has a significant impact on the effectiveness of (a).

Support
Restricted funds in this class will be applied to:

d. Development of new support groups of the charity, to foster the health and welfare of myasthenics and their families and carers.

e. Organisation of Regional Conferences to encourage mutual support between members, myasthenics, and support groups.

f. In exceptional circumstances - provision of specialist medical facilities (including staff) where the Trustees consider that such provision would have a major impact on the health and welfare of myasthenics, and alternative funding cannot be obtained.

Awareness
Restricted funds in this class will be applied to:

g. Preparation, publication and distribution of information about Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndrome and other similar disorders of the Neuro-Muscular Junction. (Including information on their causes, diagnosis and treatment, and issues concerning the lifestyle and quality-of-life of patients with these disorders). Publication and distribution includes development and maintenance of the association's internet websites.

h. Publicity and promotion of events to foster awareness, in the general public, national and local government, and other bodies, of these disorders, and the problems experienced by patients and their families and carers.

i. Activities to foster awareness in the medical profession of these disorders, and the problems experienced by patients and their families and carers.

j. Activities to foster awareness in the medical profession of the current state of best medical practice in the diagnosis and treatment of these disorders.

k. Regional and national events to disseminate information about these disorders to myasthenics, their families and carers (including information about current and planned future medical and scientific research).

For presentation purposes all restricted income receivable is allocated to one of the above three categories that best describes its restriction.

A detailed breakdown of the income and expenditure allocated to these categories is available on request.

21. MOVEMENT IN FUNDS - continued

Transfers between funds

During the year £16,715 was transferred from restricted funds to unrestricted funds as a result of the change in the charity's fundraising structure from a regional to a national basis.

As at 1 April 2021 the charity held restricted funds which had been donated for use on a regional basis. Since this was no longer applicable, the donors were contacted and offered repayment or asked if the funds could be transferred to general unrestricted funds. The above balance represents donations confirmed as transferrable to general unrestricted funds by the donor.

22. EMPLOYEE BENEFIT OBLIGATIONS

The total contribution paid to Personal Pension Plans in the year for certain employees amounted to £30,463 (2021: £34,321).

23. OTHER FINANCIAL COMMITMENTS

At the year end the charity had financial commitments in respect of rent amounting to £23,760. (2021: £23,760) and other leases amounting to £3,960. (2021: £5,016).

24. RELATED PARTY DISCLOSURES

During the year the charity paid a salary, benefits and expenses reimbursement totalling £19,750 (2021: £19,547) to an employee who is the spouse of a trustee.

The charity also paid £403 (2021: £2,425) for legal services performed by Andrew Lutley, Company Secretary.

25. ULTIMATE CONTROLLING PARTY

The charity is controlled by its Board of Trustees.

DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2022

	2022 £	2021 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	**95,583**	83,601
Legacies	**490,115**	519,560
Grants	**9,218**	29,355
In Memoriam	**46,050**	43,305
	640,966	675,821
Other trading activities		
Affinity programmes	**1,890**	623
Appeals	**7,370**	15,978
Collections	**468**	921
Corporate	**7,339**	7,065
Grants	**(53,847)**	140,428
Lotteries	**4,334**	5,382
National events	**17,906**	9,225
Regional events	**36,813**	36,263
Sales of merchandise	**4,928**	4,686
Trusts	**30,905**	86,347
	58,106	306,918
Investment income		
Deposit account interest	**908**	3,815
Current account interest	**538**	150
Dividends on shares and other investments	**6,386**	6,095
	7,832	10,060
Total incoming resources	706,904	992,799
EXPENDITURE		
Raising donations and legacies		
Merchandise	**2,173**	2,976
Events	**3,098**	3,357
Appeal mailings	**996**	349
Lottery	**3,232**	3,647
	9,499	10,329
Charitable activities		
Wages	**463,558**	509,640
Social security	**34,490**	36,906
Pensions	**30,463**	34,321
Medical research	**291,025**	267,677
Medical care	**1,529**	-
Travel and miscellaneous	**6,829**	5,600
Carried forward	**827,894**	854,144

DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2022

	2022 £	2021 £
Charitable activities		
Brought forward	**827,894**	854,144
MyNews & member communications	**4,098**	7,158
Meetings and conferences	**1,055**	1,427
	833,047	862,729
Support costs		
Management		
Rental of premises	**23,755**	23,760
Utilities and insurance	**18,177**	17,255
Office equipment	**3,845**	2,315
Printing, postage and stationery	**9,977**	11,680
Photocopier costs	**1,299**	1,009
Support website	**23,933**	30,461
IT support & software	**47,084**	38,773
H R costs	**10,356**	5,044
General expenses	**6,825**	1,131
Bank charges	**1,497**	1,573
Amortisation of intangible fixed assets	**15,525**	25,363
Depreciation of tangible fixed assets	**3,076**	6,280
	165,349	164,644
Governance costs		
Trustees' expenses	**233**	-
Auditors' remuneration	**7,268**	7,941
Legal and professional fees	**6,757**	6,774
	14,258	14,715
Total resources expended	**1,022,153**	1,052,417
Net expenditure before gains and losses	**(315,249)**	(59,618)
Realised recognised gains and losses		
Realised gains/(losses) on fixed asset investments	**18,493**	35,783
Net expenditure	**(296,756)**	(23,835)

myaware

Fighting Myasthenia Together

The College Business Centre
Uttoxeter New Road, Derby DE22 3WZ
Tel: 01332 290219
Email: info@myaware.org
Web: www.myaware.org

Myaware is a Registered Charity No. England & Wales 1046443. Scotland SC044744.
Company Limited by Guarantee No. 3038358 (England & Wales)

MYAWARE

England & Wales - Charity number 1046443

Accounts

myaware
Fighting Myasthenia Together

Myaware Report of the Trustees and Financial Statements For the Year Ended 31st March 2021

Myaware is a Registered Charity No. England & Wales 1046443. Scotland SC044744. Company Limited by Guarantee No. 3038358 (England & Wales)

Contents

- Chairman's Report 1
- CEO's Report 2
- Report of the Trustees 3 - 15
- Report of the Independent Auditors 16 - 19
- Statement of Financial Activities 20
- Balance Sheet 21
- Cash Flow Statement 22
- Notes to the Cash Flow Statement 23
- Notes to the Financial Statements 24 - 36
- Detailed Statement of Financial Activities 37- 38

Chairman's Report - Trevor Ranson

This financial year has been like no other in the history of myaware as we have all strived to adjust to the impacts of the Covid-19 pandemic. We began the financial year amidst a national lockdown which resulted in drastic changes to the support services that myaware could continue to deliver to our members. As the year went on, we all attempted to adapt to a new way of living and working whilst abiding by the government guidelines to limit the infection rates. Despite great adversity our members worked with us to maximise the support services which were implemented to replace the once face-to-face support group meetings and regional conferences.

Myaware previously operated across nine regions of the UK providing face-to-face support to those with long term diagnoses and also to those who were recently diagnosed. During this financial year, this service was replaced with regional online support groups delivered via Zoom and our dedicated support and head office team continued to respond to member enquiries via telephone, email, website and social media pages and groups.

Our age and condition specific support services for kids, those aged 18 – 39 and those diagnosed with more rare forms of myasthenia such as LEMS and CMS were also modified to enable online delivery. Although this was a new way of working our staff rose to the challenge and our members maximised their newly acquired online skills to access this support. Our social media groups have been a particularly helpful lifeline for those of all ages and type of myasthenia diagnosis. Social media has provided platforms on which to share thoughts feelings and valuable information, thus reducing feelings of isolation during highly uncertain times.

Raising awareness during this financial year has been more challenging than ever given the limitations imposed upon us. We look forward to representing our members at national GP and nurse conferences as soon as Covid-19 restrictions reduce and conferences resume.

It will come as no surprise that our research projects have been equally affected by the negative impacts of Covid-19. With limited access to research labs, some projects have had to be paused until further notice and just like everyone else our research project leaders have had to safeguard their own health.

Sadly, I must acknowledge the losses that we have all experienced during this time. I send my sincere condolences to all myaware members who have lost someone close to them, either during or as a result of this pandemic. Our thoughts are with you all and myaware continues to be here to support you.

Despite the challenges we have all faced since the pandemic began, I'm delighted to say that myaware has supported around 3000 members during this time. I believe that we have all adjusted as best we could to ensure that we can continue to provide vital support to one another. We are continually humbled by the ability that our members have displayed to adjust and adapt to the changes we have all faced over the past twelve months. I would like to thank each and every one of our members for their resilience and co-operation during this time. Myaware is exceptionally grateful to every individual and organisation that has supported us via donations or fundraising initiatives this year, it is your support and generosity which enables myaware to continue in these unprecedented and changeable times.

CEO's Report - Sarah Cuthell

This financial year has been highly challenging for all charities and myaware is no different. We started the year with 2764 active members to support throughout the Covid-19 pandemic with just 25 members of staff and by April 2021 active member numbers had increased by 4% to 2863. During this financial year myaware obtained 598 brand new members but unfortunately 499 members lapsed within this period. Retention of members has been a challenge for myaware since 2018 when GDPR was introduced, as some members don't realise that without their annual membership renewal and express consent, myaware cannot continue to contact them.

Our figures show that this year the number of members registered with myaware who have not been formally diagnosed has reduced by 34% which is very encouraging. Swift and clear diagnosis is of the highest importance and ensures effective treatment can be given and relevant support can be accessed to improve quality of life.

Membership age range



Membership type of myasthenia



The demand for myaware's Benefits and Welfare advice service has increased by 29% since last year as our member's situations have been affected by the pandemic. Notable increases in type of enquiry were in the areas of general, driving, employment and Blue Badge. Myaware has been actively promoting this service on myaware social media as well as featuring more focused articles on education and employment in our quarterly newsletter.

Our emotional support service provided by our in-house Counsellor has also continued to be in high demand this year. Our counselling service is totally confidential and free of charge to all myaware members. The value of this service has increased during such difficult and unpredictable times as the pandemic has created an increased sense of isolation, worry and mental health difficulties.

Following Covid-19 related lockdowns and restrictions, myaware shifted its focus from face-to-face support services to online support sessions delivered via Zoom. The planning around this involved research into security, technology, and best communication practices. Our support team delivered 97 Zoom sessions with an estimated 841 participants. In a poll taken after each session, participants consistently reported that they benefitted from hearing from professionals and others living with myasthenia.

REPORT OF THE TRUSTEES

Introduction

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 March 2021 which are also prepared to meet requirements of the directors' reports and accounts for the Companies Act purposes.

The financial statements comply with the Charities Act 2011, The Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Articles of Association and Accounting and reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES OF THE CHARITY

We support people affected by myasthenia and related conditions, raise awareness about the conditions and fund research to find new therapies to reduce their impact and ultimately find a cure.

We provide the following core support services:

- Support group sessions delivered via Zoom covering research information, general support discussion and benefits and welfare advice
- Monthly new members support sessions via Zoom
- Two national support groups which provide age specific support to children up to the age of 18 and young people between the ages of 18 and 39. Both groups meet online via Zoom
- Information and support via the myaware website and social media platforms
- Skype/Telephone counselling service
- Welfare and benefits advice service

We raise vital awareness of myasthenia in the following ways:

- We represent our members at local and national Neurological Alliance and Rare Disease forums
- Attend national seminars and conferences for healthcare professionals such as Pulse Live and The Royal College of General Practitioners where restrictions allow
- Myaware provides specific information for our members, healthcare professionals and the general public via our website and printed clinic packs
- Due to the pandemic we were unable to hold our second 'My Awareness Month'. However, we look forward to reinstating this in May 2021

Myaware is committed to effectively and responsibly funding research projects in the following areas:

- Cause
- Cure
- Prevention
- Treatment
- Quality of life

In relation to myasthenia and related conditions.

- Myaware is committed to training clinicians of the future in the field of myasthenia.
- Myaware is committed to effectively communicating research project outcomes and future research opportunities with transparency to our members and general stake holders.

To support these aims we undertake fundraising activities and as always are hugely grateful to the many people who have supported us financially and of course, our team of volunteers who assist us with support and fundraising activities. As always, the challenge is to raise more unrestricted funds that can be used to finance the day to day running of the charity – postage, telephone, printing, on-line services and other core costs and we are particularly grateful to those who donate money that can be used in this way.

Grant Making Policy

The Charity may award grants to scientific research, specialist myasthenia nurses and training fellowships in support of its objective and activities.

Grants are awarded by the Board of Trustees when funds become available, and only when the reserves position of the charity mitigates the risk committing funds to projects running across several years.

Research grants are awarded following a rigorous peer review process under the control and supervision of the myaware Medical Committee.

Public Benefit

The charitable company has referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing its aims and objectives and in planning it's future activities. In particular, the trustees always consider how planned activities will contribute to the aims and objectives they have set.

ACHIEVEMENT AND PERFORMANCE

How we spend our money



Support	£635,542
Research	£326,043
Awareness	£80,503
Fundraising	£10,329

REPORT OF THE TRUSTEES

Support of Members

- Our membership rose by 4% during the year. We continue to endeavour to raise awareness of the need for consent to contact in all of our communications, in order to support as many people living with myasthenia as possible
- Support costs reduced by 11% over the previous period due to inability to deliver face to face support
- Newsletters were sent quarterly to each member providing news, support, encouragement and acknowledgement to those who have supported myaware via donations and fundraising initiatives
- Newly diagnosed Information packs were sent to 598 new members providing vital information and help
- Since their introduction in October 2020 the New Member Zoom sessions have proved to be extremely popular and helpful to those taking part, with an average of 20 participants each session. 100% of participants responded that they would recommend the session to someone who had been newly diagnosed. Members also found the sessions helpful in knowing where to get help, reducing stress and feelings of isolation and knowing that they are not alone
- Supporting children with myasthenia - Parents and carers attended a Q&A Zoom session in August 20 which included a section about welfare and benefits and enabled members to gain peer support from others. Home schooling had been a particular challenge for many during the pandemic. In October 20, Kids Group members also attended a 'myfriends' fun Zoom session, where 11 families joined together for a quiz, charades, and a sharing of experience and knowledge
- Two Zoom sessions were held focusing on our Young Generation members 18-39 age category. These were well attended with positive feedback
- The CMS Patient day hosted by the myaware team via Zoom and presented by Dr Jacqueline Palace from Oxford's referral centre for CMS proved a great success with over 33 patients/ members logging on to take part. The online conference in December 2020 included speaker's Dr Munot, Prof Beeson, Dr Ramdas and Dr Jayakumar
- 841 members attended national Zoom sessions to access peer support, information and friendship
- Over 625 people used the carefully moderated myaware closed Facebook groups. Since these groups were made 'member only' groups they provide a much safer platform on which to share thoughts, concerns and experiences and receive information and support
- Telephone and email support are provided Monday to Friday, 9am to 5pm for members who need advice, information or someone to talk to. This service is delivered by our dedicated support team and head office staff
- Benefits and Welfare advice was empathetically provided to 341 members
- The myaware Counsellor is available by Skype or 'phone to help members with the emotional impact of living with a long-term condition. The demand for this service has continued due to the impacts of the pandemic and has benefited 134 individuals during this financial year

REPORT OF THE TRUSTEES

Research

During this financial year myaware has funded four main research projects relating to myasthenia:

Deep Phenotyping Study

Professor Paul Maddison, Prof Sarosh Irani, Dr Phil Ambrose (Nottingham and Oxford University Hospitals NHS Trust):
This study looks at the detailed clinical and immunological phenotyping in MG from a new, large prospective study. Dr Ambrose has currently been unable to return to Oxford and remained in Nottingham, where he has been working in both Neurology and general medicine departments for the NHS, where demand is high for physicians to assist with Covid-19 patients. His myaware research grant has been suspended but will restart when the pandemic restrictions reduce and the research laboratories in Oxford can reopen. Myaware has subsequently approved a project extension due to these extenuating circumstances, Dr Ambrose will complete the Deep Phenotyping of MG project twelve months after he is able to restart.

The Ocular Myasthenia prospective study.

Dr Sui Wong (Moorfields Eye Hospital NHS Foundation Trust):
This study seeks to follow patients who present with purely ocular myasthenia to see if they progress to generalised myasthenia. Dr Wong has completed the recruitment for this project and looks forward to the second year follow up review to be completed in 2021. Thankfully this study has not been impacted at all by the pandemic.

Supersynapse project

Professor David Beeson and Mirela Panea (Oxford University Hospitals NHS Trust): With the March 2020 'lock down' all research experiments were stopped at short notice. The research team continued to analyse data working from home but clearly this delayed ongoing research. Work slowly resumed but only after extensive modification of laboratory layout and stringent social distancing; full occupation of the laboratory was only achieved in September 20. Despite the return of the undergraduate students to Oxford no cases of Covid have occurred among the 500 Institute researchers. The supersynapse project funded by myaware was obviously delayed but as all experimental work had finished Mirela Panae was able to analyse data and write her thesis. The team in Oxford is now looking at options for how to progress gene therapy for myasthenia, and a new NHS-funded Congenital Myasthenic Syndrome fellow will be taking this forward in the future.

The establishment and use of a UK database for myasthenic disorders

Dr Isabel Leite (Oxford): started in January 2021 with the appointment of Dr Mohammad Asghraghi, on a three-year fellowship. Recruitment of patients has now started.

Dr Sui Wong (Moorfields) has also been awarded a small grant for one year, looking into “Understanding the pathophysiology of Ocular Myasthenia Gravis through Video Oculography”.

Future Project:

Myaware has recently awarded a research grant which due to the Covid pandemic has yet been able to start. **Dr Saiju Jacob and Professor Wraith** (Birmingham) will begin a project around “Developing antigen specific Immunotherapy in Myasthenia Gravis” which is likely to start in Summer 2021 and will run for three years and include the appointment of a clinical fellow.

REPORT OF THE TRUSTEES

Awareness

Myaware continues to work with umbrella organisations such as Neurological Alliance and Rare Disease UK to ensure that our member's views and needs are represented. This year our Rare Disease Day appeal in February 2021 raised £4570. This appeal raised the awareness of the challenges faced by carers of those living with myasthenia and shared the story of Georgina who cares for her Husband Peter.

Unfortunately, we were unable to hold what should have been our second 'My Awareness Month in May 2020 due to the impacts of the pandemic on our service delivery. We look forward to reinstating this in May 2021. However, our appeal in the month of May raised £2275. This raised awareness of the impacts of the pandemic on those living with myasthenia including feelings of vulnerability, isolation and the risk of job loss impacts on household finances.

Myaware continues to raise awareness of the myasthenias amongst healthcare professionals by providing information packs to neurology clinics across the UK.

In the absence of face-to-face meetings this year, our website and social media pages have become the most effective way in which to raise awareness of the myasthenia's. With this in mind, myaware began a review of over 100 web pages on our national site, these are accessed by members, general public and healthcare professionals alike. Myaware also reviewed and modified our social media groups to ensure the highest security possible when seeking peer support.

As and when pandemic restrictions reduce, we look forward to once again attending annual conferences such as Omniamed, Royal College of GP events to raise much needed awareness amongst healthcare professionals.

REPORT OF THE TRUSTEES

Review of Fundraising Activities How we raised the money

Total £992,799



2020-21 was a universally challenging year for fundraisers across the sector, with events cancelled, personal financial circumstances impacted by COVID-19 and an inability to undertake public fundraising. However, the myaware Fundraising Team rose to the challenge early on to release restricted funds, adapt to digital ways of working and to innovate with new ideas.

Fundraising priorities altered throughout the year to adapt to the ever-changing global situation and to help the Fundraising Team to maximise opportunities in its midst.

During the year we were grateful to 20 people who remembered myaware in their wills. These bequests total £519,560.

Donations have dropped by 47% since last year to £83,601, thought to be a direct impact of the pandemic and the limited affordability of donors during uncertain times. This includes £8,532.78 received by regular givers over the course of the year. Also included is Facebook fundraising which has raised £13,841.53 in total, an increase of 17% from 2019-20.

Corporate donations and affinity programmes have raised £7688 during the period.

Trusts and grants income rose by 65% this year to £226,775. We continue to be very grateful for grants awarded by trusts and grant making bodies including the National Lottery Community fund which donated £106,773 from it's Covid-19 impact fund.

Income received via events totalled £45,488. This includes £1773.53 raised by Lee and Noah's 24 Christmas songs fundraiser which gained media coverage via Radio 5 Live.

A challenge arose at the end of 2020-21, when the Gambling Commission advised myaware that the McPherson Club needed to operate as a small society lottery. This involved changes to the way the McPherson Club operates, the work for which began in March 2021. The changes may impact participation in 2021-22, but it is hoped that the Club will be just as successful as during 2020-21.

REPORT OF THE TRUSTEES

Impact and Value

Myasthenia means muscle weakness. It affects the muscles that let you move but not the automatic ones like your heart that you don't have to think about. Your brain tells your muscles to work, but the message doesn't get through. Symptoms of myasthenia include muscle weakness which makes day to day activities like walking, smiling and talking very difficult. When swallowing and breathing are affected, this can lead to a medical emergency.

Myaware works tirelessly to provide accessible support services and information to everyone who receives a myasthenia diagnosis. We think there are approximately 12,000 people in the UK with myasthenia but there are currently no accurate published figures. Myaware supports approximately 25% of those who have received a myasthenia diagnosis and our aim is to raise more awareness to ensure that everyone who receives a diagnosis can access the support that they need to live well with myasthenia.

A myasthenia diagnosis can be life-changing and we aim to make life easier for these people and their families in the following ways:

- Accessible information and support, face to face, online, on the telephone or via skype
  - 109 online support get-togethers this year providing support, information and advice
  - Three secure Facebook closed groups providing 24/7 online peer support and advice
  - National Facebook, Twitter and Instagram pages offering information and signposting
  - Telephone support via Support Workers and Regional Organisers across the UK
  - Skype/telephone counselling service
  - Benefits and Welfare advice service
  - Online information for people living with myasthenia their family members and healthcare professionals via our website

- Increased awareness amongst the public and healthcare professionals

  - Vast website offering accessible information on all aspects of living with myasthenia
  - A range of detailed information booklets on myasthenia, it's symptoms and treatments
  - Newly diagnosed information packs
  - Clinic awareness packs for GP surgeries, neurology clinics, dentists, optician and pharmacies
  - Representation of our members needs at Neurological Alliance and Rare Disease UK

- Myaware is committed to effectively and responsibly funding research projects in the following areas:

  - Cause
  - Cure
  - Prevention
  - Treatment

  Myaware is also committed to training clinicians of the future in the field of myasthenia and effectively communicating outcomes regarding current and future research opportunities with transparency.

REPORT OF THE TRUSTEES

FUTURE DEVELOPMENTS, AMBITIONS AND LONG TERM STRATEGIES

Meeting increasing demands of support from people affected by myasthenia requires the charity to maintain its tight focus on cost control.

During the financial year myaware has been continuing to work hard to comply with the General Data Protection Regulations (GDPR).

In light of pandemic impacts on face-to-face support delivery, myaware has had to implement alternative support delivery method via online platforms such as Zoom. Myaware is committed to seeking member feedback regarding if and when to resume face-to-face support.

Myaware will continue to develop the support and information provided via our website and social media pages and groups.

Myaware aims to improve the awareness of our personal wellbeing services such as counselling and benefits & welfare advice to ensure our members are able to access with ease.

Myaware will continue to be committed to effective communication and engagement with our members.

Myaware will increase its work relating to raising awareness with healthcare professionals to improve accurate and timely diagnosis.

Myaware continues to be committed to representing our members at national forums such as Neurological Alliance and Rare Disease and to feedback updates and outcomes to our members.

Myaware is committed to effectively and responsibly utilising restricted research funding to support projects in the areas of cause, cure, prevention, treatment and general improvement of quality of life, in relation to myasthenia and related conditions.

REFERENCE AND ADMINISTRATIVE DETAILS

Myaware is a company limited by guarantee

Registered Company Number in England and Wales: 3038358

Registered Charity Number in England and Wales: 1046443

Registered Charity Number in Scotland: SC044744

Registered Office
The College Business Centre
Uttoxeter New Road
Derby DE22 3WZ

Chief Executive Officer
Ms Sarah Cuthell

Bankers
Yorkshire Bank
28 St Peter's Square, Derby, DE1 1SL

Auditors
Johnson Tidsall Limited
Chartered Accountants
81 Burton Road, Derby DE1 1TJ

Company Secretary
Andrew Lutley
A J Lutley also acts as solicitors to the charity: A J Lutley Solicitors, Springfield Rookery Hill, Ashtead Park,
Ashtead KT21 1HY

REPORT OF THE TRUSTEES

Trustees

Trevor Ranson – Chairman
Andrew Robinson – Treasurer
Bruce McColl
Liz McSheehy
Saiju Jacob
Prof Bethan Peach
Jon Rio
Maria Isabel Leite
Penny Henrion
Stuart Mann
Rashmi Rungta (appointed 01.11.20)
Huw Simmonds (appointed 01.11.20)

More information regarding Trustees can be found at:
www.myaware.org/Pages/FAQs/Category/meet-the-board

STRUCTURE, GOVERNANCE AND MANAGEMENT

Myaware is company limited by guarantee, incorporated on 27th March 1995 (number 3038358), a registered charity in England and Wales (number 1046443) and a charity registered in Scotland (number SCO44744). It is governed by its Memorandum and Articles of Association adopted on 27th March 1995 and amended on 29th March 2018.

Subject to the provisions of the Companies Act 2006, the articles and to any directions given by special resolution, the business of the Company is managed by the trustees who may exercise all the powers of the Company. No alteration of the articles and no such direction shall invalidate any prior act of the trustees which would have been valid if that alteration had not been made or that direction had not been given. The powers given by this article shall not be limited by any special power given to the trustees by the articles and a meeting of trustees at which a quorum is present may exercise all the powers exercisable by the trustees.

The pay and remuneration of the senior managers of myaware is considered annually by the Trustees. The board of Trustees meets during the budget setting process to review salary levels, increment payments and inflation rises. The Trustees consider benchmark information relating to similar posts in similar organisations with the charity sector to assist with their decision.

We continue to work in partnership with other organisations with shared interest, including Neurological Alliance and Rare Disease UK.

Fundraising and Data Protection

Myaware operates within a strict fundraising policy and never uses telephone cold-calling; purchase address lists to write unsolicited letters, share the membership list to third parties or use any other methods or approaches that may be deemed as harassing or pressurising the recipient. We always respect the privacy of those who share their personal information with us.

Recruitment, appointment, induction and training of new trustees

Only members of the charity may become Trustees.

The Articles of Association allow the Trustees to appoint candidates to become a Trustee (and Director), either to fill a vacancy, or to strengthen the Board. Candidates become known to the Board through the personal knowledge or research of existing Trustees, by interested members of the organisation volunteering their services or, occasionally, as a result of advertising by the Board.

REPORT OF THE TRUSTEES

Before appointing a new Trustee, the Board will consider any perceived weaknesses in the current Board in terms of special abilities or experience which they believe to be lacking. A potential candidate will then be approached by the Chairman. Where possible the candidate will be invited to attend one or more meetings of the Board as a nonvoting observer. The candidate may then be appointed as a Trustee by a formal motion of the Board.

At present the Board does not operate a formal scheme for the training of Trustees. The Chairman takes care to ensure that they receive personal guidance on their responsibilities under the Charity's Articles, and Charity and Company law. They may also seek advice and assistance from the Treasurer and the Company Secretary. The Board will keep under review the need for a formal training process, which must be consistent with the Charity's financial and personal resources.

Medical Committee:

Prof Bethan Peach
Saiju Jacob
Maria Isabel Leite
Liz McSheehy
Sarah Cuthell (CEO)

Finance Committee:

Andrew Robinson (Treasurer)
Bruce McColl
Jon Rio
Stuart Mann
Sarah Cuthell (CEO)

The Chief Executive Officer (CEO) is appointed by the Trustees to manage the day-to-day operations of the charity. The CEO reports to the Chair as her line manager.

RISK MANAGEMENT

A risk review of the overall organisation takes place annually. The review took place in October 2020 when the trustees assessed the major risks. Subsequently, systems and procedures have been established to manage those risks.

An annual budget proposal covering anticipated income and expenditure is created by the CEO and Finance Committee and reviewed by the Trustees. Once agreed, this forms the basis of the financial reserve held by the charity to ensure that commitments can be met. The Finance Committee review performance against the agreed budget on a monthly basis and the full Board considers this quarterly.

The board consider any variation to budget and if necessary, implement changes to mitigate any risks identified.

REPORT OF THE TRUSTEES

FINANCIAL REVIEW

Financial Position

The organisation reported a total net deficit of £23,835 compared with a total net surplus of £455,013 in the previous year.

Unrestricted funds were increased by £340,937 to £1,640,760

Restricted funds decreased by £364,772 to £1,062,289

Incoming Resources

- Total incoming resources for the year were £992,799 down by £385,632 from the previous year.
- The decrease reflects £519,560 in legacy gifts received in the year compared with £888,879 in 2020.
- Income from other trading activities increased by £22,822 to £306,918.
- Investment income has decreased by £9,294 to £10,060 due to lower interest rates on bank deposit accounts.

Resources Expended

Total resources expended increased by £135,340 to £1,052,417.

Research costs were increased by £253,205 to £326,043 of which £271,537 was from restricted funds. The trustees have commenced the effective commitment of the significant legacy gift of £1.1 million from 2018 which is restricted to research.

Support costs were £79,977 down on previous year to £635,542 of which £203,147 was restricted.

Awareness costs reduced by £24,127 to £80,503. All costs were unrestricted.

Fundraising costs were reduced by £13,761 to £10,329.

Total funds stand at £2,703,049 compared with £2,726,884 last year.

Funds at the year-end were made up of unrestricted funds of £1,640,760 (2020: £1,299,823) and restricted funds of £1,062,289 (2020: £1,427,061).

REPORT OF THE TRUSTEES

Reserves Policy

Reserves are held to ensure that planned and committed expenditure over the next five years can be met. Unrestricted funds not invested in tangible and intangible fixed assets (the free reserves) are held to meet a minimum of six months budgeted expenditure and to enable the charity to fulfil its planned and committed expenditure over the next five years, which are not covered by restricted funds.

As of 31st March 2021, the six month's budgeted unrestricted expenditure equates to £385,942 and the free reserves, which amount to £1,227,680 leave a surplus of £841,738 available for future expenditure. The surplus reflects legacies bequeathed. The charity cannot predict its legacy income year on year, and this can vary significantly. 2021 was a good year for legacies and this followed an exceptional year in 2020. The surplus on funds generated is helping to fund our current year.

Going concern

COVID-19

The current pandemic has had a negative effect on the charitable sector, and myaware is no exception to this. The Trustees have set a realistic budget for 2021/22 with a net deficit on unrestricted funds of £419,729. This has been calculated on a reduction in giving and no legacies receivable in the year.

To date the charity is operating within budget and has managed its administrative costs with office staff based at home until further release of restrictions.

The charity can utilise the surplus on unrestricted funds referred to in the above reserves policy. The liquidity position is monitored by the trustees on a monthly basis and the charity is continuing to operate within its reserves policy. On this basis the trustees consider the going concern basis for the preparation of these financial statements to be appropriate.

Principal Funding Sources

The charity benefitted during the year from a number of generous legacies amounting in total to £519,560.

Charitable trusts and grant making bodies provided £226,775, donations amounted to £83,601 and events generated £45,488.

Investment Policy and Objectives

Trustees agree on investments in compliance with the Articles of Association. The return on investment for the year was 0.5% (2020 0.9%). If the change in value of investments is included, the return is 2.4% (2020 0.6%). Note that these figures do not include interest earned on bank current accounts – such interest is identified in a line item in the notes to the accounts. The Trustees consider these results to be satisfactory in the current investment climate but aim to keep this under regular review.

REPORT OF THE TRUSTEES

Statement of Trustees Responsibilities

The Trustees (who are also the directors of Myaware Company Limited by Guarantee for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with the applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including Financial Reporting Standard 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland.

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application resources, including the income and expenditure of the charitable company for that period. In preparing those financial statements, the trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charity SORP;
- Make judgements and estimates that are reasonable and prudent;
- Prepare the financial statements on the going concern basis, unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006, The Charities and Trustees Investment Act (Scotland) 2005 and The Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

- There is no relevant audit information of which the charitable company’s auditors are unaware; and
- The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

The report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

ON BEHALF OF THE BOARD:

Approved by order of the Board of Trustees on 16/12/21 and signed on it’s behalf by:



Mr Trevor Ranson – Chairman of the Board of Trustees

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF MYAWARE COMPANY LIMITED BY GUARANTEE

Opinion
We have audited the financial statements of Myaware Company Limited by Guarantee (the 'charitable company') for the year ended 31 March 2021 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In our opinion the financial statements:
- give a true and fair view of the state of the charitable company's affairs as at 31 March 2021 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment Scotland Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information
The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Report of the Trustees for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Trustees has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception
In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to take advantage of the small companies' exemption from the requirement to prepare a Strategic Report or in preparing the Report of the Trustees.

Responsibilities of trustees
As explained more fully in the Statement of Trustees' Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

In identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

-The nature and control environment of the charity

-Our discussions with management and governance including whether they had knowledge of any actual, suspected or alleged fraud

-The internal controls to mitigate the risks of fraud

Following our review, we have identified the following areas which are deemed to have the highest potential for fraud or material misstatement within the financial statements:

- The timing of revenue recognition
- The evaluation of estimates in respect of legacies
- The correct identification of restricted funds
- The timing and recognition of committed expenditure
- The risk of management override

We also considered any laws and regulations that were central to the operation of the charity including charity law, employment law and health and safety.

The following procedures were undertaken in respect of the risks where we identified the potential for material misstatement:

Income from donations and legacies was considered a risk due to the volume and nature of these transactions. Income may be pledged but there may be a timing difference between commitment and receipt. The overall income of the charity could be materially understated.

Income transaction testing was preformed to ensure completeness of income. Post year end donations and legacies were reviewed to ensure that income was recognised in the correct accounting period in accordance with the charity's accounting policy.

In respect of legacies, we also tested the accuracy of estimates by reviewing correspondence obtained from solicitors and executors which included the wills and statements of assets and liabilities of the deceased person's estate and where possible agreed to receipts after date.

Restricted funds in respect of income were tested donor correspondence to ensure that the restrictions imposed were adhered to by the charity in expending those funds. This included vouching a sample of expenditure. In addition, we tested unrestricted income mindful of any non-recognition of restricted funds.

The testing of committed expenditure in relation to grants awarded by the charity in respect of research was tested by obtaining copies of the formal grant offer and agreeing the terms to the creditor provision in the financial statements. Trustees' board meeting minutes were reviewed, and all commitments noted in the year were agreed to the financial statements to ensure completeness.

A sample of journal entries were tested for appropriateness and enquiries made of management as to the procedures in place for posting journal entries. During our audit we considered any large, unusual journals or transactions outside the normal course of business which were highlighted as a result of our testing.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF MYAWARE
COMPANY LIMITED BY GUARANTEE

We reviewed the minutes of trustees' board meetings and controls put in place by the board of trustees including a review of their risk assessment.

At the planning stage we discussed with management any laws and regulations which were central to the operation of the charity.

The financial statements were reviewed alongside our disclosure checklists to identify any unusual or unexpected relationships or any areas of non-compliance. Discussions were held with management where it was considered additional disclosures were required.

We remained alert to any indications of fraud, material misstatement or non-compliance with laws and regulations throughout the audit including those relating to the financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report
This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and to the charitable company's trustees, as a body, in accordance with section 44 (1) (c) of the Charities and Trustee Investment Scotland Act 2005 and regulation 10 of the Charities Accounts (Scotland Regulations 2006 (as amended). Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

David Mellor FCA (Senior Statutory Auditor)
for and on behalf of Johnson Tidsall Limited
Chartered Accountants
& Statutory Auditor
81 Burton Road
Derby
Derbyshire
DE1 1TJ

Date: 16/12/2024

MYAWARE
COMPANY LIMITED BY GUARANTEE

STATEMENT OF FINANCIAL ACTIVITIES
(INCORPORATING AN INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 MARCH 2021

	Notes	Unrestricted fund £	Restricted funds £	**2021 Total funds £**	2020 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	3	**673,194**	**2,627**	**675,821**	1,074,981
Other trading activities	4	**125,725**	**181,193**	**306,918**	284,096
Investment income	5	**10,060**	**-**	**10,060**	19,354
Total		**808,979**	**183,820**	**992,799**	1,378,431
EXPENDITURE ON					
Raising funds	6	**10,329**	**-**	**10,329**	24,090
Charitable activities	7				
Research		**54,506**	**271,537**	**326,043**	72,838
Support		**432,395**	**203,147**	**635,542**	715,519
Awareness		**80,503**	**-**	**80,503**	104,630
Total		**577,733**	**474,684**	**1,052,417**	917,077
Net gains/(losses) on investments		**35,783**	**-**	**35,783**	(6,341)
NET INCOME/(EXPENDITURE)		**267,029**	**(290,864)**	**(23,835)**	455,013
Transfers between funds	21	**73,908**	**(73,908)**	**-**	-
Net movement in funds		**340,937**	**(364,772)**	**(23,835)**	455,013
RECONCILIATION OF FUNDS					
Total funds brought forward		**1,299,823**	**1,427,061**	**2,726,884**	2,271,871
TOTAL FUNDS CARRIED FORWARD		**1,640,760**	**1,062,289**	**2,703,049**	2,726,884

MYAWARE
COMPANY LIMITED BY GUARANTEE
COMPANY NUMBER 03038358

BALANCE SHEET
31 MARCH 2021

	Notes	Unrestricted fund £	Restricted funds £	**2021 Total funds £**	2020 Total funds £
FIXED ASSETS					
Intangible assets	14	**23,477**	**-**	**23,477**	34,081
Tangible assets	15	**3,661**	**-**	**3,661**	7,173
Investments	16	**211,304**	**-**	**211,304**	175,521
		238,442	**-**	**238,442**	216,775
CURRENT ASSETS					
Stocks	17	**2,138**	**-**	**2,138**	3,629
Debtors	18	**859,595**	**-**	**859,595**	863,397
Cash at bank and in hand		**556,180**	**1,483,994**	**2,040,174**	1,852,504
		1,417,913	**1,483,994**	**2,901,907**	2,719,530
CREDITORS					
Amounts falling due within one year	19	**(15,595)**	**(257,805)**	**(273,400)**	(190,708)
NET CURRENT ASSETS		**1,402,318**	**1,226,189**	**2,628,507**	2,528,822
TOTAL ASSETS LESS CURRENT LIABILITIES		**1,640,760**	**1,226,189**	**2,866,949**	2,745,597
CREDITORS					
Amounts falling due after more than one year	20	**-**	**(163,900)**	**(163,900)**	(18,713)
NET ASSETS		**1,640,760**	**1,062,289**	**2,703,049**	2,726,884
FUNDS	21				
Unrestricted funds				**1,640,760**	1,299,823
Restricted funds				**1,062,289**	1,427,061
TOTAL FUNDS				**2,703,049**	2,726,884

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 16/12/2021 and were signed on its behalf by:

.....
Mr T Ranson - Trustee

MYAWARE
COMPANY LIMITED BY GUARANTEE

CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 MARCH 2021

	Notes	2021 £	2020 £
Cash flows from operating activities			
Cash generated from operations	1	**195,137**	(264,411)
Net cash provided by/(used in) operating activities		**195,137**	(264,411)
Cash flows from investing activities			
Purchase of intangible fixed assets		**(14,759)**	-
Purchase of tangible fixed assets		**(2,768)**	(3,353)
Interest received		**10,060**	19,354
Net cash (used in)/provided by investing activities		**(7,467)**	16,001
Change in cash and cash equivalents in the reporting period		**187,670**	(248,410)
Cash and cash equivalents at the beginning of the reporting period		**1,852,504**	2,100,914
Cash and cash equivalents at the end of the reporting period		**2,040,174**	1,852,504

MYAWARE
COMPANY LIMITED BY GUARANTEE

NOTES TO THE CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 MARCH 2021

1. RECONCILIATION OF NET (EXPENDITURE)/INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2021	2020
	£	£
Net (expenditure)/income for the reporting period (as per the Statement of Financial Activities)	**(23,835)**	455,013
Adjustments for:		
Depreciation charges	**31,643**	33,930
(Gain)/losses on investments	**(35,783)**	6,341
Interest received	**(10,060)**	(19,354)
Decrease in stocks	**1,491**	3,752
Decrease/(increase) in debtors	**3,802**	(659,943)
Increase/(decrease) in creditors	**227,879**	(84,150)
Net cash provided by/(used in) operations	**195,137**	(264,411)

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1/4/20	Cash flow	**At 31/3/21**
	£	£	**£**
Net cash			
Cash at bank and in hand	**1,852,504**	**187,670**	**2,040,174**
	1,852,504	**187,670**	**2,040,174**
Total	**1,852,504**	**187,670**	**2,040,174**

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

1. STATUTORY INFORMATION

Myaware is a charitable company, registered in England and Wales and Scotland. The charitable company's registered company number, registered charity numbers, registered office address and business address can be found in the reference and administrative details of the Report of the Trustees.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' ,the Companies Act 2006 and the Charities and Trustee Investment (Scotland) Act 2005. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

The currency basis for the preparation of these financial statements is pound sterling (£).

Going concern
The trustees regularly monitor the charity's reserves policy and risk assessment. The adverse effects of the Coronavirus in 2020/21 have been evaluated by the trustees and a realistic budget for 2021/22 has been prepared. Liquid funds and cash flow are monitored on a monthly basis. To date, no material uncertainties exist that would affect the preparation of the financial statements on a going concern basis.

Significant judgements and estimates
The following judgements (apart from those involving estimates) have been made in the process of applying the charitable company's accounting policies that have had the most significant effect on amounts recognised in the financial statements:

Legacies - when calculating amounts due on legacies, management considers the wills of the deceased, executors accounts and notifications received from executors.

Grants - when calculating grant commitments, management considers the nature of the grants as being within the charity's objectives and the possible future benefits for people affected by myasthenia.

Income
All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received, and the amount can be measured reliably.

Donated services and goods are recognised as income when the charity has control over them, the economic benefit is probable and can be measured reliably. In accordance with the Charities SORP (FRS102), the volunteer time of Support Groups is not recognised. Information about their contribution is provided in the Trustees' Annual Report.

For donations to be recognised the charity will have been notified of the amounts and the settlement date. If there are conditions attached to the donation and this requires a level of performance before entitlement can be obtained, then income is deferred until those conditions are fully met or the fulfilment of those conditions is within the control of the charity, and it is probable that they will be fulfilled.

For legacies, entitlement is the earlier of the charity being notified of an impending distribution or the legacy being received. At this point income is recognised.

Income from trading activities includes income earned from fundraising events and trading activities to raise funds for the charity. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred.

Investment income is earned through holding assets for investment purposes such as shares and bank deposit accounts. It includes dividends and interest. It is included when the amount can be measured reliably.

2. ACCOUNTING POLICIES - continued

Grants
Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the charity will comply with conditions attaching to them and the grants will be received using the accrual model.

Debtors
Other debtors are recognised at the settlement amount due. Prepayments are valued at the amount prepaid.

Expenditure
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings, they have been allocated to activities on a basis consistent with the use of resources.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Allocation and apportionment of support costs and governance
Resources expended are allocated to the particular activity where the cost relates directly to that activity. However, the cost of overall direction and administration on each activity, including the salary and overhead costs of the general office and regional staff, is apportioned on the following bases which are an estimate, based on staff time, of the amount attributable to each activity:

	Percentage allocation
Research	11%
Support	74%
Awareness	15%

Intangible fixed assets
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:

Computer software - over 3 years straight line

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	-	20% on cost
Computer equipment	-	33% on cost

Tangible fixed assets are stated at cost or deemed costs less accumulated depreciation. Cost includes costs directly attributable to making the asset capable of operating as intended.

Individual fixed assets costing £500 or more are capitalised at cost.

Investments
Investments are valued at market value which is deemed to be fair value. Movements in market value are reflected in the statement of financial activities as a net gain/(loss).

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Stock is valued on a first in first out basis.

Taxation
The charity is exempt from corporation tax on its charitable activities.

2. ACCOUNTING POLICIES - continued

Fund accounting
The charitable company has both restricted and unrestricted funds. All funds are used to benefit and promote its charitable objects.

Restricted funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose and the restriction means that the funds can only be used for specific projects or activities.

When donors specify that donations and grants are for particular purposes which do not amount to pre-conditions regarding entitlement, this income is included in incoming resources of restricted funds when receivable. The relevant expenditure is then matched as restricted expenditure.

Unrestricted funds are general funds that are available for use at the trustees' discretion in furtherance of any objectives of the charity.

Designated funds are unrestricted funds set aside at the discretion of the trustees for specific purposes.

Pension costs and other post-retirement benefits
The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Operating lease agreements
Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged to the SOFA on a straight line basis over the period of the lease.

Reserves
The charitable company maintains a level of reserves required to fulfil its objectives. The trustees monitor reserves at regular meetings.

Financial instruments
Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

3. DONATIONS AND LEGACIES

	2021	2020
	£	£
Donations	**83,601**	157,906
Legacies	**519,560**	888,879
Grants	**29,355**	-
In Memoriam	**43,305**	28,196
	675,821	1,074,981

The charity benefits greatly from the involvement of many helpers and volunteers, details of which are given in our annual report. In accordance with FRS102 and the Charities SORP (FRS102), the economic contribution of volunteers is not recognised in these financial statements.

Grants received, included in the above, are as follows:

	2021	2020
	£	£
Coronavirus retention scheme	**29,355**	-

4. OTHER TRADING ACTIVITIES

	2021	2020
	£	£
Affinity programmes	**623**	190
Appeals	**15,978**	9,127
Collections	**921**	4,609
Corporate	**7,065**	6,915
Grants	**140,428**	63,831
Lotteries	**5,382**	18,763
National events	**9,225**	17,567
Regional events	**36,263**	81,973
Sales of merchandise	**4,686**	7,223
Trusts	**86,347**	73,898
	306,918	284,096

5. INVESTMENT INCOME

	2021	2020
	£	£
Deposit account interest	**3,815**	11,971
Current account interest	**150**	690
Dividends on shares and other investments	**6,095**	6,693
	10,060	19,354

6. RAISING FUNDS

Raising donations and legacies

	2021	2020
	£	£
Merchandise	**2,976**	4,768
Events	**3,357**	6,160
Appeal mailings	**349**	1,410
Lottery	**3,647**	11,752
	10,329	24,090

7. CHARITABLE ACTIVITIES COSTS

	Direct Costs (see note 8)	Support costs (see note 9)	Totals
	£	£	£
Research	**308,259**	**17,784**	**326,043**
Support	**498,220**	**137,322**	**635,542**
Awareness	**56,250**	**24,253**	**80,503**
	862,729	**179,359**	**1,042,088**

8. DIRECT COSTS OF CHARITABLE ACTIVITIES

	2021	2020
	£	£
Staff costs	**580,867**	533,944
Medical research	**267,677**	(590)
Myaware Kids	**-**	27,530
Travel and miscellaneous	**5,600**	71,222
MyNews & member communications	**7,158**	14,007
Meetings and conferences	**1,427**	51,294
Medical education programme	**-**	750
	862,729	698,157

Grants payable during the year were as follows:

	2021	2020
	£	£
Commitments as at 1 April 2020	184,343	254,013
Commitments made in the year	275,772	-
Commitments released in the year	(8,095)	(590)
Grants paid during the year	(30,315)	(69,080)
Commitments as at 31 March 2021	421,705	184,343

9. SUPPORT COSTS

	Management	Governance costs	Totals
	£	£	£
Research	**16,166**	**1,618**	**17,784**
Support	**126,433**	**10,889**	**137,322**
Awareness	**22,045**	**2,208**	**24,253**
	164,644	**14,715**	**179,359**

Support costs, included in the above, are as follows:

Management

	Research	Support	Awareness	2021 Total activities	2020 Total activities
	£	£	£	£	£
Rental of premises	**1,789**	**19,532**	**2,439**	**23,760**	**23,796**
Utilities and insurance	**1,880**	**12,811**	**2,564**	**17,255**	**13,249**
Office equipment	**221**	**1,793**	**301**	**2,315**	**3,338**
Printing, postage and stationery	**1,285**	**8,643**	**1,752**	**11,680**	**19,228**
Photocopier costs	**111**	**747**	**151**	**1,009**	**1,596**
Support website	**3,351**	**22,541**	**4,569**	**30,461**	**18,322**
IT support & software	**3,197**	**31,216**	**4,360**	**38,773**	**49,421**
H R costs	**555**	**3,733**	**756**	**5,044**	**6,045**
General expenses	**124**	**837**	**170**	**1,131**	**1,291**
Bank charges	**173**	**1,164**	**236**	**1,573**	**2,709**
Amortisation of intangible fixed assets	**2,789**	**18,769**	**3,805**	**25,363**	**26,971**
Carried forward	**15,475**	**121,786**	**21,103**	**158,364**	**165,966**

9. SUPPORT COSTS - continued

Management - continued

	Research	Support	Awareness	2021 Total activities	2020 Total activities
	£	£	£	£	£
Brought forward	**15,475**	**121,786**	**21,103**	**158,364**	**165,966**
Depreciation of tangible fixed assets	**691**	**4,647**	**942**	**6,280**	**6,959**
	16,166	**126,433**	**22,045**	**164,644**	**172,925**

Governance costs

	Research	Support	Awareness	2021 Total activities	2020 Total activities
	£	£	£	£	£
Trustees' expenses	**-**	**-**	**-**	**-**	**2,624**
Auditors' remuneration	**873**	**5,876**	**1,192**	**7,941**	**7,224**
Legal and professional fees	**745**	**5,013**	**1,016**	**6,774**	**12,057**
	1,618	**10,889**	**2,208**	**14,715**	**21,905**

10. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2021	2020
	£	£
Auditors' remuneration	**7,941**	7,224
Depreciation - owned assets	**6,280**	6,959
Computer software amortisation	**25,363**	26,971

11. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 March 2021 nor for the year ended 31 March 2020.

Trustees' expenses

	2021	2020
	£	£
Trustees' expenses	**-**	2,624

During the year no trustee (2020: 11) received reimbursement of their expenses for attending meetings.

12. STAFF COSTS

	2021	2020
	£	£
Wages and salaries	**509,640**	468,190
Social security costs	**36,906**	34,846
Other pension costs	**34,321**	30,908
	580,867	533,944

The average number of full time equivalent employees during the year was 19 (2020: 17).

The average monthly number of employees during the year was as follows:

	2021	2020
Fundraising, support and awareness	**20**	18
Management and operations of the charity	**4**	4
	24	22

No employees received emoluments in excess of £60,000.

The key management personnel of the charity comprise the Chief Executive Officer. The total employee benefits of the key management personnel of the charity amounted to £61,158 including pension contributions (2020: £58,207).

13. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund	Restricted funds	Total funds
	£	£	£
INCOME AND ENDOWMENTS FROM			
Donations and legacies	1,013,425	61,556	1,074,981
Other trading activities	175,014	109,082	284,096
Investment income	19,354	-	19,354
Total	1,207,793	170,638	1,378,431
EXPENDITURE ON			
Raising funds	23,484	606	24,090
Charitable activities			
Research	72,690	148	72,838
Support	532,971	182,548	715,519
Awareness	95,776	8,854	104,630
Total	724,921	192,156	917,077
Net gains/(losses) on investments	(6,341)	-	(6,341)
NET INCOME/(EXPENDITURE)	476,531	(21,518)	455,013
RECONCILIATION OF FUNDS			
Total funds brought forward	823,292	1,448,579	2,271,871

13. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued

	Unrestricted fund £	Restricted funds £	Total funds £
TOTAL FUNDS CARRIED FORWARD	1,299,823	1,427,061	2,726,884

14. INTANGIBLE FIXED ASSETS

	Computer software £
COST	
At 1 April 2020	**80,977**
Additions	**14,759**
At 31 March 2021	**95,736**
AMORTISATION	
At 1 April 2020	**46,896**
Charge for year	**25,363**
At 31 March 2021	**72,259**
NET BOOK VALUE	
At 31 March 2021	**23,477**
At 31 March 2020	34,081

15. TANGIBLE FIXED ASSETS

	Fixtures and fittings £	Computer equipment £	Totals £
COST			
At 1 April 2020	**13,247**	**38,995**	**52,242**
Additions	**-**	**2,768**	**2,768**
At 31 March 2021	**13,247**	**41,763**	**55,010**
DEPRECIATION			
At 1 April 2020	**12,930**	**32,139**	**45,069**
Charge for year	**317**	**5,963**	**6,280**
At 31 March 2021	**13,247**	**38,102**	**51,349**
NET BOOK VALUE			
At 31 March 2021	**-**	**3,661**	**3,661**
At 31 March 2020	317	6,856	7,173

16. FIXED ASSET INVESTMENTS

	Listed investments £
MARKET VALUE	
At 1 April 2020	**175,521**
Revaluations	**35,783**
At 31 March 2021	**211,304**
NET BOOK VALUE	
At 31 March 2021	**211,304**
At 31 March 2020	175,521

There were no investment assets outside the UK.

The historical cost of fixed asset investments as at 31 March 2021 was £89,858 (2020: £89,858).

17. STOCKS

	2021	2020
	£	£
Finished goods	**2,138**	3,629

18. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021	2020
	£	£
Other debtors	**848,353**	850,225
Prepayments and accrued income	**11,242**	13,172
	859,595	863,397

19. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021	2020
	£	£
Other creditors	6,864	5,604
Committed grants	257,805	165,630
Accruals and deferred income	8,731	19,474
	273,400	190,708

20. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

	2021	2020
	£	£
Committed grants	163,900	18,713

21. MOVEMENT IN FUNDS

	At 1/4/20	Net movement in funds	Transfers between funds	At 31/3/21
	£	£	£	£
Unrestricted funds				
General fund	1,299,823	267,029	73,908	1,640,760
Restricted funds				
Research	1,204,757	(270,537)	(73,908)	860,312
Support	220,117	(21,677)	-	198,440
Awareness	2,187	1,350	-	3,537
	1,427,061	(290,864)	(73,908)	1,062,289
TOTAL FUNDS	2,726,884	(23,835)	-	2,703,049

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Gains and losses	Movement in funds
	£	£	£	£
Unrestricted funds				
General fund	808,979	(577,733)	35,783	267,029
Restricted funds				
Research	1,000	(271,537)	-	(270,537)
Support	181,470	(203,147)	-	(21,677)
Awareness	1,350	-	-	1,350
	183,820	(474,684)	-	(290,864)
TOTAL FUNDS	992,799	(1,052,417)	35,783	(23,835)

21. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1/4/19 £	Net movement in funds £	At 31/3/20 £
Unrestricted funds			
General fund	823,292	476,531	1,299,823
Restricted funds			
Research	1,157,446	47,311	1,204,757
Support	272,731	(52,614)	220,117
Awareness	18,402	(16,215)	2,187
	1,448,579	(21,518)	1,427,061
TOTAL FUNDS	2,271,871	455,013	2,726,884

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	1,207,793	(724,921)	(6,341)	476,531
Restricted funds				
Research	47,459	(148)	-	47,311
Support	130,540	(183,154)	-	(52,614)
Awareness	(7,361)	(8,854)	-	(16,215)
	170,638	(192,156)	-	(21,518)
TOTAL FUNDS	1,378,431	(917,077)	(6,341)	455,013

A current year 12 months and prior year 12 months combined position is as follows:

	At 1/4/19 £	Net movement in funds £	Transfers between funds £	At 31/3/21 £
Unrestricted funds				
General fund	823,292	743,560	73,908	1,640,760
Restricted funds				
Research	1,157,446	(223,226)	(73,908)	860,312
Support	272,731	(74,291)	-	198,440
Awareness	18,402	(14,865)	-	3,537
	1,448,579	(312,382)	(73,908)	1,062,289
TOTAL FUNDS	2,271,871	431,178	-	2,703,049

21. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	2,016,772	(1,302,654)	29,442	743,560
Restricted funds				
Research	48,459	(271,685)	-	(223,226)
Support	312,010	(386,301)	-	(74,291)
Awareness	(6,011)	(8,854)	-	(14,865)
	354,458	(666,840)	-	(312,382)
TOTAL FUNDS	2,371,230	(1,969,494)	29,442	431,178

Restricted funds
Restricted funds comprise:

Research
Restricted funds in this class will be applied to:

a. Scientific and clinical research into the causes, disease mechanisms, diagnosis and epidemiology of Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndrome and other similar disorders of the Neuro-Muscular Junction.

b. The provision of equipment and facilities to support (a).

c. Provision of specialist medical facilities (including staff) where the Trustees consider that such provision has a significant impact on the effectiveness of (a).

Support
Restricted funds in this class will be applied to:

d. Development of new support groups of the charity, to foster the health and welfare of myasthenics and their families and carers.

e. Organisation of Regional Conferences to encourage mutual support between members, myasthenics, and support groups.

f. In exceptional circumstances - provision of specialist medical facilities (including staff) where the Trustees consider that such provision would have a major impact on the health and welfare of myasthenics, and alternative funding cannot be obtained.

Awareness
Restricted funds in this class will be applied to:

g. Preparation, publication and distribution of information about Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndrome and other similar disorders of the Neuro-Muscular Junction. (Including information on their causes, diagnosis and treatment, and issues concerning the lifestyle and quality-of-life of patients with these disorders). Publication and distribution includes development and maintenance of the association's internet websites.

h. Publicity and promotion of events to foster awareness, in the general public, national and local government, and other bodies, of these disorders, and the problems experienced by patients and their families and carers.

21. MOVEMENT IN FUNDS - continued

i. Activities to foster awareness in the medical profession of these disorders, and the problems experienced by patients and their families and carers.

j. Activities to foster awareness in the medical profession of the current state of best medical practice in the diagnosis and treatment of these disorders.

k. Regional and national events to disseminate information about these disorders to myasthenics, their families and carers (including information about current and planned future medical and scientific research).

For presentation purposes all restricted income receivable is allocated to one of the above three categories that best describes its restriction.

A detailed breakdown of the income and expenditure allocated to these categories is available on request.

Transfers between funds

During the year the trustees sanctioned the use of restricted funds for research project Deep Phenotyping and Immune Profiling in Myasthenia Gravis. The project had originally been committed from unrestricted funds. A transfer of £73,908 has been made from restricted to unrestricted funds being the creditor balance on the project as at 31 March 2021.

22. EMPLOYEE BENEFIT OBLIGATIONS

The total contribution paid to Personal Pension Plans in the year for certain employees amounted to £34,321 (2020: £30,908).

23. OTHER FINANCIAL COMMITMENTS

At the year end the charity had financial commitments in respect of rent amounting to £23,760 (2020: £23,760) and other leases amounting to £5,016 (2020: £119).

24. RELATED PARTY DISCLOSURES

During the year the charity paid £2,425 (2020: £2,276) for legal services performed by Andrew Lutley, Company Secretary.

The amount donated by trustees in the year in respect of travel claims amounted to £nil (2020: £922).

25. ULTIMATE CONTROLLING PARTY

The charity is controlled by its Board of Trustees.

MYAWARE
COMPANY LIMITED BY GUARANTEE

DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2021

	2021 £	2020 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	**83,601**	157,906
Legacies	**519,560**	888,879
Grants	**29,355**	-
In Memoriam	**43,305**	28,196
	675,821	1,074,981
Other trading activities		
Affinity programmes	**623**	190
Appeals	**15,978**	9,127
Collections	**921**	4,609
Corporate	**7,065**	6,915
Grants	**140,428**	63,831
Lotteries	**5,382**	18,763
National events	**9,225**	17,567
Regional events	**36,263**	81,973
Sales of merchandise	**4,686**	7,223
Trusts	**86,347**	73,898
	306,918	284,096
Investment income		
Deposit account interest	**3,815**	11,971
Current account interest	**150**	690
Dividends on shares and other investments	**6,095**	6,693
	10,060	19,354
Total incoming resources	**992,799**	1,378,431
EXPENDITURE		
Raising donations and legacies		
Merchandise	**2,976**	4,768
Events	**3,357**	6,160
Appeal mailings	**349**	1,410
Lottery	**3,647**	11,752
	10,329	24,090
Charitable activities		
Wages	**509,640**	468,190
Social security	**36,906**	34,846
Pensions	**34,321**	30,908
Medical research	**267,677**	(590)
Myaware Kids	**-**	27,530
Travel and miscellaneous	**5,600**	71,222
Carried forward	**854,144**	632,106

MYAWARE
COMPANY LIMITED BY GUARANTEE

DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2021

	2021 £	2020 £
Charitable activities		
Brought forward	**854,144**	632,106
MyNews & member communications	**7,158**	14,007
Meetings and conferences	**1,427**	51,294
Medical education programme	**-**	750
	862,729	698,157
Support costs		
Management		
Rental of premises	**23,760**	23,796
Utilities and insurance	**17,255**	13,249
Office equipment	**2,315**	3,338
Printing, postage and stationery	**11,680**	19,228
Photocopier costs	**1,009**	1,596
Support website	**30,461**	18,322
IT support & software	**38,773**	49,421
H R costs	**5,044**	6,045
General expenses	**1,131**	1,291
Bank charges	**1,573**	2,709
Amortisation of intangible fixed assets	**25,363**	26,971
Depreciation of tangible fixed assets	**6,280**	6,959
	164,644	172,925
Governance costs		
Trustees' expenses	**-**	2,624
Auditors' remuneration	**7,941**	7,224
Legal and professional fees	**6,774**	12,057
	14,715	21,905
Total resources expended	**1,052,417**	917,077
Net (expenditure)/income before gains and losses	**(59,618)**	461,354
Realised recognised gains and losses		
Realised gains/(losses) on fixed asset investments	**35,783**	(6,341)
Net (expenditure)/income	**(23,835)**	455,013

myaware

Fighting Myasthenia Together

The College Business Centre
Uttoxeter New Road, Derby DE22 3WZ

Tel: 01332 290219
Email: info@myaware.org
Web: www.myaware.org